WO2018132876A1 - Novel glycine transport inhibitors for the treatment of pain - Google Patents
Novel glycine transport inhibitors for the treatment of pain Download PDFInfo
- Publication number
- WO2018132876A1 WO2018132876A1 PCT/AU2018/050035 AU2018050035W WO2018132876A1 WO 2018132876 A1 WO2018132876 A1 WO 2018132876A1 AU 2018050035 W AU2018050035 W AU 2018050035W WO 2018132876 A1 WO2018132876 A1 WO 2018132876A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nmr
- mhz
- compound according
- dmso
- amino
- Prior art date
Links
- 208000002193 Pain Diseases 0.000 title claims abstract description 67
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 title claims abstract description 61
- 230000036407 pain Effects 0.000 title claims abstract description 52
- 239000004471 Glycine Substances 0.000 title claims abstract description 31
- 239000003112 inhibitor Substances 0.000 title abstract description 13
- 150000001875 compounds Chemical class 0.000 claims abstract description 180
- 238000000034 method Methods 0.000 claims description 37
- 150000003839 salts Chemical class 0.000 claims description 27
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 25
- 229940024606 amino acid Drugs 0.000 claims description 24
- 235000001014 amino acid Nutrition 0.000 claims description 24
- -1 aromatic amino acids Chemical class 0.000 claims description 23
- 150000001413 amino acids Chemical group 0.000 claims description 22
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 15
- 150000001408 amides Chemical class 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 13
- 208000000094 Chronic Pain Diseases 0.000 claims description 12
- 208000004296 neuralgia Diseases 0.000 claims description 11
- 208000021722 neuropathic pain Diseases 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 8
- 125000003342 alkenyl group Chemical group 0.000 claims description 8
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 7
- 239000004472 Lysine Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 150000001412 amines Chemical group 0.000 claims description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 235000018977 lysine Nutrition 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 4
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims description 4
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 4
- 239000004395 L-leucine Substances 0.000 claims description 4
- 235000019454 L-leucine Nutrition 0.000 claims description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 4
- 229960003767 alanine Drugs 0.000 claims description 4
- 229960003136 leucine Drugs 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 229960005190 phenylalanine Drugs 0.000 claims description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 3
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims description 2
- 229930195711 D-Serine Natural products 0.000 claims description 2
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 claims description 2
- 229930182819 D-leucine Natural products 0.000 claims description 2
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims description 2
- 229930182832 D-phenylalanine Natural products 0.000 claims description 2
- 229930182831 D-valine Natural products 0.000 claims description 2
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 2
- 229930064664 L-arginine Natural products 0.000 claims description 2
- 235000014852 L-arginine Nutrition 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- 229930195714 L-glutamate Natural products 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- 229930195722 L-methionine Natural products 0.000 claims description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims description 2
- 150000008547 L-phenylalanines Chemical class 0.000 claims description 2
- 229960002885 histidine Drugs 0.000 claims description 2
- 230000002209 hydrophobic effect Effects 0.000 claims description 2
- 229960004452 methionine Drugs 0.000 claims description 2
- 229960001153 serine Drugs 0.000 claims description 2
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 claims description 2
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 claims description 2
- 229960004295 valine Drugs 0.000 claims description 2
- 125000001176 L-lysyl group Chemical class [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 claims 1
- KPNBUPJZFJCCIQ-LURJTMIESA-N methyl L-lysinate Chemical compound COC(=O)[C@@H](N)CCCCN KPNBUPJZFJCCIQ-LURJTMIESA-N 0.000 claims 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 238
- 238000005160 1H NMR spectroscopy Methods 0.000 description 157
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 87
- 239000000843 powder Substances 0.000 description 83
- 210000004027 cell Anatomy 0.000 description 76
- 239000000243 solution Substances 0.000 description 48
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 44
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 39
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 39
- 238000003556 assay Methods 0.000 description 33
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 26
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 26
- 238000012360 testing method Methods 0.000 description 25
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 24
- 102000010726 Glycine Plasma Membrane Transport Proteins Human genes 0.000 description 24
- 108010063380 Glycine Plasma Membrane Transport Proteins Proteins 0.000 description 24
- 241000700159 Rattus Species 0.000 description 24
- 230000000694 effects Effects 0.000 description 23
- 239000000556 agonist Substances 0.000 description 21
- 239000000203 mixture Substances 0.000 description 21
- 210000004556 brain Anatomy 0.000 description 20
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 18
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 230000015556 catabolic process Effects 0.000 description 16
- 238000006731 degradation reaction Methods 0.000 description 16
- 238000003786 synthesis reaction Methods 0.000 description 16
- JJUHWJQHBPFMJW-MZMPXXGTSA-N (2R)-6-amino-2-[[(Z)-octadec-9-enoyl]amino]hexanoic acid Chemical compound NCCCC[C@H](C(=O)O)NC(CCCCCCC\C=C/CCCCCCCC)=O JJUHWJQHBPFMJW-MZMPXXGTSA-N 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 239000005557 antagonist Substances 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000001963 growth medium Substances 0.000 description 12
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 12
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 12
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 11
- 101710187022 Cannabinoid receptor 2 Proteins 0.000 description 11
- 102100036214 Cannabinoid receptor 2 Human genes 0.000 description 11
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 11
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 11
- 238000011534 incubation Methods 0.000 description 11
- 230000002503 metabolic effect Effects 0.000 description 11
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 11
- YNZFFALZMRAPHQ-SYYKKAFVSA-N 2-[(1r,2r,5r)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-5-(2-methyloctan-2-yl)phenol Chemical compound OC1=CC(C(C)(C)CCCCCC)=CC=C1[C@H]1[C@H](CCCO)CC[C@@H](O)C1 YNZFFALZMRAPHQ-SYYKKAFVSA-N 0.000 description 10
- 102100033868 Cannabinoid receptor 1 Human genes 0.000 description 10
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 10
- 230000036961 partial effect Effects 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- 101710187010 Cannabinoid receptor 1 Proteins 0.000 description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- 238000004113 cell culture Methods 0.000 description 9
- 239000012091 fetal bovine serum Substances 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 229940039009 isoproterenol Drugs 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 102100023145 Sodium- and chloride-dependent glycine transporter 1 Human genes 0.000 description 8
- 101710083171 Sodium- and chloride-dependent glycine transporter 1 Proteins 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 7
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 210000000278 spinal cord Anatomy 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 230000001256 tonic effect Effects 0.000 description 7
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 6
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 6
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 6
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 235000019260 propionic acid Nutrition 0.000 description 6
- 229950010131 puromycin Drugs 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 238000013222 sprague-dawley male rat Methods 0.000 description 6
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 5
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 5
- 208000004454 Hyperalgesia Diseases 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 238000004364 calculation method Methods 0.000 description 5
- 229940127204 compound 29 Drugs 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000013100 final test Methods 0.000 description 5
- 230000000575 glycinergic effect Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000006920 protein precipitation Effects 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- UMOAAMQGRRCHPA-GJCOWUBNSA-N N-oleoyl-L-leucine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)N[C@H](C(O)=O)CC(C)C UMOAAMQGRRCHPA-GJCOWUBNSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 229940035676 analgesics Drugs 0.000 description 4
- 239000000730 antalgic agent Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 125000004494 ethyl ester group Chemical group 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000003197 gene knockdown Methods 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 238000007913 intrathecal administration Methods 0.000 description 4
- 210000001853 liver microsome Anatomy 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 125000001394 octadec-9-enoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 239000012265 solid product Substances 0.000 description 4
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 3
- ADUSZEGHFWRTQS-AIBWNMTMSA-N (2s)-2-amino-3-[(3-fluorophenyl)-(2-phenylmethoxyphenyl)methoxy]propanoic acid Chemical compound C=1C=CC=C(OCC=2C=CC=CC=2)C=1C(OC[C@H](N)C(O)=O)C1=CC=CC(F)=C1 ADUSZEGHFWRTQS-AIBWNMTMSA-N 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- ZJSQZQMVXKZAGW-UHFFFAOYSA-N 2H-benzotriazol-4-ol hydrate Chemical compound O.OC1=CC=CC2=C1N=NN2 ZJSQZQMVXKZAGW-UHFFFAOYSA-N 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000011714 Glycine Receptors Human genes 0.000 description 3
- 108010076533 Glycine Receptors Proteins 0.000 description 3
- 241000202944 Mycoplasma sp. Species 0.000 description 3
- 239000007832 Na2SO4 Substances 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 206010053552 allodynia Diseases 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 238000013262 cAMP assay Methods 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 229960003529 diazepam Drugs 0.000 description 3
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 3
- 239000013024 dilution buffer Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000012595 freezing medium Substances 0.000 description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 230000003228 microsomal effect Effects 0.000 description 3
- ZCYOBMASPXQBSZ-UHFFFAOYSA-N n-[[1-(dimethylamino)cyclopentyl]methyl]-3,5-dimethoxy-4-phenylmethoxybenzamide Chemical compound COC1=CC(C(=O)NCC2(CCCC2)N(C)C)=CC(OC)=C1OCC1=CC=CC=C1 ZCYOBMASPXQBSZ-UHFFFAOYSA-N 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000012421 spiking Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 210000000225 synapse Anatomy 0.000 description 3
- 230000000946 synaptic effect Effects 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- YBRQEYLOJNQUEA-KSEXMQBYSA-N (2R)-2-[[(Z)-hexadec-13-enoyl]amino]-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound C(C)(C)(C)OC(=O)NCCCC[C@H](C(=O)O)NC(CCCCCCCCCCC\C=C/CC)=O YBRQEYLOJNQUEA-KSEXMQBYSA-N 0.000 description 2
- UXNVVKWCGHAZIW-RASRKNKNSA-N (2R)-2-[[(Z)-octadec-9-enoyl]amino]-4-phenylbutanoic acid Chemical compound C(CCCCCCC\C=C/CCCCCCCC)(=O)N[C@@H](C(=O)O)CCC1=CC=CC=C1 UXNVVKWCGHAZIW-RASRKNKNSA-N 0.000 description 2
- XAKJNQLDKZLAKM-RKVKURJASA-N (2R)-3-(1H-indol-3-yl)-2-[[(Z)-octadec-9-enoyl]amino]propanoic acid Chemical compound N1C=C(C2=CC=CC=C12)C[C@H](C(=O)O)NC(CCCCCCC\C=C/CCCCCCCC)=O XAKJNQLDKZLAKM-RKVKURJASA-N 0.000 description 2
- LRQPUGFHAACUMH-SSSWZJSRSA-N (2R)-3-methyl-2-[[(Z)-octadec-9-enoyl]amino]butanoic acid Chemical compound CC([C@H](C(=O)O)NC(CCCCCCC\C=C/CCCCCCCC)=O)C LRQPUGFHAACUMH-SSSWZJSRSA-N 0.000 description 2
- ATFITIQQSWCPIQ-KUFMOJEASA-N (2R)-4-methylsulfanyl-2-[[(Z)-octadec-9-enoyl]amino]butanoic acid Chemical compound CSCC[C@H](C(=O)O)NC(CCCCCCC\C=C/CCCCCCCC)=O ATFITIQQSWCPIQ-KUFMOJEASA-N 0.000 description 2
- UXNVVKWCGHAZIW-IMHHWWNFSA-N (2S)-2-[[(Z)-octadec-9-enoyl]amino]-4-phenylbutanoic acid Chemical compound C(CCCCCCC\C=C/CCCCCCCC)(=O)N[C@H](C(=O)O)CCC1=CC=CC=C1 UXNVVKWCGHAZIW-IMHHWWNFSA-N 0.000 description 2
- RXDBBHRYQBDXKQ-QJRAZLAKSA-N (2S)-4-amino-2-[[(Z)-octadec-9-enoyl]amino]butanoic acid Chemical compound NCC[C@@H](C(=O)O)NC(CCCCCCC\C=C/CCCCCCCC)=O RXDBBHRYQBDXKQ-QJRAZLAKSA-N 0.000 description 2
- GCIBHHUYADGLDK-KWQGRVAKSA-N (2S)-6-[(2-methylpropan-2-yl)oxycarbonylamino]-2-[[(Z)-octadec-13-enoyl]amino]hexanoic acid Chemical compound C(C)(C)(C)OC(=O)NCCCC[C@@H](C(=O)O)NC(CCCCCCCCCCC\C=C/CCCC)=O GCIBHHUYADGLDK-KWQGRVAKSA-N 0.000 description 2
- SGIXTLBWSQGBIX-XQQSMPNESA-N (2S)-6-amino-2-[[(Z)-hexadec-13-enoyl]amino]hexanoic acid Chemical compound NCCCC[C@@H](C(=O)O)NC(CCCCCCCCCCC\C=C/CC)=O SGIXTLBWSQGBIX-XQQSMPNESA-N 0.000 description 2
- ZHRUVKURTCPCET-AQWUKCDYSA-N (2S)-6-amino-2-[[(Z)-hexadec-9-enoyl]amino]hexanoic acid Chemical compound NCCCC[C@@H](C(=O)O)NC(CCCCCCC\C=C/CCCCCC)=O ZHRUVKURTCPCET-AQWUKCDYSA-N 0.000 description 2
- DEFOUIWXXHHFOL-LXHZQTKUSA-N (2S)-6-amino-2-[[(Z)-octadec-13-enoyl]amino]hexanoic acid Chemical compound NCCCC[C@@H](C(=O)O)NC(CCCCCCCCCCC\C=C/CCCC)=O DEFOUIWXXHHFOL-LXHZQTKUSA-N 0.000 description 2
- XFBKKGFUMFHHHK-VJIACCKLSA-N (2s)-2-[[(z)-octadec-9-enoyl]amino]butanedioic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)N[C@H](C(O)=O)CC(O)=O XFBKKGFUMFHHHK-VJIACCKLSA-N 0.000 description 2
- LRQPUGFHAACUMH-GJCOWUBNSA-N (2s)-3-methyl-2-[[(z)-octadec-9-enoyl]amino]butanoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)N[C@@H](C(C)C)C(O)=O LRQPUGFHAACUMH-GJCOWUBNSA-N 0.000 description 2
- TUILUNYVOJGATE-YUQDSPFASA-N (2s)-5-amino-2-[[(z)-octadec-9-enoyl]amino]pentanoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)N[C@H](C(O)=O)CCCN TUILUNYVOJGATE-YUQDSPFASA-N 0.000 description 2
- RSYUOHACVSUMKD-AYZYJWAHSA-N (2s)-6-[(2-methylpropan-2-yl)oxycarbonylamino]-2-[[(z)-octadec-9-enoyl]amino]hexanoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)N[C@H](C(O)=O)CCCCNC(=O)OC(C)(C)C RSYUOHACVSUMKD-AYZYJWAHSA-N 0.000 description 2
- JJUHWJQHBPFMJW-CZQLGGELSA-N (2s)-6-amino-2-[[(e)-octadec-9-enoyl]amino]hexanoic acid Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)N[C@H](C(O)=O)CCCCN JJUHWJQHBPFMJW-CZQLGGELSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- WDWPDZQGQZULKS-BQYQJAHWSA-N 2-[[(E)-octadec-11-enoyl]amino]acetic acid Chemical compound C(CCCCCCCCC\C=C\CCCCCC)(=O)NCC(=O)O WDWPDZQGQZULKS-BQYQJAHWSA-N 0.000 description 2
- WHLCKJGSSXNWPO-SREVYHEPSA-N 2-[[(Z)-hexadec-10-enoyl]amino]acetic acid Chemical compound C(CCCCCCCC\C=C/CCCCC)(=O)NCC(=O)O WHLCKJGSSXNWPO-SREVYHEPSA-N 0.000 description 2
- BHEFXBNRXLRAAE-WAYWQWQTSA-N 2-[[(Z)-hexadec-11-enoyl]amino]acetic acid Chemical compound C(CCCCCCCCC\C=C/CCCC)(=O)NCC(=O)O BHEFXBNRXLRAAE-WAYWQWQTSA-N 0.000 description 2
- OFBRCYKKKGVFRR-SEYXRHQNSA-N 2-[[(Z)-hexadec-4-enoyl]amino]acetic acid Chemical compound C(CC\C=C/CCCCCCCCCCC)(=O)NCC(=O)O OFBRCYKKKGVFRR-SEYXRHQNSA-N 0.000 description 2
- BTVJWEFRGIRSOS-QXMHVHEDSA-N 2-[[(Z)-hexadec-5-enoyl]amino]acetic acid Chemical compound C(CCC\C=C/CCCCCCCCCC)(=O)NCC(=O)O BTVJWEFRGIRSOS-QXMHVHEDSA-N 0.000 description 2
- YROGPZNZDQLVRV-KTKRTIGZSA-N 2-[[(Z)-hexadec-7-enoyl]amino]acetic acid Chemical compound C(CCCCC\C=C/CCCCCCCC)(=O)NCC(=O)O YROGPZNZDQLVRV-KTKRTIGZSA-N 0.000 description 2
- PHUJVDIGRWGQAT-HJWRWDBZSA-N 2-[[(Z)-octadec-10-enoyl]amino]acetic acid Chemical compound C(CCCCCCCC\C=C/CCCCCCC)(=O)NCC(=O)O PHUJVDIGRWGQAT-HJWRWDBZSA-N 0.000 description 2
- WDWPDZQGQZULKS-FPLPWBNLSA-N 2-[[(Z)-octadec-11-enoyl]amino]acetic acid Chemical compound C(CCCCCCCCC\C=C/CCCCCC)(=O)NCC(=O)O WDWPDZQGQZULKS-FPLPWBNLSA-N 0.000 description 2
- MNJZCMQANMRHTQ-SREVYHEPSA-N 2-[[(Z)-octadec-12-enoyl]amino]acetic acid Chemical compound C(CCCCCCCCCC\C=C/CCCCC)(=O)NCC(=O)O MNJZCMQANMRHTQ-SREVYHEPSA-N 0.000 description 2
- ZXSQYWFMZRMJAY-WAYWQWQTSA-N 2-[[(Z)-octadec-13-enoyl]amino]acetic acid Chemical compound C(CCCCCCCCCCC\C=C/CCCC)(=O)NCC(=O)O ZXSQYWFMZRMJAY-WAYWQWQTSA-N 0.000 description 2
- IZVUKZDCYPUMHR-ARJAWSKDSA-N 2-[[(Z)-octadec-15-enoyl]amino]acetic acid Chemical compound C(CCCCCCCCCCCCC\C=C/CC)(=O)NCC(=O)O IZVUKZDCYPUMHR-ARJAWSKDSA-N 0.000 description 2
- IEYIOHONHVEOEC-SEYXRHQNSA-N 2-[[(Z)-octadec-6-enoyl]amino]acetic acid Chemical compound C(CCCC\C=C/CCCCCCCCCCC)(=O)NCC(=O)O IEYIOHONHVEOEC-SEYXRHQNSA-N 0.000 description 2
- ZCOUUUNLNWINBD-QXMHVHEDSA-N 2-[[(Z)-octadec-7-enoyl]amino]acetic acid Chemical compound C(CCCCC\C=C/CCCCCCCCCC)(=O)NCC(=O)O ZCOUUUNLNWINBD-QXMHVHEDSA-N 0.000 description 2
- KDTWCYTUYWVPSS-KHPPLWFESA-N 2-[[(Z)-octadec-8-enoyl]amino]acetic acid Chemical compound C(CCCCCC\C=C/CCCCCCCCC)(=O)NCC(=O)O KDTWCYTUYWVPSS-KHPPLWFESA-N 0.000 description 2
- XBPUCXAVBXOKOU-WAYWQWQTSA-N 2-[[(Z)-tetradec-9-enoyl]amino]acetic acid Chemical compound C(CCCCCCC\C=C/CCCC)(=O)NCC(=O)O XBPUCXAVBXOKOU-WAYWQWQTSA-N 0.000 description 2
- HPFXACZRFJDURI-MDZDMXLPSA-N 2-[[(e)-octadec-9-enoyl]amino]acetic acid Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)NCC(O)=O HPFXACZRFJDURI-MDZDMXLPSA-N 0.000 description 2
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 101000710899 Homo sapiens Cannabinoid receptor 1 Proteins 0.000 description 2
- 101000875075 Homo sapiens Cannabinoid receptor 2 Proteins 0.000 description 2
- 101000693265 Homo sapiens Sphingosine 1-phosphate receptor 1 Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 235000019766 L-Lysine Nutrition 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- MZSJQKKCFOSWBW-VJIACCKLSA-N N-Oleoyl asparagine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)N[C@H](C(O)=O)CC(N)=O MZSJQKKCFOSWBW-VJIACCKLSA-N 0.000 description 2
- ATFITIQQSWCPIQ-XPTLAUCJSA-N N-Oleoyl methionine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)N[C@H](C(O)=O)CCSC ATFITIQQSWCPIQ-XPTLAUCJSA-N 0.000 description 2
- YWPIANMBCWTPEE-FPLPWBNLSA-N N-[(9Z)-hexadecenoyl]glycine Chemical compound CCCCCC\C=C/CCCCCCCC(=O)NCC(O)=O YWPIANMBCWTPEE-FPLPWBNLSA-N 0.000 description 2
- UUFVSGRELDGPGL-QJRAZLAKSA-N N-oleoyl-L-glutamic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)N[C@H](C(O)=O)CCC(O)=O UUFVSGRELDGPGL-QJRAZLAKSA-N 0.000 description 2
- JJUHWJQHBPFMJW-DYYZXQNHSA-N N-oleoyl-L-lysine zwitterion Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)N[C@H](C(O)=O)CCCCN JJUHWJQHBPFMJW-DYYZXQNHSA-N 0.000 description 2
- MBDKGXAMSZIDKF-VJIACCKLSA-N N-oleoyl-L-serine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)N[C@@H](CO)C(O)=O MBDKGXAMSZIDKF-VJIACCKLSA-N 0.000 description 2
- 102000005665 Neurotransmitter Transport Proteins Human genes 0.000 description 2
- 108010084810 Neurotransmitter Transport Proteins Proteins 0.000 description 2
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102100025750 Sphingosine 1-phosphate receptor 1 Human genes 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 208000005298 acute pain Diseases 0.000 description 2
- 102000030621 adenylate cyclase Human genes 0.000 description 2
- 108060000200 adenylate cyclase Proteins 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 102000015005 beta-adrenergic receptor activity proteins Human genes 0.000 description 2
- 108040006818 beta-adrenergic receptor activity proteins Proteins 0.000 description 2
- OVYQSRKFHNKIBM-UHFFFAOYSA-N butanedioic acid Chemical compound OC(=O)CCC(O)=O.OC(=O)CCC(O)=O OVYQSRKFHNKIBM-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- SNTLJBHXMIXXRG-AXUYNXDZSA-N dimethyl (2R)-2-[[(Z)-octadec-9-enoyl]amino]butanedioate Chemical compound C(CCCCCCC\C=C/CCCCCCCC)(=O)N[C@@H](C(=O)OC)CC(=O)OC SNTLJBHXMIXXRG-AXUYNXDZSA-N 0.000 description 2
- NDJRWOIEXLFCAE-SSSWZJSRSA-N dimethyl (2R)-2-[[(Z)-octadec-9-enoyl]amino]pentanedioate Chemical compound C(CCCCCCC\C=C/CCCCCCCC)(=O)N[C@@H](C(=O)OC)CCC(=O)OC NDJRWOIEXLFCAE-SSSWZJSRSA-N 0.000 description 2
- SNTLJBHXMIXXRG-GMGKOPGTSA-N dimethyl (2S)-2-[[(Z)-octadec-9-enoyl]amino]butanedioate Chemical compound C(CCCCCCC\C=C/CCCCCCCC)(=O)N[C@H](C(=O)OC)CC(=O)OC SNTLJBHXMIXXRG-GMGKOPGTSA-N 0.000 description 2
- NDJRWOIEXLFCAE-GJCOWUBNSA-N dimethyl (2s)-2-[[(z)-octadec-9-enoyl]amino]pentanedioate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)N[C@H](C(=O)OC)CCC(=O)OC NDJRWOIEXLFCAE-GJCOWUBNSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 230000007831 electrophysiology Effects 0.000 description 2
- 238000002001 electrophysiology Methods 0.000 description 2
- 230000009762 endothelial cell differentiation Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- UXUMQSGQJGSJKB-ZMAKUTRGSA-N ethyl (2R)-2-[[(Z)-octadec-9-enoyl]amino]-4-phenylbutanoate Chemical compound C(CCCCCCC\C=C/CCCCCCCC)(=O)N[C@@H](C(=O)OCC)CCC1=CC=CC=C1 UXUMQSGQJGSJKB-ZMAKUTRGSA-N 0.000 description 2
- UXUMQSGQJGSJKB-BMMGBYBSSA-N ethyl (2S)-2-[[(Z)-octadec-9-enoyl]amino]-4-phenylbutanoate Chemical compound C(CCCCCCC\C=C/CCCCCCCC)(=O)N[C@H](C(=O)OCC)CCC1=CC=CC=C1 UXUMQSGQJGSJKB-BMMGBYBSSA-N 0.000 description 2
- ACQQOGSJRAXWNA-MDZDMXLPSA-N ethyl 2-[[(E)-octadec-11-enoyl]amino]acetate Chemical compound C(CCCCCCCCC\C=C\CCCCCC)(=O)NCC(=O)OCC ACQQOGSJRAXWNA-MDZDMXLPSA-N 0.000 description 2
- JRSUNFBLEGVXDN-VAWYXSNFSA-N ethyl 2-[[(E)-octadec-9-enoyl]amino]acetate Chemical compound C(CCCCCCC\C=C\CCCCCCCC)(=O)NCC(=O)OCC JRSUNFBLEGVXDN-VAWYXSNFSA-N 0.000 description 2
- XQBRSCWJOWUXJO-HJWRWDBZSA-N ethyl 2-[[(Z)-hexadec-10-enoyl]amino]acetate Chemical compound C(CCCCCCCC\C=C/CCCCC)(=O)NCC(=O)OCC XQBRSCWJOWUXJO-HJWRWDBZSA-N 0.000 description 2
- QHSSSQAAQKWHIN-FPLPWBNLSA-N ethyl 2-[[(Z)-hexadec-11-enoyl]amino]acetate Chemical compound C(CCCCCCCCC\C=C/CCCC)(=O)NCC(=O)OCC QHSSSQAAQKWHIN-FPLPWBNLSA-N 0.000 description 2
- LQMLCGTVEDNCRX-PFONDFGASA-N ethyl 2-[[(Z)-hexadec-4-enoyl]amino]acetate Chemical compound C(CC\C=C/CCCCCCCCCCC)(=O)NCC(=O)OCC LQMLCGTVEDNCRX-PFONDFGASA-N 0.000 description 2
- GERVEHWWJRFPFI-YPKPFQOOSA-N ethyl 2-[[(Z)-hexadec-5-enoyl]amino]acetate Chemical compound C(CCC\C=C/CCCCCCCCCC)(=O)NCC(=O)OCC GERVEHWWJRFPFI-YPKPFQOOSA-N 0.000 description 2
- SIULIDGLJSBTTE-QXMHVHEDSA-N ethyl 2-[[(Z)-hexadec-7-enoyl]amino]acetate Chemical compound C(CCCCC\C=C/CCCCCCCC)(=O)NCC(=O)OCC SIULIDGLJSBTTE-QXMHVHEDSA-N 0.000 description 2
- OGMMNJDRLOPPFI-KTKRTIGZSA-N ethyl 2-[[(Z)-hexadec-9-enoyl]amino]acetate Chemical compound C(CCCCCCC\C=C/CCCCCC)(=O)NCC(=O)OCC OGMMNJDRLOPPFI-KTKRTIGZSA-N 0.000 description 2
- WKYHMRVHDFJVBJ-KHPPLWFESA-N ethyl 2-[[(Z)-octadec-10-enoyl]amino]acetate Chemical compound C(CCCCCCCC\C=C/CCCCCCC)(=O)NCC(=O)OCC WKYHMRVHDFJVBJ-KHPPLWFESA-N 0.000 description 2
- ACQQOGSJRAXWNA-KTKRTIGZSA-N ethyl 2-[[(Z)-octadec-11-enoyl]amino]acetate Chemical compound C(CCCCCCCCC\C=C/CCCCCC)(=O)NCC(=O)OCC ACQQOGSJRAXWNA-KTKRTIGZSA-N 0.000 description 2
- NBCDOQXMJDSRAN-HJWRWDBZSA-N ethyl 2-[[(Z)-octadec-12-enoyl]amino]acetate Chemical compound C(CCCCCCCCCC\C=C/CCCCC)(=O)NCC(=O)OCC NBCDOQXMJDSRAN-HJWRWDBZSA-N 0.000 description 2
- VAAKWTQEFPHHHP-FPLPWBNLSA-N ethyl 2-[[(Z)-octadec-13-enoyl]amino]acetate Chemical compound C(CCCCCCCCCCC\C=C/CCCC)(=O)NCC(=O)OCC VAAKWTQEFPHHHP-FPLPWBNLSA-N 0.000 description 2
- AVRUFXBHKFCIAO-WAYWQWQTSA-N ethyl 2-[[(Z)-octadec-15-enoyl]amino]acetate Chemical compound C(CCCCCCCCCCCCC\C=C/CC)(=O)NCC(=O)OCC AVRUFXBHKFCIAO-WAYWQWQTSA-N 0.000 description 2
- JUISRVOQOHVDRB-PFONDFGASA-N ethyl 2-[[(Z)-octadec-6-enoyl]amino]acetate Chemical compound C(CCCC\C=C/CCCCCCCCCCC)(=O)NCC(=O)OCC JUISRVOQOHVDRB-PFONDFGASA-N 0.000 description 2
- IPITWSMDDQMLPD-YPKPFQOOSA-N ethyl 2-[[(Z)-octadec-7-enoyl]amino]acetate Chemical compound C(CCCCC\C=C/CCCCCCCCCC)(=O)NCC(=O)OCC IPITWSMDDQMLPD-YPKPFQOOSA-N 0.000 description 2
- AGPONSNLDKLLCR-SEYXRHQNSA-N ethyl 2-[[(Z)-octadec-8-enoyl]amino]acetate Chemical compound C(CCCCCC\C=C/CCCCCCCCC)(=O)NCC(=O)OCC AGPONSNLDKLLCR-SEYXRHQNSA-N 0.000 description 2
- CLKBZYWFCMMGFZ-FPLPWBNLSA-N ethyl 2-[[(Z)-tetradec-9-enoyl]amino]acetate Chemical compound C(CCCCCCC\C=C/CCCC)(=O)NCC(=O)OCC CLKBZYWFCMMGFZ-FPLPWBNLSA-N 0.000 description 2
- BLTDAQZPUGWYIH-QXMHVHEDSA-N ethyl 3-[[(Z)-octadec-9-enoyl]amino]propanoate Chemical compound C(CCCCCCC\C=C/CCCCCCCC)(=O)NCCC(=O)OCC BLTDAQZPUGWYIH-QXMHVHEDSA-N 0.000 description 2
- RVICDIQCDUVBFK-UHFFFAOYSA-N ethyl 9-oxononanoate Chemical compound CCOC(=O)CCCCCCCC=O RVICDIQCDUVBFK-UHFFFAOYSA-N 0.000 description 2
- 230000002964 excitative effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229960002870 gabapentin Drugs 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 102000056964 human CNR1 Human genes 0.000 description 2
- 102000056693 human CNR2 Human genes 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- RSQQPMFXVJGVBB-ZXAYODBVSA-N methyl (2R)-2-[[(Z)-octadec-9-enoyl]amino]-3-phenylpropanoate Chemical compound C(CCCCCCC\C=C/CCCCCCCC)(=O)N[C@@H](C(=O)OC)CC1=CC=CC=C1 RSQQPMFXVJGVBB-ZXAYODBVSA-N 0.000 description 2
- XSZDZHDHRAADLS-JPMGXVIASA-N methyl (2R)-3-hydroxy-2-[[(Z)-octadec-9-enoyl]amino]propanoate Chemical compound OC[C@H](C(=O)OC)NC(CCCCCCC\C=C/CCCCCCCC)=O XSZDZHDHRAADLS-JPMGXVIASA-N 0.000 description 2
- BDDWRKXMJREHSW-WHIOSMTNSA-N methyl (2R)-3-methyl-2-[[(Z)-octadec-9-enoyl]amino]butanoate Chemical compound CC([C@H](C(=O)OC)NC(CCCCCCC\C=C/CCCCCCCC)=O)C BDDWRKXMJREHSW-WHIOSMTNSA-N 0.000 description 2
- SSOSPDIRBOJFIR-WHIOSMTNSA-N methyl (2R)-4-methyl-2-[[(Z)-octadec-9-enoyl]amino]pentanoate Chemical compound CC(C[C@H](C(=O)OC)NC(CCCCCCC\C=C/CCCCCCCC)=O)C SSOSPDIRBOJFIR-WHIOSMTNSA-N 0.000 description 2
- LIQUWFTWDIOWPE-GMAFFVFYSA-N methyl (2R)-5-(diaminomethylideneamino)-2-[[(Z)-octadec-9-enoyl]amino]pentanoate Chemical compound N(C(=N)N)CCC[C@H](C(=O)OC)NC(CCCCCCC\C=C/CCCCCCCC)=O LIQUWFTWDIOWPE-GMAFFVFYSA-N 0.000 description 2
- OERXIXTXECIDQQ-DSTYWPJMSA-N methyl (2S)-2-[[(Z)-octadec-9-enoyl]amino]hexanoate Chemical compound C(CCCCCCC\C=C/CCCCCCCC)(=O)N[C@H](C(=O)OC)CCCC OERXIXTXECIDQQ-DSTYWPJMSA-N 0.000 description 2
- QJHDMAMUXFMRSO-DUQGCJEPSA-N methyl (2S)-2-[[(Z)-octadec-9-enoyl]amino]propanoate Chemical compound C(CCCCCCC\C=C/CCCCCCCC)(=O)N[C@H](C(=O)OC)C QJHDMAMUXFMRSO-DUQGCJEPSA-N 0.000 description 2
- MKUPWXREPWMRNL-PISNEZEASA-N methyl (2S)-4-amino-2-[[(Z)-octadec-9-enoyl]amino]-4-oxobutanoate Chemical compound NC(C[C@@H](C(=O)OC)NC(CCCCCCC\C=C/CCCCCCCC)=O)=O MKUPWXREPWMRNL-PISNEZEASA-N 0.000 description 2
- LIQUWFTWDIOWPE-YRBAHSOBSA-N methyl (2S)-5-(diaminomethylideneamino)-2-[[(Z)-octadec-9-enoyl]amino]pentanoate Chemical compound N(C(=N)N)CCC[C@@H](C(=O)OC)NC(CCCCCCC\C=C/CCCCCCCC)=O LIQUWFTWDIOWPE-YRBAHSOBSA-N 0.000 description 2
- RSQQPMFXVJGVBB-SGAGCNABSA-N methyl (2s)-2-[[(z)-octadec-9-enoyl]amino]-3-phenylpropanoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 RSQQPMFXVJGVBB-SGAGCNABSA-N 0.000 description 2
- WKRWTWRSYXRGFE-JCKUYFFHSA-N methyl (2s)-3-(1h-imidazol-5-yl)-2-[[(z)-octadec-9-enoyl]amino]propanoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)N[C@H](C(=O)OC)CC1=CN=CN1 WKRWTWRSYXRGFE-JCKUYFFHSA-N 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000000287 oocyte Anatomy 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 230000001242 postsynaptic effect Effects 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 239000011698 potassium fluoride Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 150000003408 sphingolipids Chemical class 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000005062 synaptic transmission Effects 0.000 description 2
- 230000027682 synaptic transmission, glycinergic Effects 0.000 description 2
- 210000002504 synaptic vesicle Anatomy 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- BDLLSHRIFPDGQB-WAYWQWQTSA-N (13Z)-octadecenoic acid Chemical compound CCCC\C=C/CCCCCCCCCCCC(O)=O BDLLSHRIFPDGQB-WAYWQWQTSA-N 0.000 description 1
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- QJFAABXOMYWNGP-MZMPXXGTSA-N (2R)-3-(1H-imidazol-5-yl)-2-[[(Z)-octadec-9-enoyl]amino]propanoic acid Chemical compound N1C=NC=C1C[C@H](C(=O)O)NC(CCCCCCC\C=C/CCCCCCCC)=O QJFAABXOMYWNGP-MZMPXXGTSA-N 0.000 description 1
- SGIXTLBWSQGBIX-HZQHCPKGSA-N (2R)-6-amino-2-[[(Z)-hexadec-13-enoyl]amino]hexanoic acid Chemical compound NCCCC[C@H](C(=O)O)NC(CCCCCCCCCCC\C=C/CC)=O SGIXTLBWSQGBIX-HZQHCPKGSA-N 0.000 description 1
- ZKZZLZUYMHQEPU-VJIACCKLSA-N (2S)-3-amino-2-[[(Z)-octadec-9-enoyl]amino]propanoic acid Chemical compound NC[C@@H](C(=O)O)NC(CCCCCCC\C=C/CCCCCCCC)=O ZKZZLZUYMHQEPU-VJIACCKLSA-N 0.000 description 1
- OXGMPGKZDZPDIF-SEYXRHQNSA-N (4Z)-hexadecenoic acid Chemical compound CCCCCCCCCCC\C=C/CCC(O)=O OXGMPGKZDZPDIF-SEYXRHQNSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- IPOLTUVFXFHAHI-WHIOSMTNSA-N (R)-oleoylcarnitine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C IPOLTUVFXFHAHI-WHIOSMTNSA-N 0.000 description 1
- JGMYDQCXGIMHLL-WAYWQWQTSA-N (Z)-hexadec-11-enoic acid Chemical compound CCCC\C=C/CCCCCCCCCC(O)=O JGMYDQCXGIMHLL-WAYWQWQTSA-N 0.000 description 1
- PJHOFUXBXJNUAC-KTKRTIGZSA-N (Z)-hexadec-7-enoic acid Chemical compound CCCCCCCC\C=C/CCCCCC(O)=O PJHOFUXBXJNUAC-KTKRTIGZSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- OXEDXHIBHVMDST-SREVYHEPSA-N (z)-octadec-12-enoic acid Chemical compound CCCCC\C=C/CCCCCCCCCCC(O)=O OXEDXHIBHVMDST-SREVYHEPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-KHPPLWFESA-N (z)-octadec-8-enoic acid Chemical compound CCCCCCCCC\C=C/CCCCCCC(O)=O WRIDQFICGBMAFQ-KHPPLWFESA-N 0.000 description 1
- KVXIRQZWCOAYRD-QXMHVHEDSA-N 16:1(5Z) Chemical compound CCCCCCCCCC\C=C/CCCC(O)=O KVXIRQZWCOAYRD-QXMHVHEDSA-N 0.000 description 1
- IAWXTSMHXFRLQR-UHFFFAOYSA-N 2,3-bis($l^{1}-oxidanyl)-7-nitroquinoxaline-6-carbonitrile Chemical compound O=C1C(=O)N=C2C=C(C#N)C([N+](=O)[O-])=CC2=N1 IAWXTSMHXFRLQR-UHFFFAOYSA-N 0.000 description 1
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- RVUCYJXFCAVHNC-QXMHVHEDSA-N 7Z-octadecenoic acid Chemical compound CCCCCCCCCC\C=C/CCCCCC(O)=O RVUCYJXFCAVHNC-QXMHVHEDSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 description 1
- 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 description 1
- 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 description 1
- 229930195721 D-histidine Natural products 0.000 description 1
- 229930182827 D-tryptophan Natural products 0.000 description 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000868549 Homo sapiens Voltage-dependent calcium channel gamma-like subunit Proteins 0.000 description 1
- DRAJWRKLRBNJRQ-UHFFFAOYSA-N Hydroxycarbamic acid Chemical compound ONC(O)=O DRAJWRKLRBNJRQ-UHFFFAOYSA-N 0.000 description 1
- 150000008545 L-lysines Chemical class 0.000 description 1
- 108010022337 Leucine Enkephalin Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101000726683 Metarhizium anisopliae Cuticle-degrading protease Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- QJFAABXOMYWNGP-DYYZXQNHSA-N N-Oleoyl histidine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 QJFAABXOMYWNGP-DYYZXQNHSA-N 0.000 description 1
- YLEARPUNMCCKMP-DOFZRALJSA-N N-arachidonoylglycine Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCC(O)=O YLEARPUNMCCKMP-DOFZRALJSA-N 0.000 description 1
- BAQMYDQNMFBZNA-UHFFFAOYSA-N N-biotinyl-L-lysine Natural products N1C(=O)NC2C(CCCCC(=O)NCCCCC(N)C(O)=O)SCC21 BAQMYDQNMFBZNA-UHFFFAOYSA-N 0.000 description 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- LHNKBXRFNPMIBR-UHFFFAOYSA-N Picrotoxin Natural products CC(C)(O)C1(O)C2OC(=O)C1C3(O)C4OC4C5C(=O)OC2C35C LHNKBXRFNPMIBR-UHFFFAOYSA-N 0.000 description 1
- 206010035039 Piloerection Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- PJIHCWJOTSJIPQ-AGFFZDDWSA-N S-(cis-1,2-dichlorovinyl)-L-cysteine Chemical compound OC(=O)[C@@H](N)CS\C(Cl)=C\Cl PJIHCWJOTSJIPQ-AGFFZDDWSA-N 0.000 description 1
- 229910006069 SO3H Inorganic materials 0.000 description 1
- 241001279009 Strychnos toxifera Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 102100032336 Voltage-dependent calcium channel gamma-like subunit Human genes 0.000 description 1
- 241000269368 Xenopus laevis Species 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229940093740 amino acid and derivative Drugs 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 238000011953 bioanalysis Methods 0.000 description 1
- 238000004638 bioanalytical method Methods 0.000 description 1
- BAQMYDQNMFBZNA-MNXVOIDGSA-N biocytin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCC[C@H](N)C(O)=O)SC[C@@H]21 BAQMYDQNMFBZNA-MNXVOIDGSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 239000000460 chlorine Chemical group 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- HZJHNXIAYMADBX-SREVYHEPSA-N cis-10-palmitoleic acid Chemical compound CCCCC\C=C/CCCCCCCCC(O)=O HZJHNXIAYMADBX-SREVYHEPSA-N 0.000 description 1
- UWHZIFQPPBDJPM-FPLPWBNLSA-N cis-vaccenic acid Chemical compound CCCCCC\C=C/CCCCCCCCCC(O)=O UWHZIFQPPBDJPM-FPLPWBNLSA-N 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 125000006003 dichloroethyl group Chemical group 0.000 description 1
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- HCWYSCVNSCIZCN-UHFFFAOYSA-L dipotassium;6-amino-2-(hydrazinecarbonylamino)-1,3-dioxobenzo[de]isoquinoline-5,8-disulfonate Chemical compound [K+].[K+].[O-]S(=O)(=O)C1=CC(C(N(NC(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N HCWYSCVNSCIZCN-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- CMZVCJUONJKRGZ-UHFFFAOYSA-N ethyl 11-hydroxyundecanoate Chemical compound CCOC(=O)CCCCCCCCCCO CMZVCJUONJKRGZ-UHFFFAOYSA-N 0.000 description 1
- UZJLPIKFVDJBKW-UHFFFAOYSA-N ethyl 11-oxoundecanoate Chemical compound CCOC(=O)CCCCCCCCCC=O UZJLPIKFVDJBKW-UHFFFAOYSA-N 0.000 description 1
- DYFVMVODIGRODW-UHFFFAOYSA-N ethyl 12-bromododecanoate Chemical compound CCOC(=O)CCCCCCCCCCCBr DYFVMVODIGRODW-UHFFFAOYSA-N 0.000 description 1
- IFMXKKMHMPBTBD-UHFFFAOYSA-N ethyl 12-cyanododecanoate Chemical compound CCOC(=O)CCCCCCCCCCCC#N IFMXKKMHMPBTBD-UHFFFAOYSA-N 0.000 description 1
- RDXXXMKZHHUPJK-UHFFFAOYSA-N ethyl 12-hydroxydodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCO RDXXXMKZHHUPJK-UHFFFAOYSA-N 0.000 description 1
- WVLXAAYOSTYIMM-UHFFFAOYSA-N ethyl 12-oxododecanoate Chemical compound CCOC(=O)CCCCCCCCCCC=O WVLXAAYOSTYIMM-UHFFFAOYSA-N 0.000 description 1
- VBUFDQHNGGVOEO-UHFFFAOYSA-N ethyl 13-oxotridecanoate Chemical compound CCOC(=O)CCCCCCCCCCCC=O VBUFDQHNGGVOEO-UHFFFAOYSA-N 0.000 description 1
- GHXXCVVSJXZBPO-UHFFFAOYSA-N ethyl 4-cyanobutanoate Chemical compound CCOC(=O)CCCC#N GHXXCVVSJXZBPO-UHFFFAOYSA-N 0.000 description 1
- WUPBOSISFPJABC-UHFFFAOYSA-N ethyl 5-oxopentanoate Chemical compound CCOC(=O)CCCC=O WUPBOSISFPJABC-UHFFFAOYSA-N 0.000 description 1
- WPGIMPZMPWRYAI-UHFFFAOYSA-N ethyl 6-cyanohexanoate Chemical compound CCOC(=O)CCCCCC#N WPGIMPZMPWRYAI-UHFFFAOYSA-N 0.000 description 1
- YRZBNZFCPRWFLV-UHFFFAOYSA-N ethyl 7-cyanoheptanoate Chemical compound CCOC(=O)CCCCCCC#N YRZBNZFCPRWFLV-UHFFFAOYSA-N 0.000 description 1
- SQOMZPCAODNNSO-UHFFFAOYSA-N ethyl 7-oxoheptanoate Chemical compound CCOC(=O)CCCCCC=O SQOMZPCAODNNSO-UHFFFAOYSA-N 0.000 description 1
- SPBRBECWCQSNAC-UHFFFAOYSA-N ethyl 8-bromododecanoate Chemical compound BrC(CCCCCCC(=O)OCC)CCCC SPBRBECWCQSNAC-UHFFFAOYSA-N 0.000 description 1
- XJEWBTQAVJJRQQ-UHFFFAOYSA-N ethyl 8-cyanooctanoate Chemical compound CCOC(=O)CCCCCCCC#N XJEWBTQAVJJRQQ-UHFFFAOYSA-N 0.000 description 1
- GJVAZCWMBXCJQT-UHFFFAOYSA-N ethyl 8-oxooctanoate Chemical compound CCOC(=O)CCCCCCC=O GJVAZCWMBXCJQT-UHFFFAOYSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Chemical group 0.000 description 1
- 229910052740 iodine Chemical group 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- URLZCHNOLZSCCA-UHFFFAOYSA-N leu-enkephalin Chemical compound C=1C=C(O)C=CC=1CC(N)C(=O)NCC(=O)NCC(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=CC=C1 URLZCHNOLZSCCA-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 231100000875 loss of motor control Toxicity 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- WKRWTWRSYXRGFE-ZXEGGCGDSA-N methyl (2R)-3-(1H-imidazol-5-yl)-2-[[(Z)-octadec-9-enoyl]amino]propanoate Chemical compound N1C=NC=C1C[C@H](C(=O)OC)NC(CCCCCCC\C=C/CCCCCCCC)=O WKRWTWRSYXRGFE-ZXEGGCGDSA-N 0.000 description 1
- HVCMDAHNKIHECT-FPLPWBNLSA-N methyl (Z)-hexadec-10-enoate Chemical compound C(CCCCCCCC\C=C/CCCCC)(=O)OC HVCMDAHNKIHECT-FPLPWBNLSA-N 0.000 description 1
- VSQOWXZPURLKCU-YPKPFQOOSA-N methyl (Z)-hexadec-4-enoate Chemical compound C(CC\C=C/CCCCCCCCCCC)(=O)OC VSQOWXZPURLKCU-YPKPFQOOSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000006491 negative regulation of transport Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007372 neural signaling Effects 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 229940124707 pain therapeutics Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000010254 physiological adaptation Effects 0.000 description 1
- VJKUPQSHOVKBCO-AHMKVGDJSA-N picrotoxin Chemical compound O=C([C@@]12O[C@@H]1C[C@]1(O)[C@@]32C)O[C@@H]3[C@H]2[C@@H](C(=C)C)[C@@H]1C(=O)O2.O=C([C@@]12O[C@@H]1C[C@]1(O)[C@@]32C)O[C@@H]3[C@H]2[C@@H](C(C)(O)C)[C@@H]1C(=O)O2 VJKUPQSHOVKBCO-AHMKVGDJSA-N 0.000 description 1
- 230000005371 pilomotor reflex Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005453 strychnine Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000001055 substantia gelatinosa Anatomy 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229960005137 succinic acid Drugs 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/49—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
- C07C321/12—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms
- C07C321/14—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
- C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
Definitions
- the present invention relates to novel glycine transport inhibitor compounds and their use for treating pain.
- Background of the invention
- Chronic pain is a significant global health, economic and social problem, with the annual economic burden in the USA recently estimated at $600 billion.
- the disease burden of pain has been documented in a rigorous epidemiological study, which revealed that -20% of adults have poor self-rated health as a consequence of chronic pain.
- the economic burden of unrelieved persistent pain in Australia is large and continuing to escalate, with a total cost of $34 billion in 2007.
- the major analgesics used clinically were limited to non-steroidal, local anaesthetic, opioid and anticonvulsant drugs that provide adequate pain relief in only a small proportion of chronic pain patients.
- newer classes of analgesics also have limited efficacy, with the most effective, gabapentin, at best providing only 50% reduction in pain scores in chronic pain, with the number needed to treat for a clinical response being > 4.
- GlyT2 glycine transporter 2
- Neurotransmitter transporters are responsible for regulating the synaptic concentration of monoamines (5-hydroxytryptamine, dopamine, noradrenaline) and amino acid ( ⁇ -aminobutyric acid, glycine) neurotransmitters. These membrane-bound proteins use electrochemical gradients to drive the transport of neurotransmitters across neuronal and glial membranes, serving to terminate neurotransmission and replenish intracellular levels of neurotransmitter for future release.
- neurotransmitter transporters to selectively enhance or diminish neuronal signalling makes them attractive drug targets. Indeed, a wide range of therapeutically useful drugs, including antidepressants and anxiolytics, target these proteins. Diminished glycinergic transmission is an important CNS mechanism underlying neuropathic pain including mechanical hyperalgesia and allodynia (a painful response to normally innocuous tactile stimuli). Drugs that can enhance dysfunctional glycerinergic transmission in neuropathic pain, and in particular glycine transporter inhibitors, are potential chronic pain therapeutics.
- GlyT1 and GlyT2 which serve to regulate glycine concentrations.
- GlyT1 is expressed throughout the CNS predominantly by astrocytes surrounding both inhibitory and excitatory synapses to influence Glycine and NMDA receptors (NMDAR). Enhancement of NMDAR activity by GlyT1 inhibition is an established therapeutic target in diseases with NMDAR hypofunction, such as schizophrenia, but is undesirable in chronic pain states where suppression of NMDAR function is desirable.
- GlyT2 is considered a promising therapeutic target for chronic pain.
- GlyT2 shows much more restricted expression patterns than GlyT1 and is predominantly expressed by glycinergic terminals in the spinal cord and brain stem.
- GlyT2 plays two important roles at glycinergic inhibitory synapses: regulation of extracellular glycine concentrations to control inhibitory glycinergic tone, and to recycle released glycine to provide sufficient intracellular glycine for repackaging into synaptic vesicles for subsequent release.
- GlyT2 Glycine receptors
- ALX1393 shows only a 10-fold selectivity for GlyT2 over GlyT1 , and the dose required for analgesia may also result in partial inhibition of GlyT1 and increases in glycine at excitatory synapses leading to an initial increase in NMDAR-related pain before analgesia is achieved.
- ORG25543 causes respiratory depression and loss of motor control at high doses which has been attributed to irreversible inhibition of GlyT2 with subsequent reductions in glycine loading of synaptic vesicles. Partial knock down of GlyT2 using siRNAs indicates that partial inhibitors of GlyT2 have the potential to be therapeutic in the treatment of neuropathic pain.
- GlyT2 Knockdown of GlyT2 to approximately 30% of wild type levels (which may mimic partial inhibition of transport) provides analgesia in rat models of allodynia associated with neuropathic pain.
- the equilibrium glycine concentration gradient achieved by GlyT2 is determined by the ion gradients across the cell membrane, whereas the rate at which equilibrium is achieved will be determined by the number of glycine transporters.
- partial inhibition will not alter the equilibrium glycine concentration gradient, but will prolong the time required to reach equilibrium, allowing greater glycine receptor activity. It appears that partial inhibition of glycine transport in the siRNA knock-down experiments allows sufficient glycine uptake for loading of presynaptic glycinergic vesicles to maintain, or even prolong, glycinergic neurotransmission.
- the present invention provides a compound of formula (I):
- X is an amino acid or derivative thereof
- L is an amide or retro amide
- Y is C 10 - C 24 alkyl or alkenyl
- X, L and Y may be independently substituted or unsubstituted
- the present invention provides a compound of formula (I) as defined above wherein the compound is not one or more of the compounds selected from the group consisting of:
- a pharmaceutical composition comprising a compound according to the invention, a salt or a pharmaceutically acceptable derivative thereof, together with one or more pharmaceutically acceptable carriers or adjuvants.
- a method of treating pain by administering an effective amount of a compound according to the invention, a salt or a pharmaceutically acceptable derivative thereof, to a subject in need thereof.
- a compound according to the invention for use in treatment of pain in a subject in need thereof.
- a method of treating pain by administering an effective amount of at least one compound selected from the group consisting of:
- the pain may be chronic or acute.
- the pain is chronic pain, more preferably neuropathic pain.
- Fig. 1 shows plasma concentration vs time profiles for Compounds 28, 29, 8, 1 and 36, following incubations at 37°C in human ( ⁇ ) and rat ( ⁇ ) plasma.
- Fig. 2 shows elPSC amplitude (A), tonic current (B) and decay time constant (C) graphs of Compound 28.
- Fig. 3 shows elPSC amplitude (A), tonic current (B) and decay time constant (C) graphs of Compound 39.
- Fig. 4 shows elPSC amplitude (A), tonic current (B) and decay time constant (C) graphs of Oleoyl-L-carnitine.
- Fig. 5 shows elPSC amplitude (A), tonic current (B) and decay time constant (C) graphs of N-arachidonyl glycine.
- Fig. 6 shows elPSC amplitude (A), tonic current (B) and decay time constant (C) graphs Oleoyl-L-glycine.
- Fig. 7 shows plasma and brain concentrations of Compound 29 in male Sprague Dawley rats following IP administration at 27.5 mg/kg.
- Fig. 8 shows the agonist activity of Compounds 1 , 2, 16, 25, 28, 29, 36, 65, 27 and 39 on S1 PR1 .
- Fig. 9 shows the antagonist activity of Compounds 1 , 2, 16, 25, 28, 29, 36, 65,
- FIG. 10 shows the agonist activity of Compounds 1 , 2, 16, 25, 28, 29, 36, 65, 27 and 39 on CB2.
- Fig. 11 shows the antagonist activity of Compounds 1 , 2, 16, 25, 28, 29, 36, 65, 27 and 39 on CB2.
- Fig. 12 shows the agonist activity of Compounds 1 , 2, 16, 25, 28, 29, 36, 65, 27 and 39 on CB1 .
- Fig. 13 shows the antagonist activity of Compounds 1 , 2, 16, 25, 28, 29, 36, 65, 27 and 39 on CB1 .
- Fig. 14 shows the analgesic effect of intrathecal administration of Compound 29.
- Fig. 15 shows the analgesic effect of intraperitoneal administration of Compound
- the present invention provides a compound of formula (I):
- X is an amino acid or derivative thereof
- L is an amide or retro amide
- Y is Cio - C 24 alkyl or alkenyl
- X, L and Y may be independently substituted or unsubstituted
- the present invention provides a compound of formula (I) as defined above wherein the compound is not one or more of the compounds selected from the group consisting of:
- X is a naturally occurring or non-naturally occurring amino acid.
- X is a naturally occurring hydrophobic and/or aromatic amino acid, more preferably L-tryptophan.
- X is a non- naturally occurring amino acid, more preferably a D-amino acid.
- X is selected from one or more of the group consisting of glycine, L-carnitine, L-serine, D-serine, L-lysine, D-lysine, L-lysine derivative wherein the carbon chain of the lysine side group is of C1 -C3 in length, L-arginine, L-methionine, L-leucine, D-leucine, L-alanine, D-alanine, B-alanine, L-valine,- D-valine, D-phenylalanine, L- phenylalanine derivative wherein the carbon chain of the phenylalanine side group is of two carbons in length, L-tryptophan, D-tryptophan, L-tyrosinol- L-dopamine, L-aspartate, D-aspartate, L-glutamate, L-histidine, D-histidine, L-lysine OME, L-norleu
- X is unsubstituted.
- X is substituted with 1 , 2, or 3 C 1 - C 3 alkyl groups at the a carbon of the amino acid or derivative thereof.
- the C 1 - C 3 alkyl group is methyl.
- X is lysine substituted with 1 , 2, or 3 methyl groups at the a carbon of the lysine. Substituting X as described herein, advantageously increases the metabolic stability and efficacy of the compounds of the invention by minimising in vivo degradation of the linking group, L.
- L is an amide
- L is unsubstituted.
- L is substituted with a C 1 - C 3 alkyl group at the nitrogen of the amide or retro amide.
- the C 1 -C 3 alkyl group is methyl.
- Y includes 1 - 4 cis double bonds, more preferably Y is monounsaturated and includes 1 cis double bond.
- the single cis double bond may be at any position of the C 10 - C 24 alkenyl chain, preferably 5 - 15 carbons from L, more preferably 8 - 10 carbons from L.
- Y includes 1 -4 trans double bonds. More preferably, Y is monounsaturated and includes 1 trans double bond.
- the single trans double bond may '1Ut>
- the do - C 24 alkenyl chain preferably 5 - 15 carbons from L, more preferably 8 - 10 carbons from L, more preferably 9 carbons from L.
- Y is a monounsaturated Ci 8 , Ci 6 or Ci 4 chain, preferably a monounsaturated Ci 8 chain.
- the monounsaturated Ci 8 carbon chain includes a cis-double bond in the ⁇ 3, 5, 6, 7, 8, 9, 10, 1 1 , or 12 position, more preferably in the ⁇ 9 position.
- the monounsaturated Ci 6 carbon chain includes a cis-double bond in the ⁇ 5, 6, 7, 9, or 1 1 position.
- Y is a saturated Ci 6 or Cu carbon chain.
- the compound is selected from one or more of compounds 2 - 7, 9 - 12, 1 7 - 21 , 23, 26 - 44, 47 - 54 of Table 1 .
- the compound is selected from one or more of compounds 2 - 7, 1 0 - 1 2, 17, 18, 20, 21 , 23, 28 - 34, 37, 42, 43, 48 and 52 of Table 1 .
- the invention also relates to methods of treating pain by administering an effective amount of a compound according to the invention, a salt or pharmaceutically acceptable derivative thereof, to a subject in need thereof.
- a compound according to the invention a salt or a pharmaceutically acceptable derivative thereof for use in treatment of pain in a subject in need thereof.
- the pain may be acute or chronic, preferably chronic.
- the pain is neuropathic pain.
- amino acid as used herein is intended to encompass compounds having an amino group and a carboxyl group in which the amino group and the carboxyl group are separated by at least one carbon atom.
- the amino acid may be a L- or D- isomer and may have a naturally occurring side chain or a non-naturally occurring side chain.
- An amino acid having a non-naturally occurring side chain refers to an amino acid having a side chain that does not occur in the naturally occurring L-a-amino acids.
- non-natural amino acids and derivatives include, but are not limited to amino acids substituted with 1 , 2 or 3 C1-C3 alkyl groups at the a carbon of the amino acid, L-carnitine, gamma aminobutyric acid (GABA), dopamine, L-lysine OMe and/or D- isomers of amino acids.
- amino acids substituted with 1 , 2 or 3 C1-C3 alkyl groups at the a carbon of the amino acid L-carnitine, gamma aminobutyric acid (GABA), dopamine, L-lysine OMe and/or D- isomers of amino acids.
- amino acid derivative as used herein is intended to encompass derivatives of naturally occurring and non-naturally occurring amino acids, preferably ester derivatives of naturally occurring and non-naturally occurring amino acids. It also encompasses amino acids that have had their side chain modified, for example, the hydrocarbon chain shortened or extended. Some non-limiting examples of these are shown below for lysine and phenylalanine:
- retro amide refers to a reverse amide bond wherein the nitrogen of the amide bond is located on the proximal side of the carbonyl group, ie (NHCO).
- alkyl refers to a saturated, straight-chain or branched hydrocarbon group. Specific examples of alkyl groups are methyl, ethyl, propyl, / ' so-propyl, n-butyl, / ' so-butyl, sec-butyl, te/t-butyl, n-pentyl, / ' so-pentyl, n-hexyl and 2,2-dimethylbutyl.
- alkenyl refers to an at least partially unsaturated, straight-chain or branched hydrocarbon group that contains at least two carbon atoms (i.e. C2 alkenyl).
- alkenyl groups are ethenyl (vinyl), propenyl (allyl), / ' so-propenyl, butenyl, ethinyl, propinyl, butinyl, acetylenyl, propargyl, / ' so-prenyl and hex-2-enyl group.
- alkenyl groups have one or two double bond(s).
- This expression also refers to a group that is substituted by one, two, three or more alkyl, alkenyl or heteroalkyl (e.g. -OCH 3 , -OCH 2 CH 3 , -CH 2 NHCH 3 and -CH 2 NH 2 ) groups. These groups may themselves be substituted.
- an alkyl group substituent may be substituted by one or more halogen atoms (i.e. may be a haloalkyl group, such as trifluoromethyl, dichloroethyl, dichloromethyl and iodoethyl).
- halogen atoms i.e. may be a haloalkyl group, such as trifluoromethyl, dichloroethyl, dichloromethyl and iodoethyl.
- a wording defining the limits of a range of length such as, for example, "from 1 to 5" means any integer from 1 to 5, i.e. 1 , 2, 3, 4 and 5.
- any range defined by two integers explicitly mentioned is meant to comprise and disclose any integer defining said limits and any integer comprised in said range.
- pharmaceutically acceptable derivative may include any pharmaceutically acceptable salt, hydrate or prodrug, or any other compound which upon administration to a subject, is capable of providing (directly or indirectly) a compound of the present invention or a pharmaceutically active metabolite or residue thereof.
- Suitable pharmaceutically acceptable salts include, but are not limited to, salts of acids such as hydrochloric, phosphoric, hydrobromic, malic, glycolic, fumaric, sulfuric, sulfamic, sulfanilic, formic, toluenesulfonic, methanesulfonic, benzenesulfonic, ethane disulfonic, 2-hydroxyethylsulfonic, nitric, benzoic, 2-acetoxybenzoic, citric, tartaric, lactic, stearic, salicylic, glutamic, ascorbic, pamoic, succinic, fumaric, maleic, propionic, hydroxymaleic, hydroiodic, phenylacetic, alkanoic (such as acetic, HOOC-(CH 2 ) n -COOH where n is any integer from 0 to 6, i.e.
- acids such as hydrochloric, phosphoric, hydrobromic, malic, glyco
- a pharmaceutically acceptable acid or base salt can be synthesized from a parent compound that contains a basic or acidic moiety by any conventional chemical method. Briefly, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent (such as ether, ethyl acetate, ethanol, isopropanol or acetonitrile), or in a mixture of the two.
- an organic solvent such as ether, ethyl acetate, ethanol, isopropanol or acetonitrile
- a “prodrug” is a compound that may not fully satisfy the structural requirements of the compounds provided herein, but is modified in vivo, following administration to a subject or patient, to produce a compound provided herein.
- a prodrug may be an acylated derivative of a compound as provided herein.
- Prodrugs include compounds wherein hydroxy, carboxy, amine or sulfhydryl groups are bonded to any group that, when administered to a mammalian subject, cleaves to form a free hydroxy, carboxy, amino, or sulfhydryl group, respectively.
- Examples of prodrugs include, but are not limited to, acetate, formate, phosphate and benzoate derivatives of alcohol and amine functional groups within the compounds provided herein.
- Prodrugs of the compounds provided herein may be prepared by modifying functional groups present in the compounds in such a way that the modifications are cleaved in vivo to generate the parent compounds.
- composition as used herein is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
- pharmaceutically acceptable it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
- This invention thus further provides a pharmaceutical formulation or composition
- a pharmaceutical formulation or composition comprising a compound of the invention or a pharmaceutically acceptable salt or derivative thereof together with one or more pharmaceutically acceptable carriers thereof and, optionally, other therapeutic and/or prophylactic ingredients.
- the carriers(s) must be "acceptable” in the sense of being compatible with other ingredients of the formulation and not deleterious to the recipient thereof.
- compositions or compositions include those for oral, rectal, nasal, topical (including buccal and sub-lingual), vaginal or parenteral (including intramuscular, sub-cutaneous and intravenous) administration or in a form suitable for administration by inhalation or insufflation.
- the compounds of the invention may thus be placed into the form of pharmaceutical compositions and unit dosages thereof, and in such form may be employed as solids, such as tablets or filled capsules, or liquids as solutions, suspensions, emulsions, elixirs or capsules filled with the same, all for oral use, in the form of suppositories for rectal administration; or in the form of sterile injectable solutions for parenteral (including subcutaneous) use.
- the subjects treated in the above method are mammals, including, but not limited to, cows, sheep, goats, horses, dogs, cats, guinea pigs, rats or other bovine, ovine, equine, canine, feline, rodent or murine species, and preferably a human being, male or female.
- the term "effective amount" relates to an amount of compound which, when administered according to a desired dosing regimen, provides the desired treatment of the pain, or pain prevention. Dosing may occur at intervals of minutes, hours, days, weeks, months or years or continuously over any one of these periods.
- a therapeutic, or treatment, effective amount is an amount of the compound which, when administered according to a desired dosing regimen, is sufficient to at least partially attain the desired therapeutic effect, or delay the onset of, or inhibit the progression of or halt or partially or fully reverse the onset or progression of pain.
- a prevention effective amount is an amount of compound which when administered according to the desired dosing regimen is sufficient to at least partially prevent or delay the onset of pain.
- administering should be understood to mean providing a compound of the invention to the subject in need of treatment.
- treating encompasses curing and ameliorating pain.
- the pharmaceutical composition and method of the present invention may further comprise other therapeutically active compounds which are usually applied in the treatment of pain. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles.
- the combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.
- Suitable dosages may lie within the range of about 0.1 ng per kg of body weight to 1 g per kg of body weight per dosage.
- the dosage is preferably in the range of 1 pg to 1 g per kg of body weight per dosage, such as is in the range of 1 mg to 1 g per kg of body weight per dosage.
- the dosage is in the range of 1 mg to 500 mg per kg of body weight per dosage.
- the dosage is in the range of 1 mg to 250 mg per kg of body weight per dosage.
- the dosage is in the range of 1 mg to 100 mg per kg of body weight per dosage, such as up to 50 mg per kg of body weight per dosage.
- the dosage is in the range of 1 g to 1 mg per kg of body weight per dosage.
- Suitable dosage amounts and dosing regimens can be determined by the attending physician and may depend on the type and/or severity of pain as well as the general age, health and weight of the subject.
- the active ingredient may be administered in a single dose or a series of doses. While it is possible for the active ingredient to be administered alone, it is preferable to present it as a composition, preferably as a pharmaceutical formulation.
- the present invention therefore relates to the use of a therapeutically effective amount of a compound of formula (I), or a pharmaceutically-acceptable derivative thereof, for treating pain.
- the present invention also provides a pharmaceutical composition for use in treating pain, in any of the embodiments described in the specification.
- the present invention also relates to the use of a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable derivative thereof, for the manufacture of a medicament for treating pain.
- the present invention also relates to a compound of formula (I), or a pharmaceutically acceptable derivative thereof, when used in a method of treating pain.
- the present invention also relates to a composition having an active ingredient for use in treating pain, wherein the active ingredient is a compound of formula (I), or a pharmaceutically acceptable derivative thereof.
- the present invention also relates to the use of a pharmaceutical composition containing a compound of the formula (I), or a pharmaceutically acceptable derivative thereof, in treating pain, such as described above.
- the compound of formula (I) is essentially the only active ingredient of the composition.
- the pain is neuropathic pain.
- the aqueous phase was further extracted with diethyl ether (2x80ml), and the combined extracts were washed with water (300ml), and brine (100ml), and dried over Na 2 SO 4 anhydrous, concentrated under vacuo, and the residue was purified by silica gel dry column vacuum chromatography ( DCVC) by stepwise gradient elution with dichloromethane/hexane (50:50 to 100:0).
- DCVC silica gel dry column vacuum chromatography
- Glycine transport by GlyT2 and GlyT1 is coupled to 3 Na+/1 CI- and 2Na+/1 Cl- ions respectively, creating an electrogenic process and allowing the two electrode voltage clamp technique to be used to measure glycine transport.
- Defoliculated stage V- VI oocytes were injected with 4.6 ng of cRNA encoding the transporter (Drummond Nanoinject, Drummond Scientific Co., Broomall, PA, USA).
- glycine transport currents were measured at -60 mV using Geneclamp 500 amplifier (Axon Instruments, Foster City, CA, USA) with a Powerlab 2/20 chart recorder (ADInstruments, Sydney, Australia) using chart software (ADInstruments).
- Glycine was applied, followed by co-administration of glycine (EC50) in the presence of inhibitor, until the inhibitory response was observed to plateau.
- EC50 glycine
- Each compound was tested to a maximal concentration of 3 ⁇ because these compounds form micelles at higher concentrations.
- the compounds were applied at concentrations below their CMC in ND96 which was determined using a CMC assay. Reversibility of each compound was tested by applying the EC50 dose of glycine every 5 minutes following inhibition for a 30 minute time course or until recovery was reached. Recovery is defined as glycine currents within +/- 5 % of the pre-inhibitory glycine response. Concentration response curves for the active compounds were then performed.
- NADPH NADPH is the cofactor required for CYP450-mediated metabolism
- Control samples were included (and quenched at 2, 30 and 60 minutes) to monitor for potential degradation in the absence of cofactor.
- Metabolite screening was performed using accurate mass measurements only. Compounds were incubated at a low substrate concentration and as such, structure confirmation and elucidation using MS/MS scans was not conducted. Calculations
- Test compound concentration versus time data were fitted to an exponential decay function to determine the first-order rate constant for substrate depletion.
- Table 3 Metabolic stability parameters for nine compounds based NADPH-dependent degradation profiles in human and rat liver microsomes.
- Plasma samples were quantified relative to calibration standards prepared using blank plasma of the same species. Calibration standards were spiked with test compound over a range of 0.5 to 10,000 ng/mL. Internal standard (leucine enkephalin) was added to calibration standards and incubation samples, and then immediately quenched using two volumes of acetonitrile to precipitate plasma proteins. Samples were vortex mixed and centrifuged (10,000 rpm for 3 minutes) in a microcentrifuge and the supernatant analysed by LC-MS using conditions tabulated below.
- the mean and standard deviation of measured plasma concentrations were calculated for each time point and expressed as a percentage remaining, relative to the initial time point (2 min). Where measurable degradation was detected, and assuming first order degradation kinetics, the data were fit using a mono-exponential decay function to obtain the apparent first-order degradation rate constant (k, min-1 ) and degradation half-life.
- NMDG- based recovery ACSF NMDG-based recovery ACSF
- rACSF NMDG-based recovery ACSF
- 95% O 2 and 5% C0 2 composed of (mM): 93 NMDG, 2.5 KCI, 1 .2 NaH 2 P0 4 , 30 NaHC0 3 , 20 HEPES, 25 Glucose, 5 Na ascorbate, 2 thiourea, 3 Na pyruvate, 10 MgSO 4 and 0.5 CaCI 2 , and adjusted to pH 7.4 with HCI.
- slices were transferred to normal oxygenated ACSF where they were allowed to recover for 1 hour at 34° C and then maintained at room temperature prior to transfer to the recording chamber.
- Normal ACSF had the following composition (imM): 125 NaCI, 2.5 KCI, 1 .25 NaH 2 PO 4 , 1 .2 MgCI 2 , 2.5 CaCI 2 , 25 glucose, and 1 1 NaHCO 3 and was equilibrated with 95% O 2 and 5% CO 2 .
- Electrophysioloqy Slices were transferred to a recording chamber and superfused continuously at 2 ml/min with normal ACSF that had been equilibrated with 95% O 2 and 5% CO 2 and maintained at 34°C with an inline heater and monitored by a thermister in the slice chamber.
- Dodt-contrast optics was used to identify lamina II neurons in the translucent substantia gelatinosa layer of the superficial dorsal horn.
- a Cs + -based internal solution which should minimise postsynaptic effects, was used to record electrically evoked inhibitory post-synaptic currents (elPSCs) and tonic current, and contained (imM): 140 CsCI, 10 EGTA, 5 HEPES, 2 CaCI 2 , 2 MgATP, 0.3 NaGTP, 5 QX-314.CI, 2 Lucifer Yellow CH dipotassium salt and 0.1 % biocytin (osmolarity 285-295 mosmol ⁇ 1 ). Patch electrodes had resistances between 3 and 5 ⁇ . Synaptic currents were measured in whole-cell voltage-clamp (-70 mV, not corrected for a liquid junction potential of 4 mV) from lamina II cells.
- Bipolar tungsten electrodes placed in the inner laminae were used to elicit elPSCs using a stimulus strength sufficient to evoke reliable elPSCs.
- Neurons ventral to lamina II, in regions that are known to contain glycinergic neurons were electrically stimulated.
- All elPSCs were recorded in CNQX (10 ⁇ ), AP5 (100 ⁇ ) and picrotoxin (80 ⁇ ).
- strychnine 0.5 ⁇ was added to the superfusion solution to confirm that recorded currents were glycine- mediated IPSCs.
- Drugs were superfused onto slices at a rate of 2ml/min in normal oxygenated ACSF at 34°C.
- the formulation was prepared by dissolving solid compound in DMSO prior to addition of 1 % Solutol in 50mM PBS pH 7.4 solution, which after sonication and heating yielded a very fine off-white suspension with an apparent pH of 7.05.
- This suspension of oleoyl-D-lysine was administered in a dose volume of 5 imL/kg via intraperitoneal injection (via 27G 1 /2" needle) resulting in a nominal oleoyl-D-lysine dose of 27.5 mg/kg.
- Plasma concentration versus time data were analysed using non-compartmental methods (PKSolver Version 2.0). Standard calculations for each pharmacokinetic parameter are listed below.
- the concentration of oleoyl-D-lysine in brain parenchyma was calculated on the basis of the measured concentration in brain homogenate, after correcting for the contribution of compound contained within the vascular space of brain samples as follows:
- Plasma standards were freshly prepared, with each set of standards comprising at least six different analyte concentrations.
- Solution standards were diluted from a stock solution (1 mg/mL in DMSO) with 50% acetonitrile in water.
- Plasma standards were prepared by spiking blank plasma (50 ⁇ _) with solution standards (10 ⁇ _) and the internal standard, diazepam (10 ⁇ _, 5 Mg/mL). Plasma samples were similarly prepared, except that blank acetonitrile (10 ⁇ _) was added instead of solution standards.
- Protein precipitation was carried out by the addition of acetonitrile (120 ⁇ _), vortexing (20 s) and centrifugation (10,000 rpm) in a microcentrifuge for 3 minutes. The supernatant was subsequently separated and 3 ⁇ _ injected directly onto the column for LC-MS analysis using conditions presented in the method summary section. All concentrations are expressed as the non-salt equivalent.
- Pre-weighed rat brains were homogenised in 3-volume/weight of stabilisation mixture (composed of 0.1 M EDTA and 4 g/L KF in water) using a gentleMACSTM dissociator. Extraction of the test compound from the resulting tissue homogenate was conducted using protein precipitation with methanol. Tissue homogenate standards were freshly prepared, with each set of standards comprising at least six different analyte concentrations. Tissue standards were prepared by spiking blank tissue homogenate (200 ⁇ _) with solution standards (10 ⁇ _) and the internal standard, diazepam (10 ⁇ _, 5 pg/mL). Tissue samples were similarly prepared, except that blank methanol (10 ⁇ _) was added instead of solution standards.
- Protein precipitation was carried out by the addition of methanol (600 ⁇ _), vortexing (20 s) and centrifugation (10,000 rpm) in a microcentrifuge for 3 minutes. The supernatant was subsequently separated and 3 ⁇ _ injected directly onto the column for LC-MS analysis using conditions presented in the method summary section. Results
- Plasma and brain concentration versus time profiles are presented in Figure 6, whilst calculated plasma and brain exposure parameters, values for individual rats, together with the corresponding brain-to-plasma (B:P) ratios are summarised in Tables 5 and 6.
- B:P ratios increased over the 24 h exposure period, and maximum values (ranging from 0.6-1 .6) were observed at 24 h post-dose. This may be indicative of a slow rate of compound equilibration between plasma and brain.
- B:P partitioning ratio values (based on AUC 0 -24h values in plasma and brain) may provide a better indication of the distribution of oleoyl-D-lysine into the brain, although it may still be an underestimation as it is lower than the B:P at 24 h.
- Table 5 Exposure parameters for oleoyl-D-lysine in male Sprague Dawley rats following IP administration at 27.5 mg/kg
- S1 PR1 Assays The purpose of these assays was to determine whether the compounds of the present invention have any off-target effects.
- the S1 PR1 , CB1 and CB2 receptors were chosen as they have been known to be agonised or antagonised by lipid-based molecules. S1 PR1 Assay
- sphingolipid G-protein-coupled receptor, 1 NCBI protein database NP_001391 .2
- This cell line has been tested negative for Mycoplasma sp.
- This cell line has been tested positive for Endothelial Differentiation, Sphingolipid G-Protein-coupled Receptor, 1 specific response.
- the receptor specific activity is stable for 10 weeks continuous passage.
- Growth medium 90% DMEM, 10% FBS, 250 ⁇ g/ml G418 and 1 ⁇ g/ml puromycin
- Freezing medium 10% DMSO, 90% growth medium Testing compounds on ACTOne-SI PR1 cells
- ACTOne-S1 PR1 cells (CB-80300-250) were maintained in cell culture medium consisting of 90% Dulbecco's Modified Eagle Medium (DMEM), 10% fetal bovine serum (FBS), 250 ⁇ g/ml G418 and 1 ⁇ g/ml puromycin. The day before the assay, the cells were trypsinized and diluted to the final concentration of 600K cells/ml in the growth medium. 20 ⁇ of such cell suspension was added into each well of 384-well plates. Each well contained 12K cells. The plates were then transferred to a cell culture incubator and the cells were growing overnight.
- DMEM Dulbecco's Modified Eagle Medium
- FBS fetal bovine serum
- the agonist control picked here was S1 P (125 uM stock in 4 mg/ml Fatty acid free BSA, Avanti Polar Lipids 860492P).
- the agonist stimulation solutions were prepared as below:
- testing compounds were first diluted in DMSO to 1 imM each. It was further diluted (1 :200) in agonist dilution buffer to 5 ⁇ each.
- Isoproterenol is used to stimulate the adenylyl cyclase through the activation of Gs-coupled endogenous ⁇ -adrenoceptor.
- Ro20-1724 is a PDE4 specific inhibitor.
- the cell plates were placed on a Molecular Devices SpectraMax Gemini EM and the baselines (F0) were read before the addition of any compound. 10 ⁇ of above agonist stimulation solutions (5X) was added into each well. The plates were recorded again on Gemini EM 50 min (Ft) after the compound addition. The ratio of Ft/FO (Fold) was calculated for each well; data was analyzed and graphed using GraphPad Prism.
- the assays were again performed on 384-well plates. The day before the assay, the cells were trypsinized and diluted to the final concentration of 600K cells/ml in growth medium. 20 ⁇ of such cell suspension was added into each well of 384-well plates. Each well contained 12K cells. The plates were then transferred to a cell culture incubator and the cells were growing overnight.
- testing compounds (1 mM in DMSO) were diluted (1 :200) in 1 X DPBS to 5 ⁇ each. 10 ⁇ of such solution was added into each well of 384-well plates and incubated at room temperature for 20 min. 10 ⁇ of W146 (Final) was used as a positive control.
- the cell plates were read on Gemini EM (FO). Afterwards, 12.5 ⁇ of 5X agonist stimulation solution (125 ⁇ Ro 20-1724, 1 .5 ⁇ isoproterenol and 500 nM S1 P prepared in DPBS with 0.1 mg/ml BSA) was added into each well. The cell plates were read again after 50 min (Ft).
- 5X agonist stimulation solution 125 ⁇ Ro 20-1724, 1 .5 ⁇ isoproterenol and 500 nM S1 P prepared in DPBS with 0.1 mg/ml BSA
- the compounds have no antagonist activity on S1 PR1 .
- CB2 CELL LINE DESIGNATION Cannabinoid receptor 2 cell line
- RECEPTOR INTRODUCED Human Cannabinoid receptor 2. (NCBI protein database NP_001832 with SNP at amino acid position 63.)
- This cell line has been tested negative for Mycoplasma sp.
- This cell line has been tested positive for CB2 specific response.
- the receptor specific activity is stable for 10 weeks continuous passage. Cell culture condition
- Growth medium for Cannabinoid receptor 2 cell line 90% DMEM with Glutamine, 10% FBS, 250 ⁇ g/ml G418 and 1 ⁇ g/ml puromycin 2. Freezing medium: 10% DMSO, 90% growth medium
- ACTOne-CB2 cells (CB-80300-225) were maintained in cell culture medium consisting of 90% Dulbecco's Modified Eagle Medium (DMEM), 10% fetal bovine serum (FBS), 250 ⁇ g/ml G418 and 1 ⁇ g/ml puromycin. The day before the assay, the cells were trypsinized and diluted to the final concentration of 600K cells/ml in the growth medium. 20 ⁇ of such cell suspension was added into each well of 384-well plates. Each well contained 12K cells. The plates were then transferred to a cell culture incubator and the cells were growing overnight.
- DMEM Dulbecco's Modified Eagle Medium
- FBS fetal bovine serum
- the agonist control picked here was CP-55940 (10mM stock in DMSO, Sigma C1 1 12). Dilute 10mM CP-55940 stock in DMSO containing 30 ⁇ Isoproterenol and 2.5 imM Ro 20-1724. These concentrations are 100X the expected final testing concentrations.
- Isoproterenol is used to stimulate the adenylyl cyclase through the activation of Gs-coupled endogenous ⁇ adrenoceptor.
- Ro20-1724 is a PDE4 specific inhibitor. Table 8. An example of CP-55940 concentrations in a compound dilution plate
- the compound concentration is 5X testing concentration.
- the testing compounds were first diluted in DMSO to 2 mM each. They were further diluted to 100 ⁇ in DMSO containing 30 ⁇ Isoproterenol and 2.5 mM Ro 20- 1724. Further dilute the solutions 1 :20 with 1 X DPBS in compound plates. At this step, the compound concentration is 5X testing concentration.
- the cell plates were placed on a Molecular Devices SpectraMax Gemini EM and the baselines (F0) were read before the addition of any compound. 10 ⁇ of above agonist stimulation solutions (5X) was added into each well. The plates were recorded again on Gemini EM 50 min (Ft) after the compound addition. The ratio of Ft/FO (Fold) was calculated for each well; data was analyzed and graphed using GraphPad Prism.
- the assays were again performed on 384-well plates. The day before the assay, the cells were trypsinized and diluted to the final concentration of 600K cells/ml in growth medium. 20 ⁇ of such cell suspension was added into each well of 384-well plates. Each well contained 12K cells. The plates were then transferred to a cell culture incubator and the cells were growing overnight.
- testing compounds (2 mM in DMSO) were diluted (1 :400) in 1 X DPBS to 5 ⁇ each. 10 ⁇ of such solution was added into each well of 384-well plates and incubated at room temperature for 20 min. 10 ⁇ of AM251 (Final) was used as a positive control.
- the cell plates were read on on Gemini EM (F0). Afterwards, 12.5 ⁇ of 5X agonist stimulation solution (125 ⁇ Ro 20-1724, 1 .5 ⁇ isoproterenol and 200 nM CP- 5590 in DPBS) (diluted from 100X solution prepared in DMSO) was added into each well. The cell plates were read again after 50 min (Ft).
- 5X agonist stimulation solution 125 ⁇ Ro 20-1724, 1 .5 ⁇ isoproterenol and 200 nM CP- 5590 in DPBS
- This cell line has been tested negative for Mycoplasma sp.
- This cell line has been tested positive for CB1 specific response.
- the receptor specific activity is stable for 10 weeks continuous passage.
- Growth medium for Cannabinoid receptor 1 cell line 90% DMEM with Glutamine, 10% FBS, 250 ⁇ g/ml G418 and 1 ⁇ g/ml puromycin
- Freezing medium 10% DMSO, 90% growth medium Testing compounds on ACTOne-CB1 cells
- ACTOne-CB1 cells (CB-80300-205) were maintained in cell culture medium consisting of 90% Dulbecco's Modified Eagle Medium (DMEM), 10% fetal bovine serum (FBS), 250 ⁇ g/ml G418 and 1 ⁇ g/ml puromycin. The day before the assay, the cells were trypsinized and diluted to the final concentration of 600K cells/ml in the growth medium. 20 ⁇ of such cell suspension was added into each well of 384-well plates. Each well contained 12K cells. The plates were then transferred to a cell culture incubator and the cells were growing overnight.
- DMEM Dulbecco's Modified Eagle Medium
- FBS fetal bovine serum
- G418 fetal bovine serum
- puromycin 1 ⁇ g/ml puromycin
- the cell plates were taken out from the incubator and an equal volume (20 ⁇ ) of 1X ACTOne membrane potential dye was added into each well and the plates were kept at room temperature in the dark for 2 hrs. The total volume after this step was 40 ⁇ .
- the plates will be referred to as the cell plates.
- the compound concentration is 5X testing concentration.
- the testing compounds were first diluted in DMSO to 2 mM each. I. They are further diluted to 100 ⁇ in DMSO containing 30 ⁇ Isoproterenol and 2.5 mM Ro 20- 1724. Further dilute the solutions 1 :20 with 1 X DPBS in a compound plate. At this step, the compound concentration is 5X testing concentration
- the cell plates were placed on a Molecular Devices SpectraMax Gemini EM and the baselines (F0) were read before the addition of any compound. 10 ⁇ of above agonist stimulation solutions (5X) was added into each well. The plates were recorded again on Gemini EM 60 min (Ft) after the compound addition. The ratio of Ft/FO (Fold) was calculated for each well; data was analyzed and graphed using GraphPad Prism. Results
- testing compounds (1 imM in DMSO) were diluted (1 :200) in 1 X DPBS to 5 ⁇ each. 10 ⁇ of such solution was added into each well of 384-well plates and incubated at room temperature for 20 min. 10 ⁇ of AM251 (Final) was used as a positive control.
- the cell plates were read on on Gemini EM (F0). Afterwards, 12.5 ⁇ of 5X agonist stimulation solution (125 ⁇ Ro 20-1724, 1 .5 ⁇ isoproterenol and 2 ⁇ CP- 5590 in DPBS) (diluted from 100X solution prepared in DMSO) was added into each well. The cell plates were read again after 60 min (Ft). Results
- Compound 29 was tested in rats suffering from neuropathic pain induced by partial ligation of the sciatic nerve. Two routes of compound administration were used - intrathecal and intraperitoneal.
- Lu Y et al. A feed-forward spinal cord glycinergic neural circuit gates mechanical allodynia. J. Clin Invest. 2013;123:4050-62. 7. Dohi T et al. Glycine transporter inhibitors as a novel drug discovery strategy for neuropathic pain. Pharmacol & Therap. 2009;123:54-79.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to novel glycine transport inhibitor compounds and their use for treating pain.
Description
Novel glycine transport inhibitors for the treatment of pain
Field of the invention
The present invention relates to novel glycine transport inhibitor compounds and their use for treating pain. Background of the invention
Chronic pain is a significant global health, economic and social problem, with the annual economic burden in the USA recently estimated at $600 billion. In Australia, the disease burden of pain has been documented in a rigorous epidemiological study, which revealed that -20% of adults have poor self-rated health as a consequence of chronic pain. The economic burden of unrelieved persistent pain in Australia is large and continuing to escalate, with a total cost of $34 billion in 2007. Until recently, the major analgesics used clinically were limited to non-steroidal, local anaesthetic, opioid and anticonvulsant drugs that provide adequate pain relief in only a small proportion of chronic pain patients. Unfortunately, newer classes of analgesics also have limited efficacy, with the most effective, gabapentin, at best providing only 50% reduction in pain scores in chronic pain, with the number needed to treat for a clinical response being > 4.
Recent insights into the physiological adaptations underlying chronic pain have provided an impetus to discover new classes of pain-relieving drugs, particularly for neuropathic pain. One such target is the glycine transporter 2 (GlyT2).
Neurotransmitter transporters are responsible for regulating the synaptic concentration of monoamines (5-hydroxytryptamine, dopamine, noradrenaline) and amino acid (γ-aminobutyric acid, glycine) neurotransmitters. These membrane-bound proteins use electrochemical gradients to drive the transport of neurotransmitters across neuronal and glial membranes, serving to terminate neurotransmission and replenish intracellular levels of neurotransmitter for future release.
The capacity of neurotransmitter transporters to selectively enhance or diminish neuronal signalling makes them attractive drug targets. Indeed, a wide range of therapeutically useful drugs, including antidepressants and anxiolytics, target these
proteins. Diminished glycinergic transmission is an important CNS mechanism underlying neuropathic pain including mechanical hyperalgesia and allodynia (a painful response to normally innocuous tactile stimuli). Drugs that can enhance dysfunctional glycerinergic transmission in neuropathic pain, and in particular glycine transporter inhibitors, are potential chronic pain therapeutics.
There are two closely related glycine transporters, GlyT1 and GlyT2, which serve to regulate glycine concentrations. GlyT1 is expressed throughout the CNS predominantly by astrocytes surrounding both inhibitory and excitatory synapses to influence Glycine and NMDA receptors (NMDAR). Enhancement of NMDAR activity by GlyT1 inhibition is an established therapeutic target in diseases with NMDAR hypofunction, such as schizophrenia, but is undesirable in chronic pain states where suppression of NMDAR function is desirable. By contrast, GlyT2 is considered a promising therapeutic target for chronic pain. GlyT2 shows much more restricted expression patterns than GlyT1 and is predominantly expressed by glycinergic terminals in the spinal cord and brain stem. GlyT2 plays two important roles at glycinergic inhibitory synapses: regulation of extracellular glycine concentrations to control inhibitory glycinergic tone, and to recycle released glycine to provide sufficient intracellular glycine for repackaging into synaptic vesicles for subsequent release.
The sensation of pain can be suppressed by inhibiting GlyT2, which increases glycine concentrations in the synaptic cleft and enhances neurotransmission through activation of Glycine receptors (GlyRa3) in the spinal cord. The two GlyT2 inhibitors that have been most extensively studied are ALX1393 and ORG25543. Both compounds show efficacy as analgesics in the treatment of various forms of acute and chronic pain, but there are limitations in their use. ALX1393 shows only a 10-fold selectivity for GlyT2 over GlyT1 , and the dose required for analgesia may also result in partial inhibition of GlyT1 and increases in glycine at excitatory synapses leading to an initial increase in NMDAR-related pain before analgesia is achieved. ORG25543 causes respiratory depression and loss of motor control at high doses which has been attributed to irreversible inhibition of GlyT2 with subsequent reductions in glycine loading of synaptic vesicles.
Partial knock down of GlyT2 using siRNAs indicates that partial inhibitors of GlyT2 have the potential to be therapeutic in the treatment of neuropathic pain. Knockdown of GlyT2 to approximately 30% of wild type levels (which may mimic partial inhibition of transport) provides analgesia in rat models of allodynia associated with neuropathic pain. The equilibrium glycine concentration gradient achieved by GlyT2 is determined by the ion gradients across the cell membrane, whereas the rate at which equilibrium is achieved will be determined by the number of glycine transporters. Thus, partial inhibition will not alter the equilibrium glycine concentration gradient, but will prolong the time required to reach equilibrium, allowing greater glycine receptor activity. It appears that partial inhibition of glycine transport in the siRNA knock-down experiments allows sufficient glycine uptake for loading of presynaptic glycinergic vesicles to maintain, or even prolong, glycinergic neurotransmission.
There is a need for new compounds that mimic the actions of the partial knockdown of GlyT2 for use as analgesic drugs for the treatment of various forms of pain.
Reference to any prior art in the specification is not an acknowledgment or suggestion that this prior art forms part of the common general knowledge in any jurisdiction or that this prior art could reasonably be expected to be understood, regarded as relevant, and/or combined with other pieces of prior art by a skilled person in the art.
Summary of the invention
In one aspect, the present invention provides a compound of formula (I):
X-L-Y
(I)
or pharmaceutically acceptable derivatives thereof, wherein:
X is an amino acid or derivative thereof;
L is an amide or retro amide;
Y is C10 - C24 alkyl or alkenyl;
X, L and Y may be independently substituted or unsubstituted; and
wherein the compound is not
In another aspect, the present invention provides a compound of formula (I) as defined above wherein the compound is not one or more of the compounds selected from the group consisting of:
In another aspect, there is provided a pharmaceutical composition comprising a compound according to the invention, a salt or a pharmaceutically acceptable derivative thereof, together with one or more pharmaceutically acceptable carriers or adjuvants. In another aspect, there is provided a method of treating pain by administering an effective amount of a compound according to the invention, a salt or a pharmaceutically acceptable derivative thereof, to a subject in need thereof.
In another aspect, there is provided a compound according to the invention, a salt or a pharmaceutically acceptable derivative thereof, for use in treatment of pain in a subject in need thereof.
In another aspect, there is provided use of a compound according to the invention, a salt or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for treatment of pain in a subject in need thereof.
In another aspect, there is provided a method of treating pain by administering an effective amount of at least one compound selected from the group consisting of:
In another aspect there is provided a compound selected from the group consisting of:
11
a salt, or a pharmaceutically acceptable derivative thereof, for use in treatment of pain in a subject in need thereof.
In another aspect there is provided a compound selected from the group consisting of:
a salt, or a pharmaceutically acceptable derivative thereof, in the manufacture of a medicament for treatment of pain in a subject in need thereof.
The pain may be chronic or acute. Preferably the pain is chronic pain, more preferably neuropathic pain. Further aspects of the present invention and further embodiments of the aspects described in the preceding paragraphs will become apparent from the following description, given by way of example and with reference to the accompanying drawings.
Brief description of the drawings
Fig. 1 shows plasma concentration vs time profiles for Compounds 28, 29, 8, 1 and 36, following incubations at 37°C in human (·) and rat (□) plasma.
Fig. 2 shows elPSC amplitude (A), tonic current (B) and decay time constant (C) graphs of Compound 28.
Fig. 3 shows elPSC amplitude (A), tonic current (B) and decay time constant (C) graphs of Compound 39. Fig. 4 shows elPSC amplitude (A), tonic current (B) and decay time constant (C) graphs of Oleoyl-L-carnitine.
Fig. 5 shows elPSC amplitude (A), tonic current (B) and decay time constant (C) graphs of N-arachidonyl glycine.
Fig. 6 shows elPSC amplitude (A), tonic current (B) and decay time constant (C) graphs Oleoyl-L-glycine.
Fig. 7 shows plasma and brain concentrations of Compound 29 in male Sprague Dawley rats following IP administration at 27.5 mg/kg.
Fig. 8 shows the agonist activity of Compounds 1 , 2, 16, 25, 28, 29, 36, 65, 27 and 39 on S1 PR1 . Fig. 9 shows the antagonist activity of Compounds 1 , 2, 16, 25, 28, 29, 36, 65,
27 and 39 on S1 PR1 .
Fig. 10 shows the agonist activity of Compounds 1 , 2, 16, 25, 28, 29, 36, 65, 27 and 39 on CB2.
Fig. 11 shows the antagonist activity of Compounds 1 , 2, 16, 25, 28, 29, 36, 65, 27 and 39 on CB2.
Fig. 12 shows the agonist activity of Compounds 1 , 2, 16, 25, 28, 29, 36, 65, 27 and 39 on CB1 .
Fig. 13 shows the antagonist activity of Compounds 1 , 2, 16, 25, 28, 29, 36, 65, 27 and 39 on CB1 .
Fig. 14 shows the analgesic effect of intrathecal administration of Compound 29. Fig. 15 shows the analgesic effect of intraperitoneal administration of Compound
29.
Detailed description of the embodiments
In one aspect, the present invention provides a compound of formula (I):
X-L-Y
(I)
or pharmaceutically acceptable derivatives thereof, wherein:
X is an amino acid or derivative thereof;
L is an amide or retro amide;
Y is Cio - C24 alkyl or alkenyl;
X, L and Y may be independently substituted or unsubstituted; and
wherein the compound is not
In another aspect, the present invention provides a compound of formula (I) as defined above wherein the compound is not one or more of the compounds selected from the group consisting of:
In one embodiment, X is a naturally occurring or non-naturally occurring amino acid. In a preferred embodiment, X is a naturally occurring hydrophobic and/or aromatic amino acid, more preferably L-tryptophan. In another preferred embodiment, X is a non-
naturally occurring amino acid, more preferably a D-amino acid. In a particularly preferred embodiment X is selected from one or more of the group consisting of glycine, L-carnitine, L-serine, D-serine, L-lysine, D-lysine, L-lysine derivative wherein the carbon chain of the lysine side group is of C1 -C3 in length, L-arginine, L-methionine, L-leucine, D-leucine, L-alanine, D-alanine, B-alanine, L-valine,- D-valine, D-phenylalanine, L- phenylalanine derivative wherein the carbon chain of the phenylalanine side group is of two carbons in length, L-tryptophan, D-tryptophan, L-tyrosinol- L-dopamine, L-aspartate, D-aspartate, L-glutamate, L-histidine, D-histidine, L-lysine OME, L-norleucine. In a particularly preferred embodiment, X is selected from the group consisting of glycine, D- lysine, L-tryptophan L-lysine methylester, and L-leucine.
In one embodiment, X is unsubstituted. In another embodiment, X is substituted with 1 , 2, or 3 C1 - C3 alkyl groups at the a carbon of the amino acid or derivative thereof. Preferably, the C1 - C3 alkyl group is methyl. In a particularly preferred embodiment, X is lysine substituted with 1 , 2, or 3 methyl groups at the a carbon of the lysine. Substituting X as described herein, advantageously increases the metabolic stability and efficacy of the compounds of the invention by minimising in vivo degradation of the linking group, L.
In a preferred embodiment, L is an amide.
In one embodiment, L is unsubstituted. In another embodiment, L is substituted with a C1 - C3 alkyl group at the nitrogen of the amide or retro amide. Preferably, the C1-C3 alkyl group is methyl. Substituting L as described herein and/or reversing the amide, advantageously increases the metabolic stability and efficacy of the compounds of the invention by minimising in vivo degradation of the linking group, L.
In a preferred embodiment, Y includes 1 - 4 cis double bonds, more preferably Y is monounsaturated and includes 1 cis double bond. The single cis double bond may be at any position of the C10 - C24 alkenyl chain, preferably 5 - 15 carbons from L, more preferably 8 - 10 carbons from L.
In one embodiment, Y includes 1 -4 trans double bonds. More preferably, Y is monounsaturated and includes 1 trans double bond. The single trans double bond may
'1Ut>
be at any position of the do - C24 alkenyl chain, preferably 5 - 15 carbons from L, more preferably 8 - 10 carbons from L, more preferably 9 carbons from L.
In a preferred embodiment, Y is a monounsaturated Ci8, Ci6 or Ci4 chain, preferably a monounsaturated Ci8 chain. Preferably the monounsaturated Ci8 carbon chain includes a cis-double bond in the ω 3, 5, 6, 7, 8, 9, 10, 1 1 , or 12 position, more preferably in the ω 9 position. Preferably, the monounsaturated Ci6 carbon chain includes a cis-double bond in the ω 5, 6, 7, 9, or 1 1 position.
In another embodiment, Y is a saturated Ci6 or Cu carbon chain.
Preferably, the compound is selected from one or more of compounds 2 - 7, 9 - 12, 1 7 - 21 , 23, 26 - 44, 47 - 54 of Table 1 . In another preferred embodiment the compound is selected from one or more of compounds 2 - 7, 1 0 - 1 2, 17, 18, 20, 21 , 23, 28 - 34, 37, 42, 43, 48 and 52 of Table 1 .
Table 1. Exemplary compounds of the present invention
The invention also relates to methods of treating pain by administering an effective amount of a compound according to the invention, a salt or pharmaceutically acceptable derivative thereof, to a subject in need thereof.
In another aspect, there is provided a compound according to the invention, a salt or a pharmaceutically acceptable derivative thereof for use in treatment of pain in a subject in need thereof.
In another aspect, there is provided use of a compound according to the invention, a salt or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for treatment of pain in a subject in need thereof.
In another embodiment the invention relates to methods of treating pain by administering an effective amount of at least one compound selected from the group consisting of:
32
a salt, or pharmaceutically acceptable derivative thereof, to a subject in need thereof.
In another aspect there is provided a compound selected from the group consisting of:
a salt, or a pharmaceutically acceptable derivative thereof, for use in treatment of pain in a subject in need thereof.
In another aspect there is provided a compound selected from the group consisting of:
a salt, or a pharmaceutically acceptable derivative thereof, in the manufacture of a medicament for treatment of pain in a subject in need thereof.
The pain may be acute or chronic, preferably chronic. In a particularly preferred embodiment, the pain is neuropathic pain. Definitions
The term "amino acid" as used herein is intended to encompass compounds having an amino group and a carboxyl group in which the amino group and the carboxyl
group are separated by at least one carbon atom. The amino acid may be a L- or D- isomer and may have a naturally occurring side chain or a non-naturally occurring side chain. An amino acid having a non-naturally occurring side chain refers to an amino acid having a side chain that does not occur in the naturally occurring L-a-amino acids. Examples of non-natural amino acids and derivatives include, but are not limited to amino acids substituted with 1 , 2 or 3 C1-C3 alkyl groups at the a carbon of the amino acid, L-carnitine, gamma aminobutyric acid (GABA), dopamine, L-lysine OMe and/or D- isomers of amino acids.
The term "amino acid derivative" as used herein is intended to encompass derivatives of naturally occurring and non-naturally occurring amino acids, preferably ester derivatives of naturally occurring and non-naturally occurring amino acids. It also encompasses amino acids that have had their side chain modified, for example, the hydrocarbon chain shortened or extended. Some non-limiting examples of these are shown below for lysine and phenylalanine:
The term "retro amide" as used herein refers to a reverse amide bond wherein the nitrogen of the amide bond is located on the proximal side of the carbonyl group, ie (NHCO).
The term "alkyl" refers to a saturated, straight-chain or branched hydrocarbon group. Specific examples of alkyl groups are methyl, ethyl, propyl, /'so-propyl, n-butyl, /'so-butyl, sec-butyl, te/t-butyl, n-pentyl, /'so-pentyl, n-hexyl and 2,2-dimethylbutyl.
The term "alkenyl" refers to an at least partially unsaturated, straight-chain or branched hydrocarbon group that contains at least two carbon atoms (i.e. C2 alkenyl).
Specific examples of alkenyl groups are ethenyl (vinyl), propenyl (allyl), /'so-propenyl, butenyl, ethinyl, propinyl, butinyl, acetylenyl, propargyl, /'so-prenyl and hex-2-enyl group. Preferably, alkenyl groups have one or two double bond(s).
The term "substituted" refers to a group in which one, two, three or more hydrogen atoms have been replaced independently of each other by halogen (for example, fluorine, chlorine, bromine or iodine atoms) and/or by, for example, OH, =O, SH, SO3H, NH2, N-alkyl, NH-alkyl, N3 or NO2 groups. This expression also refers to a group that is substituted by one, two, three or more alkyl, alkenyl or heteroalkyl (e.g. -OCH3, -OCH2CH3, -CH2NHCH3 and -CH2NH2) groups. These groups may themselves be substituted. For example, an alkyl group substituent may be substituted by one or more halogen atoms (i.e. may be a haloalkyl group, such as trifluoromethyl, dichloroethyl, dichloromethyl and iodoethyl).
As used herein a wording defining the limits of a range of length such as, for example, "from 1 to 5" means any integer from 1 to 5, i.e. 1 , 2, 3, 4 and 5. In other words, any range defined by two integers explicitly mentioned is meant to comprise and disclose any integer defining said limits and any integer comprised in said range.
Compounds according to the formula provided herein, which have one or more stereogenic centres, have an enantiomeric excess of at least 50%. For example, such compounds may have an enantiomeric excess of at least 60%, 70%, 80%, 85%, 90%, 95%, or 98%. Some embodiments of the compounds have an enantiomeric excess of at least 99%. It will be apparent that single enantiomers (optically active forms) can be obtained by asymmetric synthesis, synthesis from optically pure precursors, biosynthesis or by resolution of the racemates, for example, enzymatic resolution or resolution by conventional methods such as crystallization in the presence of a resolving agent, or chromatography, using, for example, a chiral HPLC column.
Certain compounds are described herein using a general formula that includes variables such as X, L and Y. Unless otherwise specified, each variable within such a formula is defined independently of any other variable, and any variable that occurs more than one time in a formula is defined independently at each occurrence. Therefore, for example, if a group is shown to be substituted with 0, 1 or 2 FT, the group may be unsubstituted or substituted with up to two R* groups and R* at each
occurrence is selected independently from the definition of R*. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds, i.e., compounds that can be isolated, characterized and tested for biological activity. The term "pharmaceutically acceptable derivative" may include any pharmaceutically acceptable salt, hydrate or prodrug, or any other compound which upon administration to a subject, is capable of providing (directly or indirectly) a compound of the present invention or a pharmaceutically active metabolite or residue thereof. Suitable pharmaceutically acceptable salts include, but are not limited to, salts of acids such as hydrochloric, phosphoric, hydrobromic, malic, glycolic, fumaric, sulfuric, sulfamic, sulfanilic, formic, toluenesulfonic, methanesulfonic, benzenesulfonic, ethane disulfonic, 2-hydroxyethylsulfonic, nitric, benzoic, 2-acetoxybenzoic, citric, tartaric, lactic, stearic, salicylic, glutamic, ascorbic, pamoic, succinic, fumaric, maleic, propionic, hydroxymaleic, hydroiodic, phenylacetic, alkanoic (such as acetic, HOOC-(CH2)n-COOH where n is any integer from 0 to 6, i.e. 0, 1 , 2, 3, 4, 5 or 6), and the like. Similarly, pharmaceutically acceptable cations include, but are not limited to sodium, potassium, calcium, aluminum, lithium and ammonium. A person skilled in the art will recognize further pharmaceutically acceptable salts for the compounds provided herein. In general, a pharmaceutically acceptable acid or base salt can be synthesized from a parent compound that contains a basic or acidic moiety by any conventional chemical method. Briefly, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent (such as ether, ethyl acetate, ethanol, isopropanol or acetonitrile), or in a mixture of the two.
A "prodrug" is a compound that may not fully satisfy the structural requirements of the compounds provided herein, but is modified in vivo, following administration to a subject or patient, to produce a compound provided herein. For example, a prodrug may be an acylated derivative of a compound as provided herein. Prodrugs include compounds wherein hydroxy, carboxy, amine or sulfhydryl groups are bonded to any group that, when administered to a mammalian subject, cleaves to form a free hydroxy,
carboxy, amino, or sulfhydryl group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate, phosphate and benzoate derivatives of alcohol and amine functional groups within the compounds provided herein. Prodrugs of the compounds provided herein may be prepared by modifying functional groups present in the compounds in such a way that the modifications are cleaved in vivo to generate the parent compounds.
The term "composition" as used herein is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts. By "pharmaceutically acceptable" it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
This invention thus further provides a pharmaceutical formulation or composition comprising a compound of the invention or a pharmaceutically acceptable salt or derivative thereof together with one or more pharmaceutically acceptable carriers thereof and, optionally, other therapeutic and/or prophylactic ingredients. The carriers(s) must be "acceptable" in the sense of being compatible with other ingredients of the formulation and not deleterious to the recipient thereof.
Pharmaceutical formulations or compositions include those for oral, rectal, nasal, topical (including buccal and sub-lingual), vaginal or parenteral (including intramuscular, sub-cutaneous and intravenous) administration or in a form suitable for administration by inhalation or insufflation. The compounds of the invention, together with a conventional adjuvant, carrier or diluent, may thus be placed into the form of pharmaceutical compositions and unit dosages thereof, and in such form may be employed as solids, such as tablets or filled capsules, or liquids as solutions, suspensions, emulsions, elixirs or capsules filled with the same, all for oral use, in the form of suppositories for rectal administration; or in the form of sterile injectable solutions for parenteral (including subcutaneous) use.
The subjects treated in the above method are mammals, including, but not limited to, cows, sheep, goats, horses, dogs, cats, guinea pigs, rats or other bovine, ovine,
equine, canine, feline, rodent or murine species, and preferably a human being, male or female.
As used herein, the term "effective amount" relates to an amount of compound which, when administered according to a desired dosing regimen, provides the desired treatment of the pain, or pain prevention. Dosing may occur at intervals of minutes, hours, days, weeks, months or years or continuously over any one of these periods. A therapeutic, or treatment, effective amount is an amount of the compound which, when administered according to a desired dosing regimen, is sufficient to at least partially attain the desired therapeutic effect, or delay the onset of, or inhibit the progression of or halt or partially or fully reverse the onset or progression of pain. A prevention effective amount is an amount of compound which when administered according to the desired dosing regimen is sufficient to at least partially prevent or delay the onset of pain.
The terms "administration of" and/or "administering a" compound should be understood to mean providing a compound of the invention to the subject in need of treatment.
The terms "treating", "treatment" and "therapy" are used herein to refer to curative therapy. Therefore, in the context of the present disclosure, the term "treating" encompasses curing and ameliorating pain. The pharmaceutical composition and method of the present invention may further comprise other therapeutically active compounds which are usually applied in the treatment of pain. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.
Suitable dosages may lie within the range of about 0.1 ng per kg of body weight to 1 g per kg of body weight per dosage. The dosage is preferably in the range of 1 pg to 1 g per kg of body weight per dosage, such as is in the range of 1 mg to 1 g per kg of
body weight per dosage. In one embodiment, the dosage is in the range of 1 mg to 500 mg per kg of body weight per dosage. In another embodiment, the dosage is in the range of 1 mg to 250 mg per kg of body weight per dosage. In yet another preferred embodiment, the dosage is in the range of 1 mg to 100 mg per kg of body weight per dosage, such as up to 50 mg per kg of body weight per dosage. In yet another embodiment, the dosage is in the range of 1 g to 1 mg per kg of body weight per dosage.
Suitable dosage amounts and dosing regimens can be determined by the attending physician and may depend on the type and/or severity of pain as well as the general age, health and weight of the subject.
The active ingredient may be administered in a single dose or a series of doses. While it is possible for the active ingredient to be administered alone, it is preferable to present it as a composition, preferably as a pharmaceutical formulation.
The present invention therefore relates to the use of a therapeutically effective amount of a compound of formula (I), or a pharmaceutically-acceptable derivative thereof, for treating pain. The present invention also provides a pharmaceutical composition for use in treating pain, in any of the embodiments described in the specification. The present invention also relates to the use of a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable derivative thereof, for the manufacture of a medicament for treating pain.
The present invention also relates to a compound of formula (I), or a pharmaceutically acceptable derivative thereof, when used in a method of treating pain. The present invention also relates to a composition having an active ingredient for use in treating pain, wherein the active ingredient is a compound of formula (I), or a pharmaceutically acceptable derivative thereof. The present invention also relates to the use of a pharmaceutical composition containing a compound of the formula (I), or a pharmaceutically acceptable derivative thereof, in treating pain, such as described above. In one embodiment, the compound of formula (I) is essentially the only active ingredient of the composition. In one embodiment, the pain is neuropathic pain.
In order that the nature of the present invention may be more clearly understood, preferred forms thereof will now be described with reference to the following non-limiting examples.
Compounds of formula (I) may be prepared using the methods depicted or described herein or known in the art for the preparation of compounds of analogous structure. It will be understood that minor modifications to methods described herein or known in the art may be required to synthesise particular compounds of formula (I).
To a solution of the carboxylic acid (5.51 mmol) in ethanol (50 mL) was added acetyl chloride (16.5 mmol). The solution was stirred at room temperature for 4 h, then concentrated under reduced pressure. The residue was dissolved in di ethyl ether (70 mL), and washed with sat. NaHCO3 (3 x 70 mL), water (70 mL) and brine (70 mL). The organic phase was dried with NaSO4 and concentrated under reduced pressure, affording the ethyl ester as a white solid.
Ethyl 8-Bromododecanoate
1H NMR (500 MHz, CDCI3), δ 4.08 (q, J=7.0Hz, 2H), 3.40 (t, J=7.5Hz 2H), 2.28 (t, J=7.5Hz 2H), 1 .84 (p, J=7.5Hz, 2H), 1 .60-1 .57 (m, 2H), 1 .41 -1 .38 (m, 2H), 1 .34-1 .30 (m, 4H), 1 .24 (t, J=7.5Hz, 3H).
Ethyl 11-Hydroxyundecanoate
1H NMR (500 MHz CDCI3), δ 4.10 (q, J=7.5Hz, 2H), 3.38 (t, J=7.5, 2H), 2.24 (t, J=7.5Hz 2H), 1 .60-1 .96 (m, 4H), 1 .34-1 .30 (m, 13H). Ethyl 12-Bromododecanoate
1H NMR (500 MHz, CDCI3), δ 4.08 (q, J=7.0Hz, 2H), 3.37 (t, J=7.0Hz, 2H), 2.24 (t, J=7.5Hz, 2H), 1 .80 (p, J=7.5Hz, 2H), 1 .60-1 .56 (m, 2H), 1 .40-1 .37 (m, 2H), 1 .24-1 .22 (m, 12H), 1 .20 (t, J=7.5Hz, 3H).
Ethyl 12-Hydroxydodecanoate 1H NMR (500 MHz, CDCI3), δ 4.10 (q, J=7.0Hz, 2H), 3.36 (t, J=6.5Hz 2H), 2.25
(t, J=7.5Hz 2H), 1 .60-1 .52 (m, 4H), 1 .24-1 .22 (m, 15H).
General procedure for the synthesis of cyano ethyl ester
To a solution of the bromo alkyl ethyl ester (8.88 mmol) and sodium cyanide (26.66mmol) in DMSO (20ml) was stirred under nitrogen atmosphere at 60°C for 18 hours. Water (70ml) was added to the reaction mixture, and the product extracted with ethyl acetate (3x 50ml). The combined extracts were washed with brine (50ml), dried over sodium sulfate, and the solvent was removed in vacuo.
Ethyl 4-cyanobutanoate
1H NMR (500 MHz, CDCI3): δ 4.06 (q, J=7.0Hz, 2H), 2.39 (t, J=7.5Hz, 2H), 2.37 (t, J=7.5Hz, 2H) 1 .91 -1 .88 (m, 2H), 1 .20 (t, J=7.0Hz, 3H) Ethyl 6-cyanohexanoate
1H NMR (500 MHz CDCI3): δ 4.10(q, J=7.0Hz, 2H), 2.30 (t, J=7.0Hz, 2H), 2.27 (t, J=7.0Hz, 2H), 1 .63-1 .58(m, 4H), 1 .44-1 .42 (m, 2H), 1 .20 (t, J=7.0Hz, 3H)
Ethyl 7-cyanoheptanoate
1H NMR (500 MHz, CDCI3): δ 4.10 (q, J=7.0Hz, 2H), 2.31 (t, J=7.0Hz, 2H), 2.27 (t, J=7.0Hz, 2H), 1 .65-1 .60(m, 4H), 1 .45-1 .44 (m, 2H), 1 .35-1 .33 (m, 2H), 1 .22 (t, J=7.5Hz, 3H)
Ethyl 8-cyanooctanoate
1H NMR (500 MHz, CDCI3): δ 4.12 (q, J=7.0Hz, 2H), 2.32 (t, J=7.0Hz, 2H), 2.27 (t, J=7.0Hz, 2H), 1 .66-1 .60 (m, 4H), 1 .44-1 .41 (m, 2H), 1 .34-1 .31 (m, 4H), 1 .24 (t, J=7.5Hz, 3H)
Ethyl 12-cyanododecanoate
1H NMR (500 MHz, CDCI3): δ 4.12 (q, J=7.0Hz, 2H), 2.30 (t, J=7.0Hz, 2H), 2.24 (t, J=7.0Hz, 2H), 1 .65-1 .56(m, 4H), 1 .43-1 .38 (m, 2H), 1 .30-1 .26 (m, 12H), 1 .24 (t, J=7.5Hz, 3H)
General method for the synthesis of aldehydes via cyano intermediates
To a solution of the cyano ethyl esters (4.8mmol) in pyridine (26ml) were added water (13ml), acetic acid (13ml), sodium hyposphite (39.06mmol) and Raney nickel. The suspension was then stirred at 40°C for 2hr. The catalyst was removed by filtration, and washed with ethanol (5ml). Water (300ml) and diethyl ether (80ml) were added to the filtrate, and the organic layer was separated. The aqueous phase was further extracted with diethyl ether (2x80ml), and the combined extracts were washed with water (300ml), and brine (100ml), and dried over Na2SO4 anhydrous, concentrated under vacuo, and the residue was purified by silica gel dry column vacuum chromatography ( DCVC) by stepwise gradient elution with dichloromethane/hexane (50:50 to 100:0).
Ethyl-5-oxopentanoate
1H NMR (500 MHz, CDCI3), δ 9.76 (t, J=1 .5Hz, 1 H), 4.1 1 (q, J=7.5Hz, 2H), 2.51 (td, J=7.5, 1 .5Hz, 2H), 2.34 (t, J=7.5Hz 2H), 1 .94-1 .91 (m, 2H), 1 .23 (t, J=7.5Hz, 3H).
Ethyl 7-oxoheptanoate 1H NMR (500 MHz, CDCI3), δ 9.74 (t, J=1 .5Hz, 1 H), 4.10 (q, J=7.5Hz, 2H), 2.41
(td, J=7.5, 1 .5Hz, 2H), 2.28 (t, J=7.5Hz 2H), 1 .65-1 .62 (m, 4H), 1 .34-1 .32 (m, 2H), 1 .23 (t, J=7.5Hz, 3H).
Ethyl 8-oxooctanoate
1H NMR (500 MHz, CDCI3), δ 9.76 (t, J=1 .5Hz, 1 H), 4.12 (q, J=7.5Hz, 2H), 2.42 (td, J=7.5, 1 .5Hz, 2H), 2.27 (t, J=.5Hz 2H), 1 .66-1 .60 (m, 4H), 1 .35-1 .32 (m, 4H), 1 .24 (t, J=.5Hz, 3H).
Ethyl 9-oxononanoate
1H NMR (500 MHz, CDCI3), δ 9.71 (t, J=1 .5Hz, 1 H), 4.07 (q, J=7.5Hz, 2H), 2.38 (td, J=7.5, 1 .5Hz, 2H), 2.24 (t, J=7.5Hz 2H), 1 .60-1 .56 (m, 4H), 1 .30-1 .24 (m, 6H), 1 .21 (t, J=7.5Hz, 3H)
Ethyl 13-oxotridecanoate
1H NMR (500 MHz, CDCI3), δ 9.71 (t, J=1 .5Hz, 1 H), 4.10 (q, J=7.0Hz, 2H), 2.38 (td, J=7.5, 1 .5Hz, 2H), 2.26 (t, J=7.5Hz 2H), 1 .61 -1 .56 (m, 4H), 1 .27-1 .24 (m, 14H), 1 .21 (t, J=7.5Hz, 3H) General procedure for synthesis of aldehydes via alcohol intermediates
To a suspension of PCC (6.68 mmol) and Celite (1 .440 g) in anhydrous DCM (20 mL) under nitrogen, was slowly added the alcohol (3.93 mmol) in anhydrous DCM (6 mL). The mixture was stirred for 2 hr under nitrogen, after which diethyl ether (50 mL) was slowly added. The resulting mixture was stirred for 10 min, and then filtered over Celite. The Celite was washed with ether (2 x 20 mL), and the filtrate concentrated in vacuo. The residue was purified on silica gel by stepwise gradient elution with dichloromethane/hexane (40:60 to 100:0).
Ethyl 11-oxoundecanoate
1H NMR (500 MHz, CDCI3), δ 9.71 (t, J=2.0Hz, 1 H), 4.10 (t, J=7.5Hz, 2H), 2.36 (td, J=7.5, 1 .5Hz, 2H), 2.28 (t, J=7.5Hz 2H), 1 .66-1 .58 (m, 4H), 1 .34-1 .29 (m, 10H), 1 .25 (t, J=7.5Hz, 3H)
Ethyl 12-oxododecanoate
1H NMR (500 MHz, CDCI3), δ 9.66 (t, J=1 .5Hz, 1 H), 4.04 (t, J=7.5Hz, 2H), 2.32 (td, J=7.5, 1 .5Hz, 2H), 2.19 (t, J=7.5Hz 2H), 1 .54-1 .50 (m, 4H), 1 .20-1 .70 (m, 12H), 1 .15 (t, J=7.5Hz, 3H)
General procedure for the synthesis of triphenylphosphouium bromides
A solution of triphenylphosphine (12.0 mmol) and the bromo-alkane (12 mmol) in deoxygenated anhydrous toluene (30ml) was refluxed for 3 days under a nitrogen atmosphere. The solvent was removed under educed pressure, and the resulting oil was triturated with n-hexane until a solid product was produced. The product was then isolated as a white solid by filtration.
Triphenyl(octyl)phosphounium bromide
1H NMR (500 MHz, CDCI3): δ 7.85-7.80 (m, 6H), 7.79-7.76 (m, 3H), 7.70-7.67 (m, 6H), 3.77-3.75 (m 2H), 1 .61 -1 .59 (m, 4H), 1 .23-1 .17 (m, 8H), 0.82 (t, J=7Hz, 3H)
Triphenyl(nonyl)phosphounium bromide 1H NMR (500 MHz CDCI3): δ 7.86-7.80 (m, 6H), 7.78-7.76 (m, 3H), 7.70-7.66 (m,
6H), 3.79-3.78 (m 2H), 1 .60-1 .59 (m, 4H), 1 .24-1 .17 (m, 10H), 0.83 (t, J=7Hz, 3H)
Triphenyl(decyl)phosphounium bromide
1H NMR (500 MHz, CDCI3): δ 7.82-7.78 (m, 6H), 7.77-7.75 (m, 3H), 7.70-7.66 (m, 6H), 3.72-3.66 (m 2H), 1 .58-1 .57 (m, 4H), 1 .21 -1 .15 (m, 12H), 0.82 (t, J=7Hz, 3H) Triphenyl(undecyl)phosphounium bromide
1H NMR (500 MHz, CDCI3): δ 7.86-7.78 (m, 6H), 7.77-7.71 (m, 3H), 7.70-7.66 (m, 6H), 3.82-3.78 (m 2H), 1 .61 -1 .60 (m, 4H), 1 .27-1 .17 (m, 14H), 0.85 (t, J=7Hz, 3H)
Triphenyl(tridecyl)phosphounium bromide
1H NMR (500 MHz, CDCI3): δ 7.84 (m, 6H), 7.86-7.80 (m, 6H), 7.78-7.71 (m, 3H), 7.70-7.67 (m, 6H) 3.79-7.78 (m 2H), 1 .61 -1 .60 (m, 4H), 1 .28-1 .17 (m, 18H), 0.85 (t, J=7Hz, 3H)
General procedure for the synthesis of MUFA ethyl esters
To a suspension of n-alkyl triphenylphosphonium bromide (7.07 mmol) in anhydrous THF (10 mL) at 0°C under a nitrogen atmosphere, was added NaN(TMS)2 (1 .0 M in THF, 6.43 mmol). The resulting orange mixture was stirred for 40 min at room temperature. The mixture was then cooled to -78°C, and the aldehyde (3.21 mmol) in THF (5 mL) was added dropwise by syringe. Stirring at -78°C was continued for 30 min after which the reaction mixture was allowed to warm to room temperature. After further stirring for 2 hr, the reaction was quenched with saturated aqueous NH4CI (20 mL), and extracted with DCM (3 x 40 mL). The combined extracts were dried over Na2SO4, and
the DCM removed in vacuo. The residue was purified on silica gel by stepwise gradient elution with dichloromethane/hexane (20:80 to 50:50). ethyl (132)-octadec-13-enoate
1H NMR (500 MHz, CDCI3): δ 5.35-5.33 (m, 2H), 4.1 1 (q, J=7.0Hz, 2H), 2.28 (t, J=7.5Hz, 2H), 2.02-2.01 (m, 4H), 1 .60 (p, J=7.0Hz, 2H), 1 .34-1 .23 (m, 23H), 0.88 (t, J=7.0Hz, 3H) ethyl (122)-octadec-12-enoate
1H NMR (500 MHz, CDCI3): δ 5.35-5.33 (m, 2H), 4.1 1 (q, J=7.0Hz, 2H), 2.26 (t, J=7.0Hz, 2H), 2.03-2.02 (m, 4H), 1 .60 (p, J=7.0Hz, 2H), 1 .35-1 .27 (m, 23H), 0.88 (t, J=7.0Hz, 3H) methyl (112)-octadec-11-enoate
1H NMR (500 MHz, CDCI3): δ 5.35-5.33 (m, 2H), 2.30 (t, J=7.0Hz, 2H), 2.01 -2.00 (m, 4H), 1 .60 (p, J=7.0Hz, 2H), 1 .31 -1 .28 (m, 23H), 0.88 (t, J=7.0Hz, 3H) ethyl (82)-octadec-8-enoate 1H NMR (500 MHz, CDCI3): δ 5.35-5.33 (m, 2H), 4.1 1 (q, J=7.0Hz, 2H), 2.24 (t,
J=7.5Hz, 2H), 2.01 -2.00 (m, 4H), 1 .62 (p, J=7.5Hz, 2H), 1 .32-1 .26 (m, 23H), 0.88 (t, J=7.0Hz, 3H) ethyl (72)-octadec-7-enoate
1H NMR (500 MHz, CDCI3): δ 5.32-5.30 (m, 2H), 4.1 1 (q, J=7.0Hz, 2H), 2.27 (t, J=7.5Hz, 2H), 2.04-2.01 (m, 4H), 1 .61 (p, J=7.0Hz, 2H), 1 .36-1 .26 (m, 23H), 0.88 (t, J=7.0Hz, 3H) ethyl (112)-hexadec-11-enoate
1H NMR (500 MHz, CDCI3): δ 5.36-5.34 (m, 2H), 4.1 1 (q, J=7.0Hz, 2H), 2.34 (t, J=7.5Hz, 2H), 2.03- 2.01 (m, 4H), 1 .62 (p, J=7.0Hz, 2H), 1 .34-1 .23 (m, 19H), 0.88 (t, J=7.0Hz, 3H)
methyl (10Z)-hexadec-10-enoate
1H NMR (500 MHz, CDCI3): δ 5.35-5.33 (m, 2H), 3.66 (s, 3H), 2.30 (t, J=7.0Hz, 2H), 2.03-2.00 (m, 4H), 1 .60 (p, J=7.0Hz, 2H), 1 .34-1 .24 (m, 16H), 0.88 (t, J=7.0Hz, 3H) ethyl (72)-hexadec-7-enoate 1H NMR (500 MHz, CDCI3): δ 5.35-5.33 (m, 2H), 4.12 (q, J=7.0Hz, 2H), 2.30 (t,
J=7.5Hz, 2H), 2.04-1 .98 (m, 4H), 1 .62 (p, J=7.5Hz, 2H), 1 .35-1 .23 (m, 19H), 0.88 (t, J=7.0Hz, 3H) ethyl (52)-hexadec-5-enoate
1H NMR (500 MHz, CDCI3): δ 5.40-5.30 (m, 2H), 4.1 1 (q, J=7.0Hz, 2H), 2.30 (t, J=7.5Hz, 2H), 2.09-2.00 (m, 4H), 1 .66 (p, J=7.5Hz, 2H), 1 .34-1 .22 (m, 19H), 0.88 (t, J=7.0Hz, 3H) methyl (4Z)-hexadec-4-enoate
1H NMR (500 MHz, CDCI3): δ 5.36-5.30 (m, 2H), 3.64 (s, 3H), 2.34-2.31 (m, 4H), 2.02 (q, J=7.0Hz, 2H), 1 .34-1 .22 (m, 18H), 0.88 (t, J=7.0Hz, 3H) General procedure for the synthesis of MUFAs
To a solution of the fatty acid ethyl ester (1 .66 mmol) in ethanol (25 mL) was added 1 .5M NaOH (12 mL). The mixture was heated to 40°C for 5 min to obtain a clear solution. Stirring was continued at room temperature for 2 hr. The volume of the reaction mixture was reduced to 20 mL by rotary evaporation, and the solution was adjusted to pH 3 with 1 .0M HCI. The product was extracted with (3x25ml) dichloromethane, then dried over Na2SO4, filtered, and solvent was removed in vacuo.
(13Z)-octadec-13-enoic acid
1H NMR (500 MHz, CDCI3): δ 5.36-5.34 (m, 2H), 2.35 (t, J=7.5Hz, 2H), 1 .99-2.06 (m, 4H), 1 .64 (p, J=7.0Hz, 2H), 1 .34-1 .27 (m, 20H), 0.89 (t, J=7.0Hz, 3H)
(12Z)-octadec-12-enoic acid
1H NMR (500 MHz, CDCI3): δ 5.36-5.34 (m, 2H), 2.35 (t, J=7.5Hz, 2H), 1 .99-2.04 (m, 4H), 1 .64 (p, J=7.0Hz, 2H), 1 .34-1 .27 (m, 20H), 0.89 (t, J=7.0Hz, 3H)
(11 Z)-octadec-11 -enoic acid 1H NMR (500 MHz, CDCI3): δ 5.35-5.33 (m, 2H), 2.30 (t, J=7.5Hz, 2H), 1 .99- 2.04
(m, 4H), 1 .60 (p, J=7.0Hz, 2H), 1 .31 -1 .28 (m, 20H), 0.88 (t, J=7.0Hz, 3H)
(8Z)-octadec-8-enoic acid
1H NMR (500 MHz, CDCI3): δ 5.35-5.34 (m, 2H), 2.35 (t, J=7.5Hz, 2H), 1 .98-2.04 (m, 4H), 1 .62 (p, J=7.0Hz, 2H), 1 .32-1 .26 (m, 20H), 0.89 (t, J=7.0Hz, 3H) (7Z)-octadec-7-enoic acid
1H NMR (500 MHz, CDCI3): δ 5.36-5.34 (m, 2H), 2.35 (t, J=7.5Hz, 2H), 1 .98-2.04 (m, 4H), 1 .64 (p, J=7.0Hz, 2H), 1 .34-1 .27 (m, 20H), 0.89 (t, J=7.0Hz, 3H)
(11 Z)-hexadec-11 -enoic acid
1H NMR (500 MHz, CDCI3): δ 5.36-5.34 (m, 2H), 2.35 (t, J=7.5Hz, 2H), 2.03- 2.01 (m, 4H), 1 .64 (p, J=7.0Hz, 2H), 1 .34-1 .27(m, 16H), 0.89 (t, J=7.0Hz, 3H)
(10Z)-hexadec-10-enoic acid
1H NMR (500 MHz, CDCI3): δ 5.36-5.34 (m, 2H), 2.35 (t, J=7.5Hz, 2H), 2.03-2.01 (m, 4H), 1 .63 (p, J=7.0Hz, 2H), 1 .35-1 .25 (m, 16H), 0.89 (t, J=7.0Hz, 3H)
(7Z)-hexadec-7-enoic acid 1H NMR (500 MHz, CDCI3): δ 5.35-5.33 (m, 2H), 2.30 (t, J=7.5Hz, 2H), 2.03-2.01
(m, 4H), 1 .60 (p, J=7.0Hz, 2H), 1 .30-1 .23 (m, 16H), 0.88 (t, J=7.0Hz, 3H)
(5Z)-hexadec-5-enoic acid
1H NMR (500 MHz, CDCI3): δ 5.34-5.30 (m, 2H), 2.36(t, J=7.5Hz, 2H), 2.01 -1 .98 (m, 4H), 1 .70 (p, J=7.5Hz, 2H), 1 .33-1 .26 (m, 16H), 0.88 (t, J=7.0Hz, 3H)
(4Z)-hexadec-4-enoic acid 1H NMR (500 MHz, CDCI3): δ 5.40-5.34 (m, 2H), 2.35-2.40 (m, 4H), 2.05 (q,
J=7.0Hz, 2H), 1 .26-1 .07 (m, 18H), 0.88 (t, J=7.0Hz, 3H)
General procedure for synthesis of 2a - 7a, 9a - 12a, 17a - 22a, 24a
To a solution of fatty acid (2.0 mmol) in anhydrous DMF (10 imL) was added hydroxybenzotriazole hydrate (2.40 mmol), and EDCI (2.80 mmol). The mixture was stirred at room temperature for 1 h, then glycine (1 .0 mmol) and triethylamine (0.607 g, 6.0 mmol) were added. The reaction mixture was stirred for 18 h, then diluted with water (50 mL). The crude product was extrated with ethyl acetate (3 x 25 imL) and purified on silica gel by stepwise gradient elution with chloroform/isopropanol (100:0 to 90:10), yielding the amides as white solids. ethyl 2-[[(Z)-octadec-15-enoyl]amino]acetate (2a)
1H NMR (500 MHz, CDCI3) δ 5.92 (s, 1 H), 5.40-5.30 (m, 2H), 4.22 (q, J=7.0Hz, 2H), 4.04 (d, J=5.5Hz, 2H), 2.24 (t, J=7.5Hz, 2H), 2.08-1 .95 (m, 4H), 1 .65 (p, J=7.0Hz, 2H), 1 .35-1 .20 (m, 23H), 0.96 (t, J=7.5Hz, 3H) ethyl 2-[[(Z)-octadec-13-enoyl]amino]acetate (3a) 1H NMR (500 MHz, DMSO-d6) δ 8.18 (t, J=6.0Hz, 1 H), 5.32-5.30 (m, 2H), 4.06
(q, J=7.0Hz, 2H), 3.76 (d, J=6.0Hz, 2H), 2.10 (t, J=7.5Hz, 2H),1 .99-1 .95 (m, 4H), 1 .46 (p, J=7.0Hz, 2H), 1 .30-1 .23(m, 20H), 1 .17(t, J=7.0Hz, 3H), 0.84 (t, J=7.0Hz, 3H) ethyl 2-[[(Z)-octadec-12-enoyl]amino]acetate (4a)
1H NMR (500 MHz, DMSO-d6) δ 8.19 (t, J=6.0Hz, 1 H), 5.35-5.33 (m, 2H), 4.21 (q, J=7.0Hz, 2H), 3.76 (d, J=5.5Hz, 2H, 2H), 2.20 (t, J=7.5Hz, 2H), 2.04-1 .99 (m, 4H), 1 .46 (p, J=7.0Hz, 2H), 1 .30-1 .23 (m, 20H), 1 .17 (t, J=7.0Hz, 3H), 0.88 (t, J=7.0Hz, 3H)
ethyl 2-[[(Z)-octadec-11-enoyl]amino]acetate (5a)
1H NMR (500 MHz, DMSO-d6) δ 8.18 (t, J=6.0Hz, 1 H), 5.32-5.30 (m, 2H), 4.06 (q, J=7.0Hz, 2H), 3.76 (d, J=6.0Hz, 2H, 2H), 2.10(t, J=7.5Hz, 2H), 2.00-1 .95(m, 4H),
1 .46 (p, J=7.0Hz, 2H), 1 .30-1 .23(m, 20H), 1 .17(t, J=7.0Hz, 3H), 0.84 (t, J=7.0Hz, 3H) ethyl 2-[[(E)-octadec-11-enoyl]amino]acetate (6a)
1H NMR (500 MHz, DMSO-d6) δ 8.18 (t, J=6.0Hz, 1 H), 5.35-5.30 (m, 2H), 4.06 (q, J=7.0Hz, 2H), 3.76 (d, J=6.0Hz, 2H, 2H), 2.09 (t, J=7.5Hz, 2H), 1 .98-1 .88(m, 4H),
1 .47 (p, J=7.0Hz, 2H), 1 .32-1 .20 (m, 20H), 1 .17 (t, J=7.0Hz, 3H), 0.84 (t, J=7.0Hz, 3H) ethyl 2-[[(Z)-octadec-10-enoyl]amino]acetate (7a) 1H NMR (500 MHz, DMSO-d6) δ 8.18 (t, J=6.0Hz, 1 H), 5.32-5.30 (m, 2H), 4.05
(q, J=7.0Hz, 2H), 3.76 (d, J=6.0Hz, 2H, 2H), 2.10 (t, J=7.5Hz, 2H), 2.00-1 .95 (m, 4H), 1 .47 (p, J=7.5Hz, 2H), 1 .30-1 .23 (m, 20H), 1 .17 (t, J=7.0Hz, 3H), 0.84 (t, J=7.0Hz, 3H) ethyl 2-[[(E)-octadec-9-enoyl]amino]acetate (9a)
1H NMR (500 MHz, DMSO-d6) δ 8.18(t, J=6.0Hz, 1 H), 5.36-5.34 (m, 2H), 4.06(q, J=7.0Hz, 2H), 3.76(d, J=6.0Hz, 2H, 2H), 2.09(t, J=7.5Hz, 2H), 1 .94- 1 .91 (m, 4H), 1 .47 (p, J=7.0Hz, 2H), 1 .30-1 .23(m, 20H), 1 .17(t, J=7.0Hz, 3H), 0.84 (t, J=7.0Hz, 3H) ethyl 2-[[(Z)-octadec-8-enoyl]amino]acetate (10a)
1H NMR (500 MHz, DMSO-d6) δ 8.19 (t, J=6.0Hz, 1 H), 5.32-5.30 (m, 2H), 4.07 (q, J=7.0Hz, 2H), 3.77 (d, J=6.0Hz, 2H, 2H), 2.10 (t, J=7.5Hz, 2H), 2.00-1 .95 (m, 4H), 1 .47 (p, J=7.5Hz, 2H), 1 .28-1 .20 (m, 20H), 1 .17 (t, J=7.0Hz, 3H), 0.84 (t, J=7.0Hz, 3H) ethyl 2-[[(Z)-octadec-7-enoyl]amino]acetate (11a)
1H NMR (500 MHz, DMSO-d6) δ 8.20 (t, J=6.0Hz, 1 H), 5.32-5.30 (m, 2H), 4.06 (q, J=7.5Hz, 2H), 3.76 (d, J=6.0Hz, 2H, 2H), 2.10 (t, J=7.0Hz, 2H), 1 .99-1 .95 (m, 4H), 1 .48 (p, J=7.0Hz, 2H), 1 .31 -1 .23 (m, 20H), 1 .17 (t, J=7.0Hz, 3H), 0.88 (t, J=7.0Hz, 3H)
ethyl 2-[[(Z)-octadec-6-enoyl]amino]acetate (12a)
1H NMR (500 MHz, DMSO-d6) δ 8.19 (t, J=6.0Hz, 1H), 5.35-5.33 (m, 2H), 4.06 (q, J=7.5Hz, 2H), 3.76 (d, J=6.0Hz, 2H, 2H), 2.10 (t, J=7.0Hz, 2H), 1.99-1.95 (m, 4H), 1.48 (p, J=7.0Hz, 2H), 1.30-1.22 (m, 20H), 1.17 (t, J=7.0Hz, 3H), 0.84 (t, J=7.0Hz, 3H) ethyl 2-[[(Z)-hexadec-11-enoyl]amino]acetate (17a)
1H NMR (500 MHz, DMSO-d6) δ 8.18 (t, J=6.0Hz, 1H), 5.33-5.31 (m, 2H), 4.07 (q, J-7.0HZ, 2H), 3.76 (d, J-6.0Hz, 2H), 2.09 (t, J=7.5Hz, 2H), 1.98-1.95 (m, 4H), 1.46 (p, J=7.0Hz, 2H), 1.28-1.23 (m, 16H), 1.16 (t, J=7.0Hz, 3H), 0.88 (t, J=7.0Hz, 3H) ethyl 2-[[(Z)-hexadec-10-enoyl]amino]acetate (18a) 1H NMR (500 MHz, DMSO-d6) δ 8.18 (t, J=6.0Hz, 1H), 5.35-5.33 (m, 2H), 4.06 (q, J=7.0Hz, 2H), 3.76 (d, J=5.5Hz, 2H), 2.09 (t, J=7.5Hz, 2H), 1.99-1.95 (m, 4H), 1.46 (p, J=7.0Hz, 2H), 1.30-1.23 (m, 16H), 1.17(t, J=7.0Hz, 3H), 0.84 (t, J=7.0Hz, 3H) ethyl 2-[[(Z)-hexadec-9-enoyl]amino]acetate (19a)
1H NMR (500 MHz, DMSO-d6) δ 8.15 (t, J=6.0Hz, 1H), 5.29-5.27 (m, 2H), 4.05 (q, J=7.0Hz, 2H), 3.74 (d, J=5.5Hz, 2H), 2.07 (t, J=7.5Hz, 2H), 1.96-1.92 (m, 4H), 1.45 (p, J=7.0Hz, 2H), 1.27-1.21 (m, 16H), 1.15 (t, J=7.0Hz, 3H), 0.82 (t, J=7.0Hz, 3H) ethyl 2-[[(Z)-hexadec-7-enoyl]amino]acetate (20a)
1H NMR (500 MHz, DMSO-d6) δ 8.18 (t, J=6.0Hz, 1H), 5.32-5.30 (m, 2H), 4.06 (q, J=7.0Hz, 2H), 3.77 (d, J=6.0Hz, 2H), 2.09 (t, J=7.5Hz, 2H), 1.97-1.95 (m, 4H), 1.48 (p, J=7.5Hz, 2H), 1.30-1.23 (m, 16H), 1.17 (t, J=7.0Hz, 3H), 0.84 (t, J=7.0Hz, 3H) ethyl 2-[[(Z)-hexadec-5-enoyl]amino]acetate (21a)
1H NMR (500 MHz, DMSO-d6) δ 8.20 (t, J=5.5Hz, 1H), 5.34-5.30 (m, 2H), 4.06 (q, J=7.0Hz, 2H), 3.77 (d, J=6.0Hz, 2H), 2.10 (t, J=7.5Hz, 2H), 2.00-1.95 (m, 4H), 1.52 (p, J=7.0Hz, 2H), 1.28-1.23 (m, 16H), 1.17 (t, J=7.0Hz, 3H), 0.84 (t, J=7.0Hz, 3H)
ethyl 2-[[(Z)-hexadec-4-enoyl]amino]acetate (22a)
1H NMR (500 MHz, DMSO-d6) δ 8.23 (t, J=6.0Hz, 1 H), 5.32-5.30 (m, 2H), 4.06 (q, J=7.0Hz, 2H), 3.77 (d, J=6.0Hz, 2H), 2.20 (t, J=7.0Hz, 2H), 2.15-2.12 (m, 2H), 1 .99- 1 .97 (m, 2H), 1 .29-1 .23(m, 18H), 1 .17 (t, J=7.0Hz, 3H), 0.84 (t, J=7.0Hz, 3H) ethyl 2-[[(Z)-tetradec-9-enoyl]amino]acetate (24a)
1H NMR (500 MHz, DMSO-d6): δ 8.19 (t, J=6.0Hz, 1 H), 5.32-5.30 (m, 2H), 4.07 (q, J=7.0Hz, 2H), 3.77 (d, J=6.0Hz, 2H), 2.10 (t, J=7.5Hz, 2H), 2.05-1 .90 (m, 4H), 1 .47 (p, J=7.5Hz,2H), 1 .30-1 .20 (m, 12H), 1 .17 (t, J=7.0Hz, 2H), 0.85 (t, J=7.0Hz, 3H)
General procedure for synthesis of 2 - 7, 9 - 12, 16 - 22, 24 To a solution of the ethyl ester (0.51 mmol) in ethanol (30 mL), was added 1 M
NaOH (10 mL). The solution was stirred at 40°C for 3 h. The ethanol was removed under reduced pressure, and the aqueous residue was adjusted to pH 2 with 0.5M HCI. The resulting suspension was filtered and the solid product washed with water (10 mL) and ethanol (5 mL). 2-[[(Z)-octadec-15-enoyl]amino]acetic acid (2)
1H NMR (500 MHz, CDCI3) δ 6.02 (s, 1 H), 5.40-5.30 (m, 2H), 4.09 (d, J=5.5Hz, 2H), 2.27 (t, J=7.5Hz, 2H), 2.10-1 .95 (m, 4H), 1 .65 (p, J=7.0Hz, 2H), 1 .35-1 .20 (m, 20H), 0.96 (t, J=7.5Hz, 3H)
2-[[(Z)-octadec-13-enoyl]amino]acetic acid (3) 1H NMR (500 MHz, DMSO-d6): δ 8.06 (t, J=5.5Hz, 1 H), 5.32-5.30 (m, 2H), 3.70
(d, J=6.0HZ, 2H), 2.09 (t, J=7.5Hz, 2H), 1 .98-1 .95 (m, 4H), 1 .47 (p, J=7.0Hz, 2H), 1 .31 - 1 .23 (m, 20H), 0.84 (t, J=7.0Hz, 3H)
2-[[(Z)-octadec-12-enoyl]amino]acetic acid (4)
1H NMR (500 MHz, DMSO-d6): δ 7.90 (t, J=5.5Hz, 1 H), 5.32-5.30 (m, 2H), 3.61 (d, J=5.5HZ, 2H), 2.08(t, J=7.5Hz, 2H), 1 .99-1 .95(m, 4H), 1 .46 (p, J=7.0Hz, 2H), 1 .30-1 .22 (m, 20H), 0.84 (t, J=7.0Hz, 3H)
2-[[(Z)-octadec-11-enoyl]amino]acetic acid (5)
1H NMR (500 MHz, DMSO-d6): δ 8.00 (t, J=5.5Hz, 1 H), 5.32-5.30 (m, 2H), 3.65 (d, J=6.0Hz, 2H), 2.07 (t, J=7.5Hz, 2H), 1 .99-1 .95(m, 4H), 1 .46 (p, J=6.5Hz, 2H), 1 .30- 1 .22(m, 20H), 0.84 (t, J=7.0Hz, 3H) 2-[[(E)-octadec-11-enoyl]amino]acetic acid (6)
1H NMR (500 MHz, DMSO-d6): δ 7.94 (t, J=5.5Hz, 1 H), 5.36-5.34 (m, 2H), 3.65 (d, J=6.0Hz, 2H), 2.08 (t, J=7.0Hz, 2H), 1 .93-1 .92 (m, 4H), 1 .46 (p, J=6.5Hz, 2H), 1 .28- 1 .22(m, 20H), 0.84 (t, J=7.0Hz, 3H)
2-[[(Z)-octadec-10-enoyl]amino]acetic acid (7) 1H NMR (500 MHz, DMSO-d6): δ 8.04 (t, J=5.5Hz, 1 H), 5.32-5.30 (m, 2H), 3.70
(d, J=6.0HZ, 2H), 2.08 (t, J=7.5Hz, 2H), 1 .99-1 .95 (m, 4H), 1 .47 (p, J=7.0Hz, 2H), 1 .30- 1 .23 (m, 20H), 0.84 (t, J=7.0Hz, 3H)
2-[[(E)-octadec-9-enoyl]amino]acetic acid (9)
1H NMR (500 MHz, DMSO-d6): δ 8.04(t, J=5.5Hz, 1 H), 5.36-5.40 (m, 2H), 3.70 (d, J=6.0Hz, 2H), 2.10 (t, J=7.0Hz, 2H), 1 .94-1 .91 (m, 4H), 1 .48 (p, J=7.0Hz, 2H), 1 .30- 1 .23 (m, 20H), 0.84 (t, J=7.0Hz, 3H)
2-[[(Z)-octadec-8-enoyl]amino]acetic acid (10)
1H NMR (500 MHz, DMSO-d6): δ 8.02 (t, J=5.0Hz, 1 H), 5.32-5.30 (m, 2H), 3.70 (d, J=6.0HZ, 2H), 2.09(t, J=7.5Hz, 2H), 1 .98-1 .95 (m, 4H), 1 .46 (p, J=7.0Hz, 2H), 1 .31 - 1 .23 (m, 20H), 0.84 (t, J=7.0Hz, 3H)
2-[[(Z)-octadec-7-enoyl]amino]acetic acid (11)
1H NMR (500 MHz, DMSO-d6): δ 8.10 (t, J=5.5Hz, 1 H), 5.32-5.30 (m, 2H), 3.70 (d, J=6.0HZ, 2H), 2.10 (t, J=7.0Hz, 2H), 1 .97 (m, 4H), 1 .48 (p, J=7.0Hz, 2H), 1 .31 -1 .23 (m, 20H), 0.84 (t, J=7.0Hz, 3H)
2-[[(Z)-octadec-6-enoyl]amino]acetic acid (12)
1H NMR (500 MHz, DMSO-d6): δ 8.04 (t, J=5.5Hz, 1H), 5.32-5.30 (m, 2H), 3.70 (d, J=6.0Hz, 2H), 2.10 (t, J=7.0Hz, 2H), 1.98-1.95 (m, 4H), 1.48 (p, J=7.5Hz, 2H), 1.30- 1.23 (m, 20H), 0.84 (t, J=7.0Hz, 3H) 2-[[(Z)-hexadec-11 -enoyl]amino]acetic acid (17)
1H NMR (500 MHz, DMSO-d6): δ 8.07 (t, J=5.5Hz, 1H), 5.32-5.30 (m, 2H), 3.70 (d, J=5.5Hz, 2H), 2.09 (t, J=7.5Hz, 2H), 1.98-1.95 (m, 4H), 1.46 (p, J=7.0Hz, 2H), 1.31- 1.23(m, 16H), 0.84 (t, J=7.0Hz, 3H)
2-[[(Z)-hexadec-10-enoyl]amino]acetic acid (18) 1H NMR (500 MHz, DMSO-d6): δ 8.02 (t, J=5.5Hz, 1H), 5.32-5.30 (m, 2H),
3.68(d, J=6.0Hz, 2H), 2.08 (t, J=7.5Hz, 2H), 1.99-1.95 (m, 4H), 1.46 (p, J=7.0Hz, 2H), 1.30-1.22 (m, 16H), 0.84 (t, J=7.0Hz, 3H)
2-[[(Z)-hexadec-9-enoyl]amino]acetic acid (19)
1H NMR (500 MHz, DMSO-d6): δ 8.05 (t, J=5.5Hz, 1H), 5.32-5.30 (m, 2H), 3.68 (d, J=6.0HZ, 2H), 2.09 (t, J=7.5Hz, 2H), 1.98-1.96(m, 4H), 1.46 (p, J=6.5Hz, 2H), 1.28- 1.23 (m, 16H), 0.84 (t, J=7.0Hz, 3H)
2-[[(Z)-hexadec-7-enoyl]amino]acetic acid (20)
1H NMR (500 MHz, DMSO-d6): δ 8.02 (t, J=5.5Hz, 1H), 5.32-5.30 (m, 2H), 3.67 (d, J=5.5Hz, 2H), 2.09 (t, J=7.5Hz, 2H), 1.97-1.96 (m, 4H), 1.47 (p, J=7.0Hz, 2H), 1.30- 1.23 (m, 16H), 0.84 (t, J=7.0Hz, 3H)
2-[[(Z)-hexadec-5-enoyl]amino]acetic acid (21)
1H NMR (500 MHz, DMSO-d6): δ 8.00 (t, J=5.5Hz, 1H), 5.32-5.30 (m, 2H), 3.60 (d, J=5.5Hz, 2H), 2.10(t, J=7.5Hz, 2H), 1.97-1.95 (m, 4H), 1.51 (p, J=7.5Hz, 2H), 1.28- 1.23(m, 16H), 0.84 (t, J=7.0Hz, 3H)
2-[[(Z)-hexadec-4-enoyl]amino]acetic acid (22)
1H NMR (500 MHz, DMSO-d6): δ 7.70 (t, J=5.5Hz, 1 H), 5.32-5.30 (m, 2H), 3.51 (d, J=5.0Hz, 2H), 2.20 (m, 2H), 2.10 (t, J=6.5Hz,2H), 1 .98-1 .95 (m, 2H), 1 .28-1 .23 (m, 18H), 0.84 (t, J=7.0Hz, 3H) 2-[[(Z)-tetradec-9-enoyl]amino]acetic acid (24)
1H NMR (500 MHz, DMSO-d6): δ 8.09 (t, J=6.0Hz, 1 H), 5.32-5.30 (m, 2H), 3.69 (d, J=6.0Hz, 2H), 2.09 (t, J=7.5Hz, 2H), 2.05-1 .90 (m, 4H), 1 .45 (p, J=7.5Hz,2H), 1 .30- 1 .18 (m, 12H), 0.84 (t, J=7.0Hz, 3H)
General procedure for synthesis of 28a - 33a, 35a, 61a, 65a - 66a
To a solution of fatty acid (2.0 mmol) in anhydrous DMF (10 mL) was added hydroxybenzotriazole hydrate (2.40 mmol), and EDCI (2.80 mmol). The mixture was stirred at room temperature for 1 h, then the BOC protected amino acid (1 .0 mmol) and triethylamine (6.0 mmol) were added. The reaction mixture was stirred for 18 h, then diluted with water (50 mL). The crude product was extrated with ethyl acetate (3 x 25 mL) and purified on silica gel by stepwise gradient elution with chloroform/isopropanol (100:0 to 90:10), yielding the desired product in yeilds ranging from 40 - 90 %.
methyl (2S)-6-(tert-butoxycarbonylamino)-2-[[(Z)-octadec-9-enoyl]amino] hexanoate (28a)
White powder.1H NMR (500 MHz, CDCI3): δ 6.04 (d, J=7.0Hz, 1H), 5.35-5.33 (m, 2H), 4.62-4.58 (m, 1H), 3.74 (s, 3H), 3.10 (m, 2H), 2.22 (t, J=7.5Hz, 2H), 2.01-1.99 (m, 4H), 1.86-1.80 (m, 1H), 1.72-1.60 (m, 4H), 1.52-1.49 (m, 2H), 1.44-1.42 (m, 9H), 1.37-1.26 (m, 22H), 0.88 (t, J=7.0Hz, 3H). methyl (2R)-6-(tert-butoxycarbonylamino)-2-[[(Z)-octadec-9-enoyl]amino] hexanoate (29a)
White powder.1H NMR (500 MHz, CDCI3): δ 6.05-6.03 (d, J=7.0Hz, 1H), 5.35- 5.33 (m, 2H), 4.60-4.57 (m, 1H), 3.74 (s, 3H), 3.11-3.08 (m, 2H), 2.21 (t, J=7.5Hz, 2H), 2.02-1.98 (m, 4H), 1.86-1.80 (m, 1H), 1.70-1.60 (m, 4H), 1.52-1.45 (m, 2H), 1.44-1.42 (m, 9H), 1.34-1.25 (m, 22H), 0.88 (t, J=7.0Hz, 3H). methyl (2S)-5-(tert-butoxycarbonylamino)-2-[[(Z)-octadec-9-enoyl]amino] pentanoate (30a) White powder.1H NMR (500 MHz, CDCI3): δ 8.13(d, J=8.0Hz, 1H), 6.76-6.75 (m,
1H), 5.32-5.30 (m, 2H), 4.18-4.17 (m. 1H), 3.60 (s, 3H), 2.88 (q, J=6.5Hz, 2H), 2.10- 2.08 (m, 2H), 1.98-1.96 (m, 4H), 1.65-1.62(m, 1H), 1.52-1.44 (m, 3H), 1.41-1.38 (m, 2H), 1.35-1.33 (m, 9H), 1.28-1.22 (m, 20H), 0.84 (t, J=7.0Hz, 3H). methyl-(2S)-4-(tert-butoxycarbonylamino)-2-[[(Z octadec-9-enoyl]amino] butanoate (31a)
White powder. 1H NMR (500 MHz, CDCI3): δ 8.13 (d, J=7.5Hz, 1H), 6.79-6.77 (m,1H), 5.32-5.30 (m, 2H), 4.24-4.20 (m.1H), 3.60 (s, 3H), 2.69-2.90 (m, 2H), 2.09 (t, J=7.0Hz, 2H), 1.97 (q, J=7.0Hz, 4H), 1.85-1.78 (m, 1H), 1.69-1.64 (m, 1H), 1.46 (p, J=7.0Hz, 2H), 1.37-1.35(πι, 9H), 1.30-1.20 (m, 20H), 0.84 (t, J=7.0Hz, 3H). methyl (2S)-3-(tert-butoxycarbonylamino)-2-[[(Z)-octadec-9-enoyl]amino] propanoate (32a)
White powder.1H NMR (500 MHz, CDCI3): δ: 8.02 (d, J=7.5Hz, 1H), 6.85-6.83 (m, 1H), 5.32-5.30 (m, 2H), 4.27-4.25 (q, J=7.0Hz, 1H), 3.58 (s, 3H), 3.24-3.22 (m, 2H),
2.09 (t, J=7.5Hz, 2H), 1.97 (q, J=7.0Hz, 4H), 1.46 (p, J=7.0Hz, 2H), 1.37-1.35(m, 9H), 1.30-1.20 (m, 20H), 0.84 (t, J=7.0Hz, 3H). methyl (2S)-6-(tert-butoxycarbonylamino)-2-[[(ir)-octadec-9-enoyl]amino] hexanoate (33a) White powder.1H NMR (500 MHz, CDCI3): δ 6.04 (br, 1H), 5.35-5.33 (m, 2H),
4.62-4.58 (m, 2H), 3.75 (s, 3H), 3.10 (m, 2H), 2.22 (t, J=7.5Hz, 2H), 2.00-1.90 (m, 4H), 1.86-1.80 (m, 1H), 1.70-1.60 (m, 4H), 1.501.4 (m, 11 H), 1.37-1.26 (m, 22H), 0.86 (t, J=7.0Hz, 3H). methyl (2S)-6-(tert-butoxycarbonylamino)-2-[[(Z)-octadec-13-enoyl]amino] hexanoate (35a)
White powder.1H NMR (500 MHz, DMSO d6): δ 8.10 (d, J=7.5Hz, 1H), 6.74 (t, J=5.5Hz, 1H), 5.32-5.30 (m, 2H), 4.19-4.14 (m, 1H), 3.60 (s, 3H), 2.88-2.84 (m, 2H), 2.08 (t, J=7.5Hz, 2H), 1.98-1.95 (m, 4H), 1.66-1.60 (m, 1H), 1.58-1.51 (m, 1H), 1.47- 1.44 (m, 2H), 1.35 (m, 9H), 1.30-1.22 (m, 24H), 0.85 (t J=7.0Hz, 3H). methyl (2R)-6-(tert-butoxycarbonylamino)-2-[[(2)-hexadec-13- enoyl]amino]hexanoate (61a)
White powder.1H NMR (500 MHz, CDCI3): 6.09-6.07 (m, 1H), 5.34-5.30 (m, 2H), 4.60-4.58 (m, 2H), 3.72 (s, 3H), 3.10-3.07 (m, 2H), 2.20 (t, J=7.5Hz, 2H), 2.05-1.98 (m, 4H), 1.83-1.79 (m, 1H), 1.68-1.64 (m, 1H), 1.63-1.60 (m, 2H), 1.41 (m, 9H), 1.37-1.24 (m, 20H), 0.93 (t, J=7.0Hz, 3H). methyl (2S)-6-(tert-butoxycarbonylamino)-2-[[(2)-hexadec-13-enoyl]amino ]hexanoate (65a)
White powder.1H NMR (500 MHz, CDCI3): δ 8.09 (d, J=7.5Hz, 1H), 6.75 (m, 1H), 5.33-5.26 (m, 2H), 4.17-4.16 (m, 1H) 3.59 (s, 3H), 2.88-2.84 (m, 2H), 2.10 (t, J=7.5Hz, 2H), 2.00-1.96 (m, 4H), 1.70-1.65 (m, 1H), 1.56-1.52 (m, 1H), 1.47-1.44 (m, 2H), 1.35(m, 9H), 1.30-1.23 (m, 20H), 0.90 (t, J=7.0Hz, 3H).
methyl (2S)-6-(tert-butoxycarbonylamino)-2-[[(2)-hexadec-9-enoyl]amino] hexanoate. (66a)
White powder.1H NMR (500 MHz, CDCI3): δ 7.94 (d, J=7.5Hz, 1H), 673 (m, 1H)), 5.34-5.26 (m, 2H), 4.12-4.10 (m, 1H), 2.88-2.84 (m, 2H), 2.11-2.06 (m, 2H), 1.99-1.95 (m, 4H), 1.65-1.62 (m, 1 H), 1.54-1.50 (m, 1 H), 1.48-1.44 (m, 2H), 1.35(m, 9H) 1.27-1.23 (m, 20H), 0.84 (t, J=7.0Hz, 3H).
General procedure for synthesis of 28b - 33b, 35b, 61b, 65b - 66b
To a solution of 28a - 33a, 35a, 61a, 65a - 66a (0.50 mmol) in ethanol (30 mL) was added 1M NaOH (10 mL). The solution was stirred at 40°C for 3 h. The ethanol was removed under reduced pressure, and the aqueous residue was adjusted to pH 2 with 0.5M HCI. The resulting suspension was filtered and the solid product washed with water (10 mL) and ethanol (5 mL), yielding 28b - 33b, 35b, 61b, 65b - 66b in yields ranging from 60 - 95%.
(2S)-6-(tert-butoxycarbonylamino)-2-[[(Z)-octadec-9-enoyl]amino]hexanoic acid (28b)
White powder.1H NMR (500 MHz, DMSO-d6): δ 7.95 (d, J=7.5Hz, 1H), 6.74 (t, J=5.5Hz, 1H), 5.32-5.30 (m, 2H), 4.12-4.11 (m, 1H), 2.88-2.84 (m, 2H), 2.10-2.08 (m, 2H), 1.98-1.96 (m, 6H), 1.65-1.62 (m, 1H), 1.54-1.51 (m, 1H), 1.49-1.44 (m, 2H), 1.35- 1.33 (m, 9H), 1.28-1.22 (m, 22H), 0.84 (t, J=7.0Hz, 3H). (2R)-6-(tert-butoxycarbonylamino)-2-[[(Z>octadec-9-enoyl]amino]hexanoic acid (29b)
White powder. 1H NMR (500 MHz, DMSO-d6): δ 7.95(d, J=8.0Hz, 1H), 6.73 (t, J=5.5Hz, 1H), 5.32-5.30 (m, 2H), 4.13-4.10 (m. 1H), 2.87-2.84 (m, 2H), 2.10-2.06 (m, 2H), 1.98-1.96 (m, 5H), 1.68-1.60 (m, 1H), 1.54-1.51 (m, 1H), 1.49-1.44 (m, 2H), 1.35- 1.33 (m, 9H), 1.28-1.22 (m, 23H), 0.84 (t, J=7.0Hz, 3H).
(2S)-5-(tert-butoxycarbonylamino)-2-[[(2)-octadec-9-enoyl]amino]pentanoic acid (30b)
White powder.1H NMR (500 MHz, DMSO-d6): δ 7.78 (d, J=8.0Hz, 1H), 678-6.77 (m,1H), 5.32-5.30 (m, 2H), 4.14-4.11 (m.1H), 2.88 (q, J=6.5Hz, 2H), 2.10-2.08 (m, 2H), 1.98-1.96 (m, 5H), 1.65-1.62 (m, 1H), 1.51-1.38 (m, 4H), 1.35-1.33 (m, 9H), 1.28-1.22 (m, 20H), 0.84 (t, J=7.0Hz, 3H).
(2S)-4-(tert-butoxycarbonylamino)-2-[[(2)-octadec-9-enoyl]amino]butanoic acid (31b)
White powder.1H NMR (500 MHz, DMSO-d6): δ 8.00 (d, J=8.0Hz, 1H), 6.76-6.74 (m, 1H), 5.32-5.30 (m, 2H), 4.17-4.14 (m.1H), 2.99-2.88 (m, 2H), 2.09 (t, J=7.0Hz, 2H), 1.98-1.96 (m, 4H), 1.84-1.79 (m, 1H), 1.66-1.60 (m, 1H), 1.48-1.45 (m, 2H), 1.38-1.34 (m, 9H), 1.28-1.22 (m, 20H), 0.84 (t, J=7.0Hz, 3H).
(2S)-3-(tert-butoxycarbonylamino)-2-[[(2)-octadec-9-enoyl]amino]propanoic acid (32b) White powder.1H NMR (500 MHz, DMSO-d6): δ 7.86 (d, J=8.0Hz, 1 H), 6.75-6.73
(m,1H), 5.32-5.30 (m, 2H), 4.24-4.20 (m, 1H), 3.24-3.22 (m, 2H), 2.09 (t, J=7.0Hz, 2H), 1.97 (q, J=7.0Hz, 4H), 1.48-1.45 (m, 2H), 1.38-1.34 (m, 9H), 1.28-1.22 (m, 20H), 0.84 (t, J=7.0Hz, 3H).
(2S)-6-(tert-butoxycarbonylamino)-2-[[(E>octadec-9-enoyl]amino]hexanoic acid (33b)
White powder.1H NMR (500 MHz, DMSO-d6): δ 8.06 (d, J=8.0Hz, 1H), 7.96 (br, 3H), 5.35 (m, 2H), 4.12 (m, 1H), 2.72 (br, 2H), δ 2.098 (t, J=7.5Hz, 2H), 1.98- 1.80 (m, 4H), 1.48-1.45 (m, 2H), 1.38-1.34 (m, 9H), 1.28-1.22 (m, 20H), 0.82 (t, J=7.0Hz, 3H).
(2S)-6-(tert-butoxycarbonylamino)-2-[[(Z)-octadec-13-enoyl]amino]hexanoic acid (35b)
White powder.1H NMR (500 MHz, DMSO-d6): δ 7.95 (d, J=7.5Hz, 1H), 6.74 (t, J=5.5Hz, 1H), 5.32-5.30 (m, 2H), 4.11-4.10 (m, 1H), 2.88-1.84 (m, 2H), 2.10-2.08 (m,
2H), 1.98-1.96 (m, 4H), 1.68-1.62(m, 1H), 1.54-1.51 (m, 1H), 1.49-1.44 (m, 2H), 1.35- 1.33 (m, 9H), 1.28-1.22 (m, 24H), 0.84 (t, J=7.0Hz, 3H).
(2R)-6-(tert-butoxycarbonylamino)-2-[[(Z)-hexadec-13-enoyl]amino]hexanoic acid (61b) White powder.1H NMR (500 MHz, DMSO-d6): δ 7.94 (d, J=7.5Hz, 1H), 674 (m,
1 H)), 5.34-5.26 (m, 2H), 4.11 -4.10 (m, 1 H), 2.88-2.84 (m, 2H), 2.11 -2.06 (m, 2H), 1.99- 1.95 (m, 4H), 1.65-1.62 (m, 1H), 1.54-1.50 (m, 1H), 1.48-1.44 (m, 2H), 1.35(m, 9H) 1.27-1.23 (m, 20H), 0.90 (t, J=7.0Hz, 3H).
(2S)-6-(tert-butoxycarbonylamino)-2-[[(2)-hexadec-13-enoyl]amino]hexanoic acid (65b)
White powder.1H NMR (500 MHz, DMSO-d6): δ 8.05 (d, J=7.5Hz, 1H), 6.75 (m, 1H) 5.33-5.26 (m, 2H), 4.16-4.12 (m, 1H), 2.88-2.84 (m, 2H), 2.10 (t, J=7.5Hz, 2H), 2.00-1.96 (m, 4H), 1.70-1.65 (m, 1H), 1.60-1.46 (m, 5H), 1.35(m, 9H), 1.37-1.23 (m, 18H), 0.90 (t, J=7.0Hz, 3H). (2S)-6-(tert-butoxycarbonylamino)-2-[[(2)-hexadec-9-enoyl]amino]hexanoic acid (66b)
White powder.1H NMR (500 MHz, DMSO-d6): δ 7.94 (d, J=7.5Hz, 1H), 673 (m, 1 H)), 5.34-5.26 (m, 2H), 4.12-4.10 (m, 1 H), 2.88-2.84 (m, 2H), 2.11 -2.06 (m, 2H), 1.99- 1.95 (m, 4H), 1.65-1.62 (m, 1H), 1.54-1.50 (m, 1H), 1.48-1.44 (m, 2H), 1.35(m, 9H) 1.27-1.23 (m, 20H), 0.84 (t, J=7.0Hz, 3H).
General procedure for synthesis of 28 - 33, 35, 61, 65 - 66
28b - 33b, 35b, 61b, 65b - 66b were dissolved in dichloromethane (2 mL) and 2M HCI in diethyl ether (2 mL) was added. The solution was stirred at room temperature for 4 hours and then concentrated in vacuo. The resulting solid was washed with diethyl ether, yielding 28 - 33, 35, 61 , 65 - 66.
(2S)-6-amino-2-[[(Z)-octadec-9-enoyl]amino]hexanoic acid.HCI (28)
Light yellow powder. 1H NMR (500 MHz, DMSO d6): δ 8.05 (d, J=7.5Hz, 1H), 7.90 (s, 3H), 5.32-5.30 (m, 2H), 4.14-4.12 (m, 1H), 2.74-2.71 (m, 2H), 2.10 (t, J=7.5Hz, 2H), 1.98-1.9 (m, 4H), 1.67-1.65 (m, 1 H), 1.57-1.44 (m, 5H), 1.31 -1.23 (m, 22H), 0.84 (t, J=7.0Hz, 3H). 13C NMR (100 MHz, DMSO-d6): δ 173.69, 172.31, 129.60(2C), 51.49, 38.38, 34.99, 31.24, 30.33, 29.10, 29.06, 28.79, 28.66(2C), 28.64, 28.59, 28.55, 26.59, 26.54, 26.44, 25.21, 22.40, 22.06, 13.92. HRMS (ESI) m/z [M+H]+ calcd for C24H46N2O3, 411.3581; found, 411.3589.
(2R)-6-amino-2-[[(Z)-octadec-9-enoyl]amino]hexanoic acid.HCI (29) Light yellow powder. 1H NMR (500 MHz, DMSO d6): δ 8.05 (d, J=7.5Hz, 1H),
7.90 (s, 3H), 5.32-5.30 (m, 2H), 4.14-4.12 (m, 1H), 2.72 (m, 2H), 2.10 (t, J=7.5Hz, 2H), 1.98-1.95 (m, 4H), 1.66 (m, 1H), 1.57-1.44 (m, 5H), 1.31-1.23 (m, 22H), 0.84 (t, J=7.0Hz, 3H). 13C NMR (100 MHz, DMSO-d6): δ 173.72, 172.36, 129.63(2C), 51.53, 38.42, 35.03, 31.27, 30.33, 29.14, 29.10, 28.83, 28.70(2C), 28.68, 28.63, 28.59, 26.62, 26.58, 26.48, 25.25, 22.44, 22.09, 13.96. HRMS (ESI) m/z [M+H]+ calcd for C24H46N2O3, 411.3581; found, 411.3579.
(2S)-5-amino-2-[[(Z)-octadec-9-enoyl]amino]pentanoic acid.HCI (30)
Light yellow powder. 1H NMR (500 MHz, DMSO d6): δ 8.10 (d, J=8.0Hz, 1H), 7.94 (s, 3H), 5.32-5.30 (m, 2H), 4.17-4.16 (m, 1H), 2.75-2.73 (m, 2H), 2.10 (t, J=7.5Hz, 2H), 1.97 (q, J=6.0Hz, 4H), 1.76-1.74 (m, 1H), 1.60-1.56 (m, 3H), 1.47-1.45 (m, 2H), 1.31-1.23 (m, 20H), 0.84 (t, J=7.0Hz, 3H). 13C NMR (100 MHz, DMSO-d6): δ 173.44, 171.37, 129.64(2C), 51.23, 38.34, 35.06, 31.28, 29.15, 29.09(2C), 28.82, 28.72(2C), 28.68, 28.58, 28.00, 26.63, 26.57, 25.25, 22.80, 22.09, 13.96. HRMS (ESI) m/z [M+H]+ calcd for C23H44N2O3, 397.3425; found 397.3428. (2S)-4-amino-2-[[(Z)-octadec-9-enoyl]amino]butanoic acid.HCI (31)
Light yellow powder. 1H NMR (500 MHz, DMSO d6): δ 8.22 (d, J=7.5Hz, 1H), 7.97 (s, 3H), 5.32-5.30 (m, 2H), 4.27-4.26 (m, 1H), 2.79-2.77 (m, 2H), 2.10 (t, J=7.5Hz, 2H), 1.98-1.95 (m, 5H), 1.88-1.86 (m, 1H), 1.48-1.46 (m, 2H), 1.31-1.23 (m, 20H), 0.84 (t, J=7.0Hz, 3H).13C NMR (100 MHz, DMSO-d6): δ 172.77, 172.54, 129.63(2C), 49.68,
36.15, 35.18, 31.26, 29.14, 29.08, 28.97(2C), 28.82, 28.71, 28.67, 28.62, 28.58, 26.62, 26.56, 25.19, 22.08, 13.94. HRMS (ESI) m/z [M+H]+ calcd for C22H42N2O3, 383.3268; found, 383.3273.
(2S)-3-amino-2-[[(Z)-octadec-9-enoyl]amino]propanoic acid.HCI : (32) Light yellow powder.1H NMR (500 MHz, DMSO-d6): δ 8.31 (d, J=8.0Hz, 1 H), 8.0
(s, 3H), 5.32-5.30 (m, 2H), 4.47-4.44 (m, 1H), 3.22-2.19 (m, 1H), 2.99-2.97 (m, 1H), 2.15-2.13 (m, 2H), 1.97(q, J=6.0Hz, 4H), 1.49-1.47 (m, 2H), 1.31-1.23 (m, 20H), 0.84 (t, J=7.0Hz, 3H). 13C NMR (100 MHz, DMSO-d6): δ 172.92, 170.81, 129.63(2C), 49.82, 35.18, 31.26, 29.14, 29.08(2C), 28.82(2C), 28.74, 28.67, 28.62, 28.58, 26.62, 26.56, 24.88, 22.08, 13.95. HRMS (ESI) m/z [M+H]+ calcd for C2iH4oN2O3, 369.3112; found, 369.3109.
(2S)-6-amino-2-[[(E)-octadec-9-enoyl]amino]hexanoic acid.HCI (33)
1H NMR (500MHz, DMSO-d6): δ 8.06 (d, J=7.5Hz,1H), 7.96 (br, 3H), 5.35-5.30 (m, 2H), 4.16 - 4.12 (m, 1H), 2.72 (br, 2H), 2.09 (t, 2H, J=7.5Hz), 1.92 (m, 4Hz), 1.66 (m, 1H), 1.56- 1.46 (m, 5H), 1.33 - 1.21 (m, 22H), 0.84 (t, J=7.0Hz, 3H).13C NMR (100MHz, CDCI3): δ 174.16, 172.80, 130.50 (2C), 51.99, 38.84, 35.47, 32.40, 31.72, 30.81, 29.12, 29.03, 28.77, 28.65(2C), 28.63, 28.60, 28.56, 26.92, 25.69, 22.89, 22.54, 14.40. HRMS (ESI) mlz [M + H]+ calcd for C24H46N2O3, 411.3581 ; found, 411.3597.
(2S)-6-amino-2-[[(Z)-octadec-13-enoyl]amino]hexanoic acid.HCI (35) Light yellow powder. 1H NMR (500 MHz, DMSO-d6): δ 8.04 (d, J=7.5Hz, 1H),
7.89 (s, 3H), 5.32-5.30 (m, 2H), 4.15-4.11 (m.1H), 2.72 (m, 2H), 2.09 (t, J=7.0Hz, 2H), 1.97 (m, 4H), 1.67-1.65 (m, 1H), 1.58-1.44 (m, 5H), 1.31-1.23 (m, 22H), 0.84 (t, J=7.0Hz, 3H).13C NMR (100 MHz, DMSO-d6): δ 173.71, 172.35, 129.62, 129.58, 51.49, 38.43, 35.03, 31.36, 30.37, 29.09, 29.01, 28.97, 28.86(2C), 28.82, 28.64, 28.58, 28.56, 26.47, 26.31 , 25.25, 22.44, 21.71 , 13.81. HRMS (ESI) m/z [M+H]+ calcd for C24H46N2O3, 411.3581 ;found,411.3589.
(2R)-6-amino-2-[[(Z)-hexadec-13-enoyl]amino]hexanoic acid.HCI (61 )
Light yellow powder. 1 H NMR (500 MHz, DMSO-d6): δ 8.03 (d, J=8.0Hz, 1 H), 7.82 (s, 3H), 5.33-5.27 (m, 2H), 4.15-4.12 (m, 1 H), 2.75-2.71 (m, 2H), 2.10 (t, J=7.5Hz, 2H), 2.00-1 .96 (m, 4H), 1 .68-1 .65 (m, 1 H), 1 .58-1 .45 (m, 5H), 1 .37-1 .23 (m, 18H), 0.90 (t, J=7.0Hz, 3H). 13C NMR (100 MHz, DMSO-d6): δ 173.73, 172.35, 131 .27, 129.01 , 51 .49, 38.48, 35.04, 30.36, 29.1 1 , 29.01 (2C), 28.96(2C), 28.88, 28.81 , 28.62, 28.59, 26.47, 25.24, 22.42, 20.00, 14.24 HRMS (ESI) m/z [M+H]+ calcd for C22H42N2O3, 383.3268; found, 383. 3263.
(2S)-6-amino-2-[[(Z)-hexadec-13-enoyl]amino]hexanoic acid.HCI (65) Light yellow powder. 1 H NMR (500 MHz, DMSO-d6): δ 8.05 (d, J=7.5Hz, 1 H),
7.90 (s, 3H), 5.34-5.26 (m, 2H), 4.16-4.12 (m, 1 H), 2.75-2.71 (m, 2H), 2.10 (t, J=7.5Hz, 2H), 2.00-1 .96 (m, 4H), 1 .70-1 .65 (m, 1 H), 1 .60-1 .46 (m, 5H), 1 .37-1 .23 (m, 18H), 0.90 (t, J=7.0Hz, 3H). 13C NMR (100 MHz, DMSO-d6): δ 173.73, 172.35, 131 .27, 129.01 , 51 .49, 36.66, 35.03, 30.36, 29.1 1 , 29.01 (2C), 28.96(2C), 28.88, 28.81 , 28.62, 28.59, 26.47, 25.24, 22.42, 20.00, 14.24. HRMS (ESI) m/z [M+H]+ calcd for C22H42N2O3, 383.3268; found, 383. 3268.
(2S)-6-amino-2-[[(Z)-hexadec-9-enoyl]amino]hexanoic acid.HCI (66)
Light yellow powder. 1 H NMR (500 MHz, DMSO-d6): δ 8.04 (d, J=7.5Hz, 1 H), 7.90 (s, 3H), 5.32-5.30 (m, 2H), 4.13-4.12 (m, 1 H), 2.74-2.71 (m, 2H), 2.09 (t, J=8.0Hz, 2H), 1 .99-1 .95 (m, 4H), 1 .68-1 .65 (m, 1 H), 1 .56-1 .45 (m, 5H), 1 .32-1 .23 (m, 18H), 0.84 (t, J=7.0Hz, 3H). 13C NMR (100 MHz, DMSO-d6): δ 173.73, 172.35, 129.65(2C), 51 .51 , 38.42, 35.06, 31 .12, 30.37, 29.12(2C), 29.08, 28.67, 28.61 , 28.56, 28.26, 26.60, 26.47, 25.24, 22.43, 22.07, 13.94. HRMS (ESI) m/z [M+H]+ calcd for C22H42N2O3, 383.3268; found, 383. 3266. Synthesis of 36
28a was dissolved in dichloromethane (2 imL) and 2M HCI in diethyl ether (2 imL) was added. The solution was stirred at room temperature for 4 hours and then concentrated in vacuo. The resulting solid was washed with diethyl ether, yielding 36.
methyl (2S)-6-amino-2-[[(Z)-octadec-9-enoyl]amino]hexanoate.HCI (36)
Wax, 1H NMR (500 MHz, DMSO d6): δ 8.20-8.18 (d, J=7.0Hz, 1 H), 7.86 (s, 3H), 5.32-5.30 (m, 2H), 4.19-4.17 (m, 1 H), 3.60 (s, 3H), 2.75-2.71 (m, 2H), 2.10 (t, J=7.5Hz, 2H), 1 .99-1 .95 (m, 4H), 1 .68-1 .50 (m, 4H), 1 .48-1 .45 (m, 2H), 1 . 28-1 .23 (m, 22H), 0.84 (t, J=7.0Hz, 3H). 13C NMR (100 MHz DMSO-d6): δ 172.71 , 172.47, 129.64, 129.62, 51 .73, 51 .63, 38.39, 34.66, 32.26, 30.21 , 29.1 1 , 29.08(2C), 28.81 (2C), 28.66(2C), 28.56, 26.60, 26.56, 26.43, 25.18, 22.31 , 22.08, 13.94. HRMS (ESI) m/z [M+H]+ calcd for C25H48N2O3, 425.3738; found,425.3740.
To a solution of oleic acid (2.0 mmol) in anhydrous DMF (10 mL) was added hydroxybenzotriazole hydrate (2.40 mmol), and EDCI (2.80 mmol). The mixture was stirred at room temperature for 1 h, then the substituted amine (1 .0 mmol) and triethylamine (6.0 mmol) were added. The reaction mixture was stirred for 18 h, then diluted with water (50 mL). The crude product was extrated with ethyl acetate (3 x 25 mL) and purified on silica gel by stepwise gradient elution with chloroform/isopropanol (100:0 to 90:10), yielding the desired products in yields from 40 - 85%.
methyl (2S)-3-hydroxy-2-[[(Z>octadec-9-enoyl]amino]propanoate (26a)
White powder.1H NMR (500 MHz, CDCI3): δ 6.40 (d, J=7.5Hz, 1H), 5.35-5.32 (m, 2H), 4.70-4.67 (m, 1H), 3.99-3.96 (dd, J=4.0, 11.0Hz, 1H), 3.93-3.91 (dd, J=3.5, 11.0Hz, 1H), 3.79 (s, 3H), 2.26 (t, J=7.5Hz, 2H), 2.04-1.99 (m, 4H), 1.65 (p, J=7.0Hz, 2H), 1.34-1.24 (m, 20H), 0.88 (t, J=7.0Hz, 3H). methyl (2R)-3-hydroxy-2-[[(Z)-octadec-9-enoyl]amino]propanoate (27a)
White powder.1H NMR (500 MHz, CDCI3): δ 6.36 (d, J=7.5Hz, 1H), 5.35-5.32 (m, 2H), 4.70-4.67 (m, 1H), 3.98-3.93 (m, 2H), 3.79 (s, 3H), 2.46 (t, J=6.0Hz, 3H).2.26 (t, J=7.5Hz, 2H), 2.03-1.99 (m, 4H), 1.65 (p, J=7.0Hz, 2H), 1.31-1.27 (m, 20H), 0.88 (t, J=7.0Hz, 3H). methyl (2S)-4-methyl-2-[[(2)-octadec-9-enoyl]amino]pentanoate (34a)
White powder.1H NMR (500 MHz, CDCI3): δ 5.80 (d, J=8.5Hz, 1H), 5.34-5.32 (m, 2H), 4.66-4.64 (m, 1H), 3.73 (s, 3H), 2.20 (t, J=7.5Hz, 2H), 2.00 (q, J=6.5Hz, 4H), 1.66-1.62 (m, 5H), 1.53-1.50 (m, 1H), 1.30-1.26 (m, 20H), 0.95-0.93 (m, 6H), 0.87 (t, J=7.0Hz, 3H). methyl (2S)-5-guanidino-2-[[(Z)-octadec-9-enoyl]amino]pentanoate (37a)
White powder.1H NMR (500 MHz, CDCI3): δ 7.64(m, 1H), 7.38 (d, J=7.5Hz, 1H), 6.92 (m, 3H), 5.35-5.31 (m, 2H), ), 4.57 (m, 1H), 4.45-4.40 (m, 1H), 3.74 (s, 3H), 3.32- 3.20 (m, 2H), 2.28 (t J=7.5Hz„ 2H),1.99 (q, J=6.0Hz, 4H), 1.90-1.76 (m, 2H), 1.68-1.58 (m, 4H), 1.31 -1.23 (m, 20H), 0.88 (t, J=7.0Hz, 3H). methyl (2S)-4-methylsulfanyl-2-[[(Z)-octadec-9-enoyl] amino] butanoate
(38a)
White powder.1H NMR (500 MHz, CDCI3): δ 6.14 (d, J=7.5Hz, 1H), 5.34-5.32 (m, 2H), 4.74-4.70 (m, 1H), 3.75 (s, 3H), 2.52-2.48 (m, 2H), 2.22 (t, J=7.5Hz, 2H).2.19- 2.14 (m, 1H), 2.08 (s, 3H), 1.99-1.94 (m, 5H), 1.63 (p, J= 7.0 Hz, 2H), 1.32-1.24 (m, 20H), 0.87 (t, J=7.0Hz, 3H).
methyl (2S)-4-methyl-2-[[(2)-octadec-9-enoyl]amino]pentanoate (39a)
White powder.1H NMR (500 MHz, CDCI3): δ 5.80 (d, J=8.5Hz, 1H), 5.34-5.32 (m, 2H), 4.66-4.64 (m, 1H), 3.73 (s, 3H), 2.20 (t, J=7.5Hz, 2H), 2.00 (q, J=6.5Hz, 4H), 1.66-1.62 (m, 5H), 1.53-1.50 (m, 1H), 1.30-1.26 (m, 20H), 0.95-0.93 (m, 6H), 0.87 (t, J=7.0Hz, 3H). methyl (2R)-4-methyl-2-[[(Z)-octadec-9-enoyl]amino]pentanoate (40a)
White powder.1H NMR (500 MHz, DMSO-d6): δ 5.80 (d, J=8.5Hz, 1H), 5.34-5.32 (m, 2H), 4.66-4.64 (m, 1H), 3.73 (s, 3H), 2.20 (t, J=7.5Hz, 2H), 2.00 (q, J=6.5Hz, 4H), 1.66-1.62 (m, 5H), 1.53-1.50 (m, 1H), 1.30-1.26(m, 20H), 0.95-0.93(m, 6H), 0.87 (t, J=7.0Hz, 3H). methyl (2S)-2-[[(Z)-octadec-9-enoyl]amino]hexanoate (41a)
White powder.1H NMR (500 MHz, DMSO-d6): δ 8.12 (d, J=7.5Hz, 1H), 5.31-5.30 (m, 2H), 4.20-4.17 (m, 1H), 3.59 (s, 3H), 2.12-2.06 (m, 2H), 1.97 (q, J=6.5Hz, 4H), 1.68- 1.62 (m, 1H), 1.60-1.54 (m, 1H), 1.46 (p, J=6.5Hz, 2H), 1.29-1.22 (m, 24H), 0.84 (t, J=7.0Hz, 6H). methyl (2S)-[[(Z)-octadec-9-enoyl]amino]propanoate (42a)
White powder.1H NMR (500 MHz DMSO-d6): δ 8.17 (d, J=6.5Hz, 1H), 5.32-5.30 (m, 2H), 4.24-4.21 (m, 1H), 3.59 (s, 3H), 2.07 (t, J=7.5Hz, 2H), 1.97 (q, J=7.0Hz, 4H), 1.45 (p, J=7.0Hz, 2H), 1.30-1.23 (m, 23H), 0.84 (t, J=7.0Hz, 3H). methyl (2R)-2-[[(2)-octadec-9-enoyl]amino]propanoate (43a)
White powder.1H NMR (500 MHz DMSO-d6): δ 8.17 (d, J=7.0Hz, 1H), 5.32-5.30 (m, 2H), 4.24-4.21 (m, 1H) 3.59 (s, 3H), 2.07 (t, J=7.5Hz, 2H), 1.97 (q, J=7.0Hz, 4H), 1.45 (p, J=7.5Hz, 2H), 1.30- 1.23 (m, 23H), 0.84 (t, J=7.0Hz, 3H). ethyl 3-[[(Z)-octadec-9-enoyl]amino]propanoate (44a) White powder.1H NMR (500 MHz, CDCI3): δ 6.04 (m, 1H), 5.35-5.32 (m, 2H),
4.17-4.13 (q, J=7.0Hz, 2H) 3.51 (q, J=7.0Hz, 2H), 2.52 (t, J=6.0Hz, 2H), 2.13 (t,
J=7.5.0Hz, 2H), 1 .97 (q, J=6.0Hz, 4H), 1 .61 -1 .58 (m, 2H), 1 .31 -1 .23 (m, 23H), 0.88 (t, J=7.0Hz, 3H). methyl (2S)-3-methyl-2-[[(2)-octadec-9-enoyl]amino]butanoate (45a)
White powder. 1H NMR (500 MHz DMSO-d6): δ 8.03 (d, J=8.0Hz, 1 H), 5.32-5.30 (m, 2H), 4.17-4.14 (m, 1 H) 3.61 (s, 3H), 2.18-2.08 (m 2H), 2.02-1 .95 (m, 5H), 1 .48-1 .44 (m, 2H) 1 .28-1 .23 (m, 20H), 0.87 (dt, J=7.0, 9.50 Hz, 9H). methyl (2R)-3-methyl-2-[[(Z)-octadec-9-enoyl]amino]butanoate (46a)
White powder. 1H NMR (500 MHz DMSO-d6): δ 8.03 (d, J=8.0Hz, 1 H), 5.32-5.30 (m, 2H), 4.16-4.13 (m, 1 H) 3.60 (s, 3H), 2.17-2.07 (m 2H), 2.01 - 1 .95 (m, 5H), 1 .47- 1 .44 (m, 2H) 1 .28- 1 .23 (m, 20H), 0.87 (dt, J=7.0, 9.50 Hz, 9H). methyl (2R)-2-[[(Z)-octadec-9-enoyl]amino]-3-phenyl-propanoate (47a)
White powder. 1H NMR (500 MHz, CDCI3): δ 7.32-7.26 (m, 3H), 7.12-7.10 (d, J=7.0Hz, 2H), 5.89-5.87 (d, J=7.5Hz, 1 H), 5.37-5.35 (m, 2H), 4.94-4.91 (m, 1 H), 3.75 (s, 3H), 3.20-3.16 (dd, J=6.0, 14.0Hz, 1 H) 3.13-3.09 (dd, J=5.5, 14.0Hz, 1 H), 2.20 (t, J=7.5Hz, 2H), 2.04 (q, J=6.5Hz, 4.0H), 1 .60 (p, J=7.0Hz, 2H), 1 .30-1 .17 (m, 20H), 0.89 (t, J=7.0Hz, 3H). ethyl (2S)-2-[[(Z)-octadec-9-enoyl]amino]-4-phenyl-butanoate (48a)
White powder. 1 H NMR (500 MHz, DMSO-d6): δ 8.25-8.20 (m, 1 H), 7.30-7.24 (m, 2H), 7.20-7.14 (m, 3H), 5.35-5.25 (m, 2H), 4.18-4.12 (m, 1 H), 4.10-4.00 (m, 2H), 2.66- 2.52 (m, 2H), 2.16-2.08 (m, 2H), 2.00-1 .80 (m, 6H), 1 .49 (d, J=7.0Hz, 2H), 1 .30-1 .20 (m, 20H), 1 .15 (t, J=7.0Hz, 2H), 0.83 (d, J=7.0Hz, 3H). ethyl (2R)-2-[[(Z)-octadec-9-enoyl]amino]-4-phenyl-butanoate (49a)
White powder. 1H NMR (500 MHz, DMSO-d6): δ 8.22 (d, J=7.5Hz, 1 H), 7.28-7.24 (m, 2H), 7.18-7.15 (m, 3H), 5.31 -5.28 (m, 2H), 4.18-4.12 (m, 1 H), 4.10-3.98 (m, 2H), 2.70-2.50 (m, 2H), 2.12 (dp, J=7.0, 4.0Hz, 2H), 2.00-1 .80 (m, 6H), 1 .49 (d, J=7.0Hz, 2H), 1 .32-1 .18 (m, 20H), 1 .15 (t, J=7.0Hz, 2H), 0.83 (d, J=7.0Hz, 3H).
methyl (2S)-3-(1H-indol-3-yl)-2-[[(2)-octadec-9-enoyl]amino]propanoate
(50a)
White powder.1H NMR (500 MHz, CDCI3): δ 8.14 (s, 1H), 7.53 (d, J=8.0Hz, 1H), 7.35 (d, J=8.0Hz, 1H), 7.20 (t, J=7.5Hz, 1H), 7.12 (t, J=7.5Hz, 1H), 6.98 (d, J=7.5Hz, 1H), 5.95 (d, J=7.5Hz, 1H), 5.35-5.33 (m, 2H), 4.14-4.10 (m, 1H), 3.70 (s, 3H), 3.33- 3.31 (t, J=5.0Hz, 2H), 2.15-2.12 (t, J=7.5Hz, 2H), 2.02-1.98 (m, 4H), 1.59-1.56 (m, 2H), 1.32-1.25 (m, 20H), 0.88 (t, J=7.0Hz, 3H) dimethyl (2S)-2-[[(Z)-octadec-9-enoyl]amino]butanedioate (53a)
White powder.1H NMR (500 MHz, CDCI3): δ 6.44 (d, J=8.5Hz, 1H), 5.35-5.33 (m, 2H), 4.88-4.86 (m, 1H), 3.79 (s, 3H), 3.72 (s, 3H), 3.09-3.04 (dd, J=4.5, 17.0Hz, 1H), 2.91-2.86 (dd, J=4.5, 17.0Hz, 1H), 2.25 (t, J=7.0Hz, 2H), 2.04 (q, J=7.0Hz, 4H), 1.68 (p, J=7.0Hz, 2H), 1.36-1.30 (m, 20H), 0.90 (t, J=7.0Hz, 3H). dimethyl (2R)-2-[[(Z)-octadec-9-enoyl]amino]butanedioate (54a)
White powder, 1H NMR (500 MHz, CDCI3): δ 6.44 (d, J=8.5Hz, 1H), 5.35-5.33 (m, 2H), 4.88-4.86 (m, 1H), 3.76 (s, 3H), 3.69 (s, 3H), 3.06-3.02 (dd, J=4.5, 17.0Hz, 1H), 2.87-2.83 (dd, J=4.5, 17.0Hz, 1H), 2.22 (t, J=7.5Hz, 2H), 2.0 (q, J=6.5Hz, 4H), 1.63 (p, J=7.0Hz, 2H), 1.34-1.26 (m, 20H), 0.88 (t, J=7.0Hz, 3H). methyl (2S)-4-amino-2-[[(Z)-octadec-9-enoyl]amino]-4-oxo-butanoate (55a)
White powder.1H NMR (500 MHz, DMSO-d6): δ 8.10 (d, J=8.0Hz, 1H), 7.35 (s, 1 H), 6.88 (s, 1 H), 5.34-5.28 (m, 2H), 4.55-4.50 (m, 1 H), 3.57 (s, 3H), 2.55-2.40 (m, 2H), 2.06 (t, J=7.5Hz, 2H), 2.00-1.94 (m, 4H), 1.45 (p, J=7.0Hz, 2H), 1.32-1.18 (m, 20H), 0.84 (d, J=7.0Hz, 3H). dimethyl (2S)-2-[[(Z)-octadec-9-enoyl]amino]pentanedioate (56a)
White powder.1H NMR (500 MHz, CDCI3): δ 6.12 (d, J=7.5Hz, 1H), 5.35-5.33 (m, 2H), 4.66-4.61 (m, 1H), 3.75 (s, 3H), 3.68 (s, 3H), 2.45-2.33 (m, 2H), 2.23-2.19 (m, 2H), 2.03-1.98 (m, 5H), 1.63 (p, J=7.0Hz, 2H), 1.30-1.26 (m, 20H), 0.88 (t, J=7.0Hz, 3H).
dimethyl (2R)-2-[[(Z)-octadec-9-enoyl]amino]pentanedioate (57a)
White powder. 1H NMR (500 MHz, CDCI3): δ 6.20 (d, J=7.5Hz, 1 H), 5.33-5.31 (m, 2H), 4.63-4.59 (m, 1 H), 3.73 (s, 3H), 3.66 (s, 3H), 2.43-2.31 (m, 2H), 2.22-2.17 (m, 2H), 2.01 -1 .95 (m, 5H), 1 .61 (p, J=7.0Hz, 2H), 1 .30-1 .25 (m, 20H), 0.86 (t, J=7.0Hz, 3H). methyl (2S)-3-(1 H-imidazol-5-yl)-2-[[(Z)-octadec-9-enoyl]amino]propanoate (58a)
White powder. 1H NMR (500 MHz, CDCI3), δ 7.56(s, 1 H), 7.10 (s, 1 H), 6.80 (s, 1 H), 5.35-5.33 (m, 2H), 4.83-4.80 (m, 1 H), 3.60 (s, 3H), 3.08 (m, 2H), 2.23 (t, J=7.5Hz, 2H), 2.01 -1 .98 (m, 2H), 1 .64-1 .60 (m, 4H), 1 .30-1 .26 (m, 20H), 0.88 (t, J=7.0Hz, 3H) methyl (2S)-2-[[(Z)-octadec-9-enoyl]amino]-3-phenyl-propanoate (59a)
White powder. 1H NMR (500 MHz, CDCI3): δ 7.32-7.26 (m, 3H), 7.12-7.10 (d, J=7.0Hz, 2H), 5.89-5.87 (d, J=7.5Hz, 1 H), 5.37-5.35 (m, 2H), 4.94-4.91 (m, 1 H), 3.75 (s, 3H), 3.20-3.16 (dd, J=6.0, 14.0Hz, 1 H) 3.13-3.09 (dd, J=5.5, 14.0Hz, 1 H), 2.20 (t, J=7.5Hz, 2H), 2.04 (q, J=6.5Hz, 4.0H), 1 .60 (p, J=7.0Hz, 2H), 1 .30-1 .17 (m, 20H), 0.89 (t, J=7.0Hz, 3H). methyl (2R)-4-methylsulfanyl-2-[[(Z)-octadec-9-enoyl] amino] butanoate
(60a) White powder. 1 H NMR (500 MHz, CDCI3): δ 6.12 (d, J=7.5Hz, 1 H), 5.34-5.32
(m, 2H), 4.74-4.70 (m, 1 H), 3.75 (s, 3H), 2.52-2.48 (m, 2H), 2.22 (t, J=7.5Hz, 2H). 2.19- 2.14 (m, 1 H), 2.08 (s, 3H), 1 .99-1 .94 (m, 5H), 1 .63 (p, J= 7.0 Hz, 2H), 1 .32-1 .24 (m, 20H), 0.87 (t, J=7.0Hz, 3H). methyl (2R)-5-guanidino-2-[[(Z)-octadec-9-enoyl]amino]pentanoate (62a) White powder. 1H NMR (500 MHz, CDCI3): δ 7.83 (m, 1 H), 7.20 (d, J=7.5Hz, 1 H),
7.05-7.03 (m, 3H), 5.34-5.32(m, 2H), 4.45-4.40 (m, 1 H), 3.74 (s, 3H), 3.36-3.20 (m, 2H), 2.28 (t J=7.5Hz, 2H), 1 .99 (q, J=6.0Hz, 4H), 1 .90-1 .76 (m, 2H), 1 .68-1 .58 (m, 4H), 1 .31 -1 .23 (m, 20H), 0.88 (t, J=7.0Hz, 3H).
methyl (2R)-3-(1H-indol-3-yl)-2-[[(2)-octadec-9-enoyl]amino]propanoate
(63a)
White powder.1H NMR (500 MHz, DMSO-d6): δ 10.84 (s, 1H), 8.18 (d, J=8.0Hz, 1H), 7.47 (d, J=8.0Hz, 1H), 7.31 (t, J=7.5Hz, 1H), 7.11 (t, J=7.5Hz, 1H), 7.03 (d, J=7.5Hz, 1H), 6.96 (d, J=7.5Hz, 1H), 5.35-5.33 (m, 2H), 4.49-4.47 (m, 1H), 3.70 (s, 3H), 3.33-3.31 (t, J=5.0Hz, 2H), 2.15-2.12 (t, J=7.5Hz, 2H), 2.02-1.98 (m, 4H), 1.59-1.56 (m, 2H), 1.32-1.25 (m, 20H), 0.88 (t, J=7.0Hz, 3H). methyl (2R)-3-(1H-imidazol-5-yl)-2-[[(Z)-octadec-9-enoyl]amino]propanoate
(64a) White powder. 1H NMR (500 MHz, CDCI3): δ 8.75 (s, 1H), 7.42 (s, 1H), 7.16 (s,
1H), 5.34-5.33 (m, 2H), 4.83-4.80 (m, 1H), 3.76 (s, 3H), 3.40-3.38 (m, 1H), 3.25-3.21 (m, 1H), 2.30 (t, J=7.5Hz, 2H), 2.01-1.98 (m, 4H), 1.64-1.60 (m, 2H), 1.30-1.26 (m, 20H), 0.88 (t, J=7.0Hz, 3H).
General procedure for synthesis of 26, 27, 34, 37-50, 53-60, 62-64 To a solution of the ester (0.51 mmol) in ethanol (30 mL), was added 1M NaOH
(10 mL). The solution was stirred at 40°C for 3 h. The ethanol was removed under reduced pressure, and the aqueous residue was adjusted to pH 2 with 0.5M HCI. The resulting suspension was filtered and the solid product washed with water (10 mL) and ethanol (5 mL). (2S)-3-hydroxy-2-[[(Z)-octadec-9-enoyl]amino]propanoic acid (26)
White powder.1H NMR (500 MHz, DMSO-d6): δ 7.87 (d, J=7.5Hz, 1H), 5.32-5.30 (m, 2H), 4.23-4.21 (m, 1H), 3.66-3.63 (dd, J=5.5,11.0Hz), 1H), 3.59-3.55 (dd, J=4.5, 11.0Hz, 1H), 2.10 (t, J=7.5Hz, 2H), 1.98-1.97 (m, 4H), 1.46 (p, J=7.0Hz, 2H), 1.31-1.23 (m, 20H), 0.84 (t, J=7.0Hz, 3H). 13C NMR (100 MHz, DMSO-d6): δ 172.37, 171.38, 129.63, 129.59, 40.82, 35.09, 31.36, 29.08, 29.00(2C), 28.94, 28.85, 28.81, 28.62, 28.57, 26.55, 26.30, 25.19, 21.70, 13.81. HRMS (ESI) m/z [M+H]+ calcd for C2iH39NO4, 370.2952; found, 370.2953.
(2R)-3-hydroxy-2-[[(2)-octadec-9-enoyl]amino]propanoic acid (27)
White powder.1H NMR (500 MHz, DMSO-d6): δ 7.88 (d, J=7.5Hz, 1H), 5.32-5.30 (m, 2H), 4.24-4.22 (m, 1H), 3.66-3.63 (dd, J=5.5, 11.0Hz, 1H), 3.59-3.55 (dd, J=4.5, 11.0Hz, 1 H), 2.11 (t, J=7.5Hz, 2H), 1.98-1.95 (m, 4H), 1.46 (p, J=7.0Hz, 2H), 1.31 -1.23 (m, 20H ), 0.84 (t, J=7.0Hz, 3H). 13C NMR (100 MHz, DMSO-d6): δ 172.27, 172.16, 129.65, 129.63, 61.46, 54.52, 35.03, 31.27, 29.13, 29.10, 28.83, 28.72, 28.69, 28.64, 28.59, 28.57, 26.62, 26.57, 25.21, 22.09, 13.95. HRMS (ESI) m/z [M+H]+ calcd for C2iH39NO4, 370.2952; found, 370.2955.
(2S)-4-methyl-2-[[(Z)-octadec-9-enoyl]amino]pentanoic acid (34) White powder.1H NMR (500 MHz, DMSO-d6): δ 7.98 (d, J=8.0Hz, 1 H), 5.32-5.30
(m, 2H), 4.20-4.18 (m, 1H), 2.09-2.06 (m, 2H), 1.97 (q, J=6.5Hz, 4H), 1.62-1.58 (m, 1H), 1.50-1.43 (m, 4H), 1.30-1.17 (m, 20H), 0.83 (t, J=7.0Hz, 9H).13C NMR (100 MHz, DMSO-de): δ 174.32, 172.19, 129.62(2C), 50.00, 35.02, 31.26, 29.08, 28.81, 28.67, 28.62, 28.59(3C), 28.57, 28.49, 26.62, 26.57, 25.25, 24.32, 22.89, 22.08, 21.17, 13.94. HRMS (ESI) m/z [M+H]+ calcd for C24H45NO3, 396.3472; found, 396.3472
(2S)-5-guanidino-2-[[(2)-octadec-9-enoyl]amino]pentanoic acid.HCI (37)
White powder. 1H NMR (500 MHz, DMSO-d6): δ 7.49 (d, J=7.5Hz, 1H), 5.32- 5.30 (m, 2H), 3.92-3.90 (m, 1H), 3.01 (t, J=6.5Hz, 2H), 2.11-2.09 (m, 2H), 1.98-1.95 (m, 4H), 1.61-1.38 (m, 6H), 1.31-1.23 (m, 20H), 0.84 (t, J=7.0Hz, 3H).13C NMR (100 MHz, DMSO-d6): δ 175.98, 170.99, 157.32, 129.64, 129.60, 53.50, 35.03, 31.28, 29.77, 29.15, 29.10(2C), 28.83, 28.77, 28.74, 28.68, 28.61, 28.58, 26.63, 26.57, 25.42, 25.16, 22.09, 13.94. HRMS (ESI) m/z [M+H]+ calcd for C24H46N4O3, 439.3643; found,439.3644.
(2S)-4-methylsulfanyl-2-[[(Z)-octadec-9-enoyl]amino] butanoic acid (38)
White powder.1H NMR (500 MHz, DMSO-d6): δ 8.04 (d, J=7.5Hz, 1H), 5.32-5.30 (m, 2H), 4.29-4.26 (m, 1H), 2.47-2.40 (m, 2H), 2.11-2.07 (m, 2H), 2.02 (s, 3H), 1.98- 1.97 (m, 4H), 1.93-1.90 (m, 1H), 1.83-1.80 (m, 1H), 1.46 (p, J=7.0Hz, 2H), 1.31-1.23 (m, 20H), 0.84 (t, J=7.0Hz, 3H). 13C NMR (100 MHz, DMSO-d6): δ 173.48, 172.34, 129.60(2C), 50.75, 35.04, 31.28, 30.70, 29.74, 29.12, 29.10(2C), 28.84, 28.68, 28.67,
28.59, 28.56, 26.62, 26.57, 25.22, 22.09, 14.57, 13.92. HRMS (ESI) m/z [M+H]+ calcd for C23H43NO3, 414.3036; found, 414.3038.
(2R)-4-methyl-2-[[(2)-octadec-9-enoyl]amino]pentanoic acid (39)
White powder.1H NMR (500 MHz, DMSO-d6): δ 7.98 (d, J=8.0Hz, 1H), 5.32-5.30 (m, 2H), 4.20-4.18 (m, 1 H), 2.09-2.06 (m, 2H), 1.97 (q, J=6.5Hz, 4H), 1.62-1.58 (m, 1 H), 1.50-1.43 (m, 4H), 1.30-1.17 (m, 20H), 0.83 (t, J=7.0Hz, 9H). 13C NMR (100 MHz, DMSO-de): δ 174.32, 172.19, 129.62(2C), 50.00, 35.02, 31.26, 29.08, 28.81, 28.67, 28.62, 28.59(3C), 28.57, 28.49, 26.62, 26.57, 25.25, 24.32, 22.89, 22.08, 21.17, 13.94. HRMS (ESI) m/z [M+H]+ calcd for C24H45NO3, 396.3472; found, 396.3472 (2S)-4-methyl-2-[[(Z)-octadec-9-enoyl]amino]pentanoic acid (40)
White powder.1H NMR (500 MHz, DMSO-d6): δ 7.98 (d, J=7.5Hz, 1H), 5.32-5.30 (m, 2H), 4.21-4.17 (m, 1H), 2.10-2.06 (m, 2H), 1.97 (q, J=6.5 Hz, 4H), 1.63-1.58 (m, 1H), 1.52-1.42 (m, 4H), 1.27-1.20 (m, 20H), 0.84 (t, J=7.0Hz, 9H).13C NMR (100 MHz, DMSO-d6): δ 174.31, 172.18, 129.61 (2C), 49.99, 35.01, 31.27, 29.09, 28.82, 28.67, 28.63, 28.60(3C), 28.58, 28.50, 26.62, 26.56, 25.25, 24.31, 22.87, 22.08, 21.15, 13.93. HRMS (ESI) m/z [M+H]+ calcd for C24H45NO3, 396.3472; found, 396.3470.
(2S)-2-[[(2)-octadec-9-enoyl]amino]hexanoic acid (41)
White powder.1H NMR (500 MHz, DMSO-d6): δ 7.97(d, J=7.5Hz, 1H), 5.32-5.30 (m, 2H), 4.14-4.01 (m, 1H), 2.11-2.09(m, 2H), 1.98-1.95 (m, 4H), 1.61-1.53 (m, 2H), 1.47-1.43 (m, 2H), 1.31-1.23 (m, 24H), 0.84 (t, J=7.0Hz, 6H).13C NMR (100 MHz, DMSO-d6): δ 173.92, 172.21, 129.62, 129.61, 51.55, 34.99, 31.27, 30.72, 29.10, 29.09, 28.82, 28.67, 28.66, 28.59, 28.58, 28.53, 27.59, 26.61, 26.57, 25.27, 22.08, 21.69, 13.93, 13.78. HRMS (ESI) m/z [M+H]+ calcd for C24H46NO3, 396.3472; found, 396.3470.
(2S)-2-[[(2)-octadec-9-enoyl]amino]propanoic acid (42) White powder.1H NMR (500 MHz DMSO-d6): δ 8.00 (d, J=8.0Hz, 1 H), 5.32-5.30
(m, 2H), 4.16-4.13 (m, 1H) 2.06 (t, J=8.0Hz, 2H), 1.97 (m, 4H), 1.45 (p, J=7.0Hz, 2H), 1.28-1.23 (m, 23H), 0.84 (t, J=7.0Hz, 3H). 13C NMR (100 MHz, DMSO-d6): δ 174.31, 171.94, 129.63, 129.62, 47.30, 34.98, 31.28, 29.12, 29.10, 28.84(2C), 28.69, 28.61,
28.59, 28.57, 26.61 , 26.57, 25.18, 22.09, 17.21 , 13.93. HRMS (ESI) m/z [M+H]+ calcd for C21 H39NO3, 354.3003; found, 354.3009.
(2R)-2-[[(2)-octadec-9-enyl] amino]propanoic acid (43)
White powder. 1H NMR (500 MHz DMSO-d6): δ 8.02 (d, J=7.5Hz, 1 H), 5.32-5.30 (m, 2H), 4.18-4.15 (m, 1 H) 2.06 (t, J=7.5Hz, 2H), 1 .99-1 .95 (m, 4H), 1 .45 (p, J=7.5Hz, 2H), 1 .28-1 .23 (m, 23H), 0.84 (t, J=7.0Hz, 3H). 13C NMR (100 MHz, DMSO-d6): δ 174.28, 171 .93, 129.61 , 129.60, 47.30, 34.98, 31 .28, 29.13, 29.1 1 , 28.84(2C), 28.69, 28.61 , 28.59, 28.57, 26.61 , 26.56, 25.18, 22.09, 17.21 , 13.93. HRMS (ESI) m/z [M+H]+ calcd for C21 H39NO3, 354.3003; found, 354.3003. 3-[[(2)-octadec-9-enoyl]amino]propanoic acid (44)
White powder. 1H NMR (500 MHz, DMSO-d6): δ 7.81 (t, J=5.0Hz, 1 H), 5.32-5.30 (m, 2H), 3.19 (q, J=7.0Hz, 4H), 2.32 (t, J=7.0Hz, 2H), 1 .97 (q, J=6.0Hz, 4H), 1 .49-1 .46 (m, 2H), 1 .31 -1 .23 (m, 20H), 0.84 (t, J=7.0Hz, 3H). 13C NMR (100 MHz, DMSO-d6): δ 173.10, 172.32, 129.89(2C), 35.40, 34.88, 34.18, 31 .39, 29.23, 29.21 , 28.94, 28.80, 28.77, 28.74, 28.69, 28.64, 26.71 , 26.68, 25.36, 22.20, 14.06. HRMS (ESI) m/z [M+H]+ calcd for C20H37NO3, 340.2846; found, 340.2850.HRMS (ESI) m/z [M+H]+ calcd for C21 H39NO3, 354.3003; found, 354.3003.
(2S)-3-methyl-2-[[(Z)-octadec-9-enoyl]amino]butanoic acid (45)
White powder. 1H NMR (500 MHz DMSO-d6): δ 7.85(d, J=8.5Hz, 1 H), 5.32-5.30 (m, 2H), 4.50-4.47 (m, 1 H) 2.18-2.09 (m 2H), 2.04-1 .95 (m, 5H), 1 .48-1 .44 (m, 2H), 1 .28-1 .23 (m, 20H), 0.84 (t, J=7.0Hz, 9H). 13C NMR (100 MHz, DMSO-d6): δ 172.25, 172.36, 129.59(2C), 57.07, 34.98, 31 .28, 29.78, 30.66, 29.83, 29.10, 28.82(2C), 28.69(2C), 28.65, 28.59, 26.61 , 26.56, 25.37, 22.08, 19.17, 18.02, 13.92. HRMS (ESI) m/z [M+H]+ calcd for C23H43NO3, 382.3316; found, 382.3319. (2R)-3-methyl-2-[[(Z)-octadec-9-enoyl]amino]butanoic acid (46)
White powder. 1H NMR (500 MHz DMSO-d6): δ 7.85 (d, J=9.0Hz, 1 H), 5.32-5.30 (m, 2H), 4.13-4.10 (m, 1 H) 2.16-2.10 (m 2H), 2.00-1 .95 (m, 5H), 1 .48-1 .44 (m, 2H) 1 .28- 1 .23 (m, 20H), 0.84 (t, J=7.0Hz, 9H). 13C NMR (100 MHz, DMSO-d6): δ 172.96, 172.14,
129.38(2C), 56.80, 34.72, 31 .28, 30.43, 29.53, 28.84, 28.83(2C), 28.56, 28.42, 28.38, 28.32, 28.31 , 26.34, 26.30, 25.1 1 , 21 .83, 18.93, 17.79, 13.92. HRMS (ESI) m/z [M+H]+ calcd for C23H43NO3, 382.3316; found, 382.3318.
(2R)-2-[[(2)-octadec-9-enoyl]amino]-3-phenyl-propanoic acid (47) White powder. 1H NMR (500 MHz, DMSO-d6): δ 7.77 (d, J=8.0Hz, 1 H), 7.20-7.12
(m,5H), 5.32-5.30 (m, 2H), 4.27-4.25 (m, 1 H), 3.07-3.06 (dd, J=5.5, 14.0Hz, 1 H), 2.85- 2.80 (dd, J=6.0, 14.0Hz, 1 H), 1 .98-1 .95 (m, 6H), 1 .36 (p, J=7.0Hz, 2H), 1 .30-1 .17 (m, 18H), 1 .1 1 -2.09 (m, 2H)), 0.84 (t, J=7.0Hz, 3H). ). 13C NMR (100 MHz, DMSO-d6): δ 173.62, 171 .46, 138.69, 129.65, 129.60, 129.27, 127.76, 125.83, 54.34, 37.24, 35.41 , 31 .29, 29.16, 29.12, 28.85(2C), 28.75, 28.70(2C), 28.61 , 28.58, 28.55, 26.65, 26.59, 25.30, 22.10, 13.94. HRMS (ESI) m/z [M+H]+ calcd for C27H43NO3, 430.3315; found, 430.3319.
(2S)-2-[[(Z)-octadec-9-enoyl]amino]-4-phenyl-butanoic acid (48)
White powder. 1H NMR (500 MHz, DMSO-d6): δ 8.10 (d, J=8.0Hz, 1 H), 7.28-7.24 (m, 2H), 7.18-7.14 (m, 3H), 5.33-5.26 (m, 2H), 4.16-4.10 (m, 1 H), 2.66-2.52 (m, 2H), 2.20-2.08 (m, 2H), 1 .98-1 .80 (m, 6H), 1 .49 (d, J=7.0Hz, 2H), 1 .32-1 .18 (m, 20H), 0.84 (d, J=7.0Hz, 3H). 13C NMR (100 MHz, DMSO-d6): δ 173.74, 172.32, 170.28, 141 .04, 129.59, 129.58, 129.28, 125.87, 59.73, 51 .20, 35.06, 32.86, 32.50, 31 .27, 29.12, 29.09, 28.83, 28.68, 28.61 (2C), 28.58, 26.62, 26.56, 25.28, 22.09, 20.74, 14.07, 13.92. HRMS (ESI) m/z [M+H]+ calcd for C28H45NO3, 443.3472; found, 443.3469.
(2R)-2-[[(Z)-octadec-9-enoyl]amino]-4-phenyl-butanoic acid (49)
White powder. 1H NMR (500 MHz, DMSO-d6): δ 8.09 (d, J=8.0Hz, 1 H), 7.28-7.24 (m, 2H), 7.18-7.14 (m, 3H), 5.34-5.28 (m, 2H), 4.14-4.08 (m, 1 H), 2.66-2.52 (m, 2H), 2.18-2.08 (m, 2H), 2.00-1 .80 (m, 6H), 1 .49 (d, J=7.0Hz, 2H), 1 .32-1 .18 (m, 20H), 0.84 (d, J=7.0Hz, 3H). 13C NMR (100 MHz, DMSO-d6): δ 173.74, 172.31 , 141 .09, 129.62, 129.61 , 128.30, 125.89, 51 .15, 35.02, 32.88, 31 .49, 31 .26, 29.10, 29.07, 28.81 , 28.66(4C), 28.59(3C), 28.57, 26.60, 26.55, 25.27, 22.08, 13.94. HRMS (ESI) m/z [M+H]+ calcd for C28H45NO3, 443.3472; found, 443.3475.
(2S)-3-(1 H-indol-3-yl)-2-[[(2)-octadec-9-enoyl]amino]propanoic acid.HCI (50)
Off-white solid.1H NMR (500 MHz, DMSO-d6): δ 10.80 (s, 1H), 7.9 (d, J=8.0Hz, 1H), 7.52-7.50 (d, J=7.50Hz, 1H), 7.31-7.30 (d, J=8.0Hz, 1H), 7.11-7.10 (d, J=2.0Hz, 1H), 7.03 (t, J=7.0Hz, 1H), 6.95 (t, J=7.0Hz, 1H), 5.32-5.30 (m, 2H), 4.45-4.44 (m, 1H), 3.16-3.12 (dd, J=5.5, 14.0Hz, 1H), 2.99-2.95 (m, 1H), 2.06-2.04 (m, 2H), 1.98-1.95 (m, 4H), 1.39-1.37 (m, 2H), 1.31-1.23 (m, 20H), 0.84 (t, J=7.0Hz, 3H).13C NMR (100 MHz, DMSO-de): δ 173.58, 172.10, 136.06, 129.66, 129.60, 127.23, 123.45, 120.82, 118.25, 118.17, 110.10, 110.06, 52.86, 35.08, 31.26, 29.12, 29.09, 28.82, 28.67, 28.58, 28.54, 28.52, 27.13(2C), 26.62, 26.57, 25.27, 22.08, 13.94. HRMS (ESI) m/z [M+H]+ calcd for C29H44N2O3, 469.3425; found, 469.3429.
(2S)-2-[[(Z)-octadec-9-enoyl]amino]butanedioic acid (53)
White powder.1H NMR (500 MHz, DMSO-d6): δ 7.95(d, J=7.5Hz, 1H), 7.31 (s, 1H), 6.86 (s, 1H), 5.32-5.30 (m, 2H), 4.47-4.45 (m, 1H), 2.54-2.50 (m, 1H), 2.43-2.38 (dd, J=7.5, 15.5Hz, 1 H), 2.05 (t, J=7.0Hz, 2H), 1.97 (q, J=6.0Hz, 4H), 1.46-1.43 (m, 2H), 1.31-1.23 (m, 20H), 0.84 (t, J=7.0Hz, 3H). 13C NMR (100 MHz, DMSO-d6): δ 172.56, 172.03, 171.67, 129.65, 129.62, 48.48, 35.02, 31.26, 29.12, 29.09, 28.82(2C), 28.68, 28.67, 28.57, 28.55, 28.53, 26.61, 26.56, 25.19, 22.08, 13.94. HRMS (ESI) m/z [M+H]+ calcd for C22H39NO5, 398.2901, found, 398.2909.
(2R)-2-[[(2)-octadec-9-enoyl]amino]butanedioic acid (54) White powder.1H NMR (500 MHz, DMSO-d6): δ 8.07 (d, J=8.0Hz, 1 H), 5.32-5.30
(m, 2H), 4.50-4.47 (m, 1H), 2.67-2.62 (dd, J=5.5, 16.0Hz, 1H), 2.54-2.50 (m, 1H), 2.05 (t, J=7.5Hz, 2H), 1.98-1.95 (m, 4H), 1.45-1.43 (m, 2H), 1.31-1.23 (m, 20H), 0.84 (t, J=7.0Hz, 3H). 13C NMR (100 MHz, DMSO-d6): δ 172.64, 172.22, 171.77, 129.72, 129.69, 48.58, 36.15, 35.11, 31.36, 29.22, 29.18, 28.92, 28.78, 28.77, 28.67, 28.65, 28.62, 26.70, 26.65, 25.28, 22.17, 14.01. HRMS (ESI) m/z [M+H]+ calcd for C22H39NO5, 398.2901, found, 398.2901.
(2S)-4-amino-2-[[(Z)-octadec-9-enoyl]amino]-4-oxo-butanoic acid (55)
White powder.1H NMR (500 MHz, DMSO-d6): δ 7.95 (d, J=8.0Hz, 1H), 7.31 (s, 1H), 6.86 (s, 1H), 5.34-5.28 (m, 2H), 4.48-4.43 (m, 1H), 2.54-2.38 (m, 2H), 2.06 (t,
J=8.0Hz, 2H), 2.00-1.94 (m, 4H), 1.44 (p, J=7.0Hz, 2H), 1.32-1.18 (m, 20H), 0.84 (d, J=7.0Hz, 3H). 13C NMR (100 MHz, DMSO-d6): δ 172.97, 171.95, 171.21, 129.63, 129.60, 48.67, 36.78, 35.06, 31.26, 29.13(2C), 29.08, 28.81, 28.70, 28.66(2C), 28.57, 26.61, 26.56, 25.21, 22.07, 13.94. HRMS (ESI) m/z [M+H]+ calcd for C22H40N2O4, 397.3061; found, 397.3065.
(2S)-2-[[(Z)-octadec-9-enoyl] amino] pentanedioic acid (56)
White powder.1H NMR (500 MHz, DMSO-d6): δ 8.0 (d, J=7.5Hz, 1H), 5.32-5.30 (m, 2H), 4.21-4.16 (m, 1H), 2.27-2.23 (m, 2H), 2.09-2.07 (m, 2H), 1.98-1.95 (m, 5H), 1.78-1.72 (m, 1H), 1.46-1.43 (m, 2H), 1.31-1.23 (m, 20H), 0.84 (t, J=7.0Hz, 3H). 13C NMR (100 MHz, DMSO-d6): δ 173.75, 173.50, 172.40, 129.64, 129.60, 51.06, 35.09, 31.37, 30.13, 29.23, 29.20(2C), 28.94, 28.79, 28.69(3C), 26.70, 26.65, 26.41, 25.30, 22.18, 13.95. HRMS (ESI) m/z [M+H]+ calcd for C23H4iNO5, 412.3058; found, 412.3061.
(2R)-2-[[(2)-octadec-9-enoyl]amino]pentanedioic acid (57)
White powder.1H NMR (500 MHz, DMSO-d6): δ 8.0 (d, J=8.0Hz, 1H), 5.32-5.30 (m, 2H), 4.20-4.15 (m, 1H), 2.26-2.23 (m, 2H), 2.09-2.07 (m, 2H), 1.98-1.95 (m, 5H), 1.78-1.72 (m, 1H), 1.47-1.45 (m, 2H), 1.31-1.23 (m, 20H), 0.84 (t, J=7.0Hz, 3H). 13C NMR (100 MHz, DMSO-d6): δ 173.71, 173.46, 172.33, 129.63(2C), 50.99, 35.02, 31.27, 30.11, 29.12 (2C), 29.09, 28.82, 28.67(3C), 28.58, 26.61, 26.56, 26.34, 25.22, 22.08, 13.94.95. HRMS (ESI) m/z [M+H]+ calcd for C23H4iNO5, 412.3058; found, 412.3060. (2S)-3-(1H-imidazol-5-yl)-2-[[(Z)-octadec-9-enoyl] amino] propanoic acid.HCI
(58)
White powder. 1H NMR (500 MHz, DMSO-d6), δ 8.80(s, 1H), 8.28(d, J=8.0Hz, 1H), 7.27(s, 1H), 5.32-5.30 (m, 2H), 4.50-4.47 (m, 1H), 3.08(dd, J=5.0, 15.0Hz, 1H), 2.97-2.95 (m, 2H), 2.05 (t, J=7.5Hz, 2H), 1.98-1.95 (m, 4H), 1.42-1.40 (m, 2H), 1.31- 1.23 (m, 20H), 0.84 (t, J=7.0Hz, 3H).13C NMR (100 MHz, DMSO-d6): δ 172.36, 172.32, 133.73, 129.67, 129.63, 116.74, 51.26, 36.72, 31.28, 29.16, 29.02, 28.84(2C), 28.68(2C), 28.59, 28.56, 28.51, 26.63, 26.58, 26.45, 25.14, 22.10, 13.97. HRMS (ESI) m/z [M+H]+ calcd for C24H41N3O3, 420.3221 ; found, 420.3224.
(2S)-2-[[(2)-octadec-9-enoyl]amino]-3-phenyl-propanoic acid (59)
White powder, 1H NMR (500 MHz, DMSO-d6): δ 7.77 (d, J=8.0Hz, 1H), 7.20-7.12 (m,5H), 5.32-5.30 (m, 2H), 4.27-4.25 (m, 1H), 3.07-3.06 (dd, J=5.5, 14.0Hz, 1H), 2.85- 2.80 (dd, J=6.0, 14.0Hz, 1H), 1.98-1.95 (m, 6H), 1.36 (p, J=7.0Hz, 2H), 1.30-1.17 (m, 18H), 1.11-2.09 (m, 2H)), 0.84 (t, J=7.0Hz, 3H). 13C NMR (100 MHz, DMSO-d6): δ 173.62, 171.46, 138.69, 129.65, 129.60, 129.27, 127.76, 125.83, 54.34, 37.24, 35.41,
31.29, 29.16, 29.12, 28.85(2C), 28.75, 28.70(2C), 28.61, 28.58, 28.55, 26.65, 26.59,
25.30, 22.10, 13.94. HRMS (ESI) m/z [M+H]+ calcd for C27H43NO3, 430.3315; found, 430.3317. (2R)-4-methylsulfanyl-2-[[(Z)-octadec-9-enoyl]amino] butanoic acid (60)
White powder.1H NMR (500 MHz, DMSO-d6): δ 8.04 (d, J=7.5Hz, 1H), 5.32-5.30 (m, 2H), 4.29-4.26 (m, 1H), 2.47-2.42 (m, 2H), 2.11-2.07 (m, 2H), 2.02 (s, 3H), 1.98- 1.97 (m, 4H), 1.93-1.90 (m, 1H), 1.83-1.80 (m, 1H), 1.46 (p, J=7.0Hz, 2H), 1.31-1.23 (m, 20H), 0.84 (t, J=7.0Hz, 3H). 13C NMR (100 MHz, DMSO-d6): δ 173.48, 172.34, 129.60(2C), 50.75, 35.04, 31.28, 30.70, 29.74, 29.12, 29.10(2C), 28.84, 28.68, 28.67, 28.59, 28.56, 26.62, 26.57, 25.22, 22.09, 14.57, 13.92. HRMS (ESI) m/z [M+H]+ calcd for C23H43NO3, 414.3036; found, 414.3039.
(2R)-5-guanidino-2-[[(2)-octadec-9-enoyl]amino]pentanoic acid.HCI (62)
White powder. 1H NMR (500 MHz, DMSO-d6): δ 8.05 (d, J=7.5Hz, 1H), 7.71 (t, J=5.5Hz, 1H), 7.42-7.13 (m, 3H), 5.32-5.30 (m, 2H), 4.18-4.13 (m, 1H), 3.01 (t, J=6.5Hz, 2H), 2.09-2.04 (m, 2H), 1.98-1.95 (m, 4H), 1.72-1.69 (m, 2H), 1.58-1.55 (m, 2H), 1.45-1.36 (m, 2H), 1.30-1.23 (m, 20H), 0.84 (t, J=7.0Hz, 3H).13C NMR (100 MHz, DMSO-de): δ 175.98, 170.99, 157.32, 129.64, 129.60, 53.50, 35.03, 31.28, 29.77, 29.15, 29.10(2C), 28.83, 28.77, 28.74, 28.68, 28.61, 28.58, 26.63, 26.57, 25.42, 25.16, 22.09, 13.94. HRMS (ESI) m/z [M+H]+ calcd for C24H46N4O3, 439.3643; found,439.3644.
(2R)-3-(1 H-indol-3-yl)-2-[[(Z)-octadec-9-enoyl]amino]propanoic acid.HCI (63)
White solid.1H NMR (500 MHz, DMSO-d6): δ 10.80 (s, 1H), 7.99 (d, J=8.0Hz, 1H), 7.52-7.50 (d, J=7.50Hz, 1H), 7.31-7.30 (d, J=8.0Hz, 1H), 7.11-7.10 (d, J=2.0Hz, 1H), 7.03 (t, J=7.0Hz, 1H), 6.95 (t, J=7.0Hz, 1H), 5.32-5.30 (m, 2H), 4.45-4.44 (m, 1H),
3.16-3.12 (dd, J=5.5, 14.0Hz, 1 H), 2.99-2.95 (m, 1 H), 2.06-2.04 (m, 2H), 1 .98-1 .95 (q, J=6.0Hz, 4H), 1 .39-1 .37 (m, 2H), 1 .31 -1 .23 (m, 20H), 0.84 (t, J=7.0Hz, 3H). 13C NMR (100 MHz, DMSO-de): δ 173.58, 172.10, 136.06, 129.66, 129.60, 127.23, 123.45, 120.82, 1 18.25, 1 18.17, 1 10.10, 1 10.06, 52.86, 35.08, 31 .26, 29.12, 29.09, 28.82, 28.67, 28.58, 28.54, 28.52, 27.13(2C), 26.62, 26.57, 25.27, 22.08, 13.94. HRMS (ESI) m/z [M+H]+ calcd for C29H44N2O3, 469.3425; found, 469.3420.
(2R)-3-(1 H-imidazol-5-yl)-2-[[(Z)-octadec-9-enoyl] amino] propanoic acid.HCI
(64)
White powder. 1H NMR (500 MHz, DMSO-d6), δ 8.86 (s, 1 H), 8.22 (d, J=8.0Hz, 1 H), 7.30 (s, 1 H), 5.32-5.30 (m, 2H), 4.50-4.47 (m, 1 H), 3.12-3.08 (m, 2H), 2.98-2.92 (m, 1 H), 2.05 (t, J=7.5Hz, 2H), 1 .98-1 .95 (m, 4H), 1 .42-1 .40 (m, 2H), 1 .31 -1 .23 (m, 20H), 0.84 (t, J=7.0Hz, 3H). 13C NMR (100 MHz, DMSO-d6): δ 172.36, 172.32, 133.73, 129.67, 129.63, 1 16.74, 51 .26, 36.72, 31 .28, 29.16, 29.02, 28.84, 28.68(2C), 28.59, 28.56, 28.51 , 28.47, 26.63, 26.58, 26.45, 25.14, 22.10, 13.97 HRMS (ESI) m/z [M+H]+ calcd for C24H41 N3O3, 420.3221 ; found, 420.3220.
Inhibitory activity
Methods for assessing the activity of compounds of the invention is described in Carland et al (2013), which is incorporated herein by reference.
Briefly, inhibition of glycine transporters, GlyT1 and GlyT2, by compounds of the invention was examined by injecting RNA encoding these proteins into Xenopus laevis oocytes and measuring the concentration dependent glycine currents in the presence and absence of the compounds.
Glycine transport by GlyT2 and GlyT1 is coupled to 3 Na+/1 CI- and 2Na+/1 Cl- ions respectively, creating an electrogenic process and allowing the two electrode voltage clamp technique to be used to measure glycine transport. Defoliculated stage V- VI oocytes were injected with 4.6 ng of cRNA encoding the transporter (Drummond Nanoinject, Drummond Scientific Co., Broomall, PA, USA). When transporter expression levels are sufficient 2-5 days following injection, glycine transport currents were measured at -60 mV using Geneclamp 500 amplifier (Axon Instruments, Foster
City, CA, USA) with a Powerlab 2/20 chart recorder (ADInstruments, Sydney, Australia) using chart software (ADInstruments).
Glycine was applied, followed by co-administration of glycine (EC50) in the presence of inhibitor, until the inhibitory response was observed to plateau. Each compound was tested to a maximal concentration of 3 μΜ because these compounds form micelles at higher concentrations. The compounds were applied at concentrations below their CMC in ND96 which was determined using a CMC assay. Reversibility of each compound was tested by applying the EC50 dose of glycine every 5 minutes following inhibition for a 30 minute time course or until recovery was reached. Recovery is defined as glycine currents within +/- 5 % of the pre-inhibitory glycine response. Concentration response curves for the active compounds were then performed.
The activity assay results are provided in Table 2, below.
Table 2. Inhibitory activity of exemplary compounds of the present invention
The physical properties of the compounds of the invention have distinct advantages over traditional compounds, because they do not allow complete and prolonged inhibition, which are responsible for the toxic side effects of existing drugs.
Metabolic stability in rat and human liver microsomes
The metabolic stability of exemplary compounds of the invention was tested using human and rat liver microsomes in vitro.
Incubation methods The metabolic stability assay was performed by incubating each test compound
(1 μΜ) with human (Xenotech, Lot #1410230) and rat (Xenotech, Lot #1410271 ) liver microsomes at 37°C and 0.4 img/mL protein concentration. The metabolic reaction was initiated by the addition of a NADPH-regenerating system (i.e. NADPH is the cofactor required for CYP450-mediated metabolism) and quenched at various time points over the 60 minute incubation period by the addition of acetonitrile containing diazepam as internal standard. Control samples (containing no NADPH) were included (and quenched at 2, 30 and 60 minutes) to monitor for potential degradation in the absence of cofactor.
Sample preparation
Following protein precipitation with acetonitrile, samples were centrifuged for 4 minutes at 4,500 rpm. The supernatant was removed and analysed by LC/MS (see below).
Analytical conditions
Metabolite screening was performed using accurate mass measurements only. Compounds were incubated at a low substrate concentration and as such, structure confirmation and elucidation using MS/MS scans was not conducted. Calculations
Test compound concentration versus time data were fitted to an exponential decay function to determine the first-order rate constant for substrate depletion.
The in vitro half-life of each of the test compounds in the presence and absence of NADPH, along with metabolic stability calculations (in vitro intrinsic clearance, predicted blood clearance and predicted hepatic extraction ratio) are presented in Table 3.
Table 3: Metabolic stability parameters for nine compounds based NADPH-dependent degradation profiles in human and rat liver microsomes.
Note: degradation half-life in non-NADPH control samples is an estimate based on up to three time points 1 Apparent non-NADPH mediated degradation was observed in metabolism control samples and the apparent degradation half-life in control incubations is shown in parentheses. Predicted clearance parameters are therefore not determined (ND) as the assumptions for in vivo clearance predictions are no longer valid (Obach, 1999).
2 No measurable concentration of the parent compound was detected at the initial time point (i.e. 2 minutes), hence, the clearance parameters could not be calculated (c.n.c).
3 This compound showed minimal microsomal degradation (<15%) over the course of the incubation.
There was no measurable degradation of compounds 29, 36 and 50 in microsomal control incubations, suggesting that there was no major non-cofactor dependent microsomal metabolism contributing to the overall rates of metabolism. These compounds would be expected to show low hepatic clearance in vivo.
Metabolic stability in rat and human plasma
The metabolic stability of exemplary compounds of the invention was tested using human and rat plasma in vitro.
Incubation
Human plasma (pooled; n=3 donors) was separated from whole blood procured from the Australian Red Cross Blood Service. Rat plasma (pooled; multiple rats) from male Sprague Dawley rats was procured from Animal Resources Centre (ARC; Perth). Plasma was stored frozen at -80°C, on the day of the experiment, plasma was thawed in a water bath maintained at 37°C.
Aliquots of plasma were spiked with DMSO/acetonitrile/water solutions of test compound to a nominal compound concentration of 1000 ng/mL. The maximum final DMSO and acetonitrile concentrations were 0.2% (v/v) and 0.4% (v/v) respectively. Immediately after compound spiking, plasma was vortex mixed and aliquots of spiked plasma (50 μΙ_) were transferred into fresh micro centrifuge tubes and were maintained at 37°C. At various time points over the 240 min incubation period, triplicate plasma samples were taken and immediately snap-frozen in dry ice. All samples were stored frozen at -80°C until analysis by LC-MS. Bioanalysis
Plasma samples were quantified relative to calibration standards prepared using blank plasma of the same species. Calibration standards were spiked with test compound over a range of 0.5 to 10,000 ng/mL. Internal standard (leucine enkephalin) was added to calibration standards and incubation samples, and then immediately
quenched using two volumes of acetonitrile to precipitate plasma proteins. Samples were vortex mixed and centrifuged (10,000 rpm for 3 minutes) in a microcentrifuge and the supernatant analysed by LC-MS using conditions tabulated below.
The mean and standard deviation of measured plasma concentrations were calculated for each time point and expressed as a percentage remaining, relative to the initial time point (2 min). Where measurable degradation was detected, and assuming first order degradation kinetics, the data were fit using a mono-exponential decay function to obtain the apparent first-order degradation rate constant (k, min-1 ) and degradation half-life.
Results
The results of the metabolic study are shown in Table 4, below, and in Figure 1 . In Figure 1 , data is expressed as mean ± SD (n = 3) and where measurable degradation was observed, the data were fitted using a mono-exponential decay function.
Table 4. Metabolic stability of five compounds in human and rat plasma in vitro
Where compounds exhibited loss that was less than 15% over the course of the 240 min incubation, the degradation half-life was estimated to be >1022 min.
Spinal cord electrophysiology
Preparation of spinal cord slices
Adult male Sprague-Dawley rats (6-8 weeks at the time of slice preparation) were anaesthetized with isoflurane, decapitated and the lumbar region of the spinal cord was removed. Parasagittal slices (340 pm thick) of spinal cord were cut on a vibratome (Leica VT 1200s) in oxygenated ice-cold sucrose-based artificial CSF (sACSF) that contained (mM): 100 sucrose, 63 NaCI, 2.5 KCI, 1 .2 NaH2PO4, 1 .2 MgCI2, 25 glucose, and 25 NaHCO3. Slices were transferred to a submerged chamber containing NMDG- based recovery ACSF (rACSF) for 15 minutes at 34°C, equilibrated with 95% O2 and 5% C02 and composed of (mM): 93 NMDG, 2.5 KCI, 1 .2 NaH2P04, 30 NaHC03, 20 HEPES, 25 Glucose, 5 Na ascorbate, 2 thiourea, 3 Na pyruvate, 10 MgSO4 and 0.5 CaCI2, and adjusted to pH 7.4 with HCI. Following the recovery incubation, slices were transferred to normal oxygenated ACSF where they were allowed to recover for 1 hour at 34° C and then maintained at room temperature prior to transfer to the recording
chamber. Normal ACSF had the following composition (imM): 125 NaCI, 2.5 KCI, 1 .25 NaH2PO4, 1 .2 MgCI2, 2.5 CaCI2, 25 glucose, and 1 1 NaHCO3 and was equilibrated with 95% O2 and 5% CO2.
Electrophysioloqy Slices were transferred to a recording chamber and superfused continuously at 2 ml/min with normal ACSF that had been equilibrated with 95% O2 and 5% CO2 and maintained at 34°C with an inline heater and monitored by a thermister in the slice chamber. Dodt-contrast optics was used to identify lamina II neurons in the translucent substantia gelatinosa layer of the superficial dorsal horn. A Cs+-based internal solution, which should minimise postsynaptic effects, was used to record electrically evoked inhibitory post-synaptic currents (elPSCs) and tonic current, and contained (imM): 140 CsCI, 10 EGTA, 5 HEPES, 2 CaCI2, 2 MgATP, 0.3 NaGTP, 5 QX-314.CI, 2 Lucifer Yellow CH dipotassium salt and 0.1 % biocytin (osmolarity 285-295 mosmol Γ1). Patch electrodes had resistances between 3 and 5 ΜΩ. Synaptic currents were measured in whole-cell voltage-clamp (-70 mV, not corrected for a liquid junction potential of 4 mV) from lamina II cells. Bipolar tungsten electrodes placed in the inner laminae (lamina III region) were used to elicit elPSCs using a stimulus strength sufficient to evoke reliable elPSCs. Neurons ventral to lamina II, in regions that are known to contain glycinergic neurons were electrically stimulated. All elPSCs were recorded in CNQX (10 μΜ), AP5 (100 μΜ) and picrotoxin (80 μΜ). At the conclusion of each experiment strychnine (0.5 μΜ) was added to the superfusion solution to confirm that recorded currents were glycine- mediated IPSCs. Drugs were superfused onto slices at a rate of 2ml/min in normal oxygenated ACSF at 34°C.
Results The results of the spinal cord electrophysiology are presented in Figures 2 - 6.
The results show that Compounds 28 and 39 are effective at increasing tonic current, elPSC amplitude and decay time constants.
Plasma and brain exposure of oleyl-D-lysine following IP administration
To assess the plasma and brain exposure of oleyl-D-lysine, Sprague Dawley rates were administered (via IP) a 27.5 mg/kg dose of the compound, according to the following procedure. Summary of procedure
Small scale formulation trials (~200 μΙ_ volume) indicated oleoyl-D-lysine was a solution when formulated using a vehicle of 10% (v/v) DMSO, with 1 % Solutol in 50 imM PBS 7.4. On the day of dosing the formulation was scaled up to a volume of 24.9 imL, which yielded a fine uniform suspension.
The formulation was prepared by dissolving solid compound in DMSO prior to addition of 1 % Solutol in 50mM PBS pH 7.4 solution, which after sonication and heating yielded a very fine off-white suspension with an apparent pH of 7.05. This suspension of oleoyl-D-lysine was administered in a dose volume of 5 imL/kg via intraperitoneal injection (via 27G 1 /2" needle) resulting in a nominal oleoyl-D-lysine dose of 27.5 mg/kg.
Rat Exposure
All animal studies were conducted using established procedures in accordance with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes, and the study protocols were reviewed and approved by the Monash Institute of Pharmaceutical Sciences Animal Ethics Committee.
The systemic exposure of oleoyl-D-lysine was studied in non-fasted male Sprague Dawley rats weighing 250 - 306 g. Rats had access to food and water ad libitum throughout the pre- and postdose sampling period. A single blood sample (1 imL) was collected via cardiac puncture from each rat
(anaesthetised using gaseous Isoflurane) at designated times up to 24 h (3 rats per time point). At the time of blood sampling, the whole brain was also rapidly removed from the carcass. No urine samples were collected as rats were housed in bedded cages.
Blood was collected into polypropylene Eppendorf tubes containing heparin as anticoagulant and stabilisation cocktail containing Complete® (a protease inhibitor cocktail) and potassium fluoride) to minimise the potential for ex vivo compound degradation in blood/plasma samples. Once collected, blood samples were centrifuged immediately, supernatant plasma was removed, and stored at - 80°C until analysis by LC-MS. The whole brains were blotted to remove excess blood, placed into pre-
weighed polypropylene vials and weighed. The brains were snap frozen in dry ice and subsequently stored frozen (-80°C) until analysis. A summary of the bioanalytical method and assay validation details is included in Appendix 2.
Standard Calculations
Plasma concentration versus time data were analysed using non-compartmental methods (PKSolver Version 2.0). Standard calculations for each pharmacokinetic parameter are listed below.
Calculation of Brain Exposure Parameters
The concentration of oleoyl-D-lysine in brain parenchyma was calculated on the basis of the measured concentration in brain homogenate, after correcting for the contribution of compound contained within the vascular space of brain samples as follows:
103
Substitute Sheet
(Rule26)RO/AU
Sample processing and analysis The extraction of the test compound from plasma samples was conducted using protein precipitation with acetonitrile. Both solution and plasma standards were freshly prepared, with each set of standards comprising at least six different analyte concentrations. Solution standards were diluted from a stock solution (1 mg/mL in DMSO) with 50% acetonitrile in water. Plasma standards were prepared by spiking blank plasma (50 μΙ_) with solution standards (10 μΙ_) and the internal standard, diazepam (10 μΙ_, 5 Mg/mL). Plasma samples were similarly prepared, except that blank acetonitrile (10 μΙ_) was added instead of solution standards. Protein precipitation was carried out by the addition of acetonitrile (120 μΙ_), vortexing (20 s) and centrifugation (10,000 rpm) in a microcentrifuge for 3 minutes. The supernatant was subsequently separated and 3 μΙ_ injected directly onto the column for LC-MS analysis using conditions presented in the method summary section. All concentrations are expressed as the non-salt equivalent.
Pre-weighed rat brains were homogenised in 3-volume/weight of stabilisation mixture (composed of 0.1 M EDTA and 4 g/L KF in water) using a gentleMACS™ dissociator. Extraction of the test compound from the resulting tissue homogenate was conducted using protein precipitation with methanol. Tissue homogenate standards
were freshly prepared, with each set of standards comprising at least six different analyte concentrations. Tissue standards were prepared by spiking blank tissue homogenate (200 μΙ_) with solution standards (10 μΙ_) and the internal standard, diazepam (10 μΙ_, 5 pg/mL). Tissue samples were similarly prepared, except that blank methanol (10 μΙ_) was added instead of solution standards. Protein precipitation was carried out by the addition of methanol (600 μΙ_), vortexing (20 s) and centrifugation (10,000 rpm) in a microcentrifuge for 3 minutes. The supernatant was subsequently separated and 3 μΙ_ injected directly onto the column for LC-MS analysis using conditions presented in the method summary section. Results
Following IP administration of oleoyl-D-lysine, all rats exhibited mild piloerection and reduced activity, however all rats appeared to recover approximately 2 hours post- dose.
Plasma and brain concentration versus time profiles are presented in Figure 6, whilst calculated plasma and brain exposure parameters, values for individual rats, together with the corresponding brain-to-plasma (B:P) ratios are summarised in Tables 5 and 6.
In plasma and brain collected from a single rat that was not dosed with oleoyl-D- lysine, there was no detectable level of oleoyl-D-lysine. This supports the specificity of the LC-MS method and infers that the measured concentrations observed in rats that were dosed with the compound are due to the oleoyl-D-lysine itself, and not an endogenous interference.
Following IP administration, oleoyl-D-lysine was rapidly absorbed with maximum plasma concentrations observed at the first sampling time. The apparent terminal half- life of the plasma profile (based on the last 3 time points) was ~ 10 h.
In contrast to the plasma concentration-time profile, brain concentrations remained relatively constant for the duration of the 24 h sampling period. B:P ratios increased over the 24 h exposure period, and maximum values (ranging from 0.6-1 .6) were observed at 24 h post-dose. This may be indicative of a slow rate of compound
equilibration between plasma and brain. As such, the time-averaged brain-to-plasma (B:P) partitioning ratio values (based on AUC0-24h values in plasma and brain) may provide a better indication of the distribution of oleoyl-D-lysine into the brain, although it may still be an underestimation as it is lower than the B:P at 24 h. Table 5: Exposure parameters for oleoyl-D-lysine in male Sprague Dawley rats following IP administration at 27.5 mg/kg
c.n.c. - Could not calculate as the flat profile precluded an estimation of half-life and extrapolation to infinity
Table 6: Individual and mean ± SD (n=3) plasma and brain concentrations and brain to plasma (B:P) ratios of oleoyl-D-lysine in male Sprague Dawley rats following IP administration at 27.5 mg/kg
ND - Not detected Cell-based agonist and antagonist assays on ACTOne-CB1 , CB2 and
S1 PR1 cells
The purpose of these assays was to determine whether the compounds of the present invention have any off-target effects. The S1 PR1 , CB1 and CB2 receptors were chosen as they have been known to be agonised or antagonised by lipid-based molecules.
S1 PR1 Assay
ACTOne-S1 PR1 cells used for the assay
CELL LINE DESIGNATION Endothelial Differentiation, Sphingolipid
G-Protein-coupled Receptor, 1 cell line (CB-80300-250)
ORIGIN (PARENTAL CELL) HEK 293-CNG cell (CB-80200-200)
GENE INTRODUCED Genbank Locus ID 1901
RECEPTOR INTRODUCED Human endothelial differentiation,
sphingolipid G-protein-coupled receptor, 1 (NCBI protein database NP_001391 .2)
Usage cAMP assay for Gi-coupled human Endothelial Differentiation, Sphingolipid G- Protein-coupled Receptor, 1 (S1 PR1 )
Quality control
1 . This cell line has been tested negative for Mycoplasma sp.
2. This cell line has been tested positive for Endothelial Differentiation, Sphingolipid G-Protein-coupled Receptor, 1 specific response.
3. Surviving rate: More than 2.5 million/vial on the second day after thawing.
4. The receptor specific activity is stable for 10 weeks continuous passage. Cell culture condition
1 . Growth medium: 90% DMEM, 10% FBS, 250 μg/ml G418 and 1 μg/ml puromycin
2. Freezing medium: 10% DMSO, 90% growth medium
Testing compounds on ACTOne-SI PR1 cells
ACTOne-S1 PR1 cells (CB-80300-250) were maintained in cell culture medium consisting of 90% Dulbecco's Modified Eagle Medium (DMEM), 10% fetal bovine serum (FBS), 250 μg/ml G418 and 1 μg/ml puromycin. The day before the assay, the cells were trypsinized and diluted to the final concentration of 600K cells/ml in the growth medium. 20 μΙ of such cell suspension was added into each well of 384-well plates. Each well contained 12K cells. The plates were then transferred to a cell culture incubator and the cells were growing overnight.
On the second day, the cell plates were taken out from the incubator and an equal volume (20 μΙ) of 1X ACTOne membrane potential dye was added into each well and the plates were kept at room temperature in the dark for 2 hrs. The total volume after this step was 40 μΙ. The plates will be referred to as the cell plates. i) Agonist Assay
The agonist control picked here was S1 P (125 uM stock in 4 mg/ml Fatty acid free BSA, Avanti Polar Lipids 860492P). The agonist stimulation solutions were prepared as below:
1 . Dilute Ro 20-1724 (Sigma B8279) stock to 125 μΜ and isoproterenol (Sigma I6504) stock to 1 .5 μΜ in 1X DPBS with 0.1 mg/ml BSA (Sigma A8806). It was referred as agonist dilution buffer. 2. Dilute 125 μΜ S1 P stock in agonist dilution buffer as shown in Table 1 . These concentrations are 5X of the expected final testing concentrations.
3. The testing compounds were first diluted in DMSO to 1 imM each. It was further diluted (1 :200) in agonist dilution buffer to 5 μΜ each.
Isoproterenol is used to stimulate the adenylyl cyclase through the activation of Gs-coupled endogenous β-adrenoceptor. Ro20-1724 is a PDE4 specific inhibitor.
The cell plates were placed on a Molecular Devices SpectraMax Gemini EM and the baselines (F0) were read before the addition of any compound. 10 μΙ of above agonist stimulation solutions (5X) was added into each well. The plates were recorded
again on Gemini EM 50 min (Ft) after the compound addition. The ratio of Ft/FO (Fold) was calculated for each well; data was analyzed and graphed using GraphPad Prism.
The final concentrations of S1 P used are listed in Table 7.
Table 7. An example of the final testing concentrations of S1 P
The testing compounds were assayed the same way. Results
As can be seen from Figure 8, the compounds tested have no agonist activity on S1 PR1 . ii) Antagonist Assay
Based on the above data, 100 nM S1 P (final) was used in the antagonist assay.
The assays were again performed on 384-well plates. The day before the assay, the cells were trypsinized and diluted to the final concentration of 600K cells/ml in growth medium. 20 μΙ of such cell suspension was added into each well of 384-well plates. Each well contained 12K cells. The plates were then transferred to a cell culture incubator and the cells were growing overnight.
On the second day, the cell plates were taken out from the incubator and an equal volume (20 μΙ) of 1X ACTOne membrane potential dye was added into each well and the plates were kept at room temperature in the dark for 2 hrs. The total volume after this step was 40 μΙ.
The testing compounds (1 mM in DMSO) were diluted (1 :200) in 1 X DPBS to 5 μΜ each. 10 μΙ of such solution was added into each well of 384-well plates and
incubated at room temperature for 20 min. 10 μΜ of W146 (Final) was used as a positive control.
The cell plates were read on Gemini EM (FO). Afterwards, 12.5 μΙ of 5X agonist stimulation solution (125 μΜ Ro 20-1724, 1 .5 μΜ isoproterenol and 500 nM S1 P prepared in DPBS with 0.1 mg/ml BSA) was added into each well. The cell plates were read again after 50 min (Ft).
Results
As can be seen from Figure 9, the compounds have no antagonist activity on S1 PR1 .
CB2 Assay
ACTOne-CB2 cells used for the assay
CELL LINE DESIGNATION Cannabinoid receptor 2 cell line (CB2)
(CB-80300-225)
ORIGIN (PARENTAL CELL) HEK 293-CNG cell (CB-80200-200)
GENE INTRODUCED Genbank LocusID 1269
RECEPTOR INTRODUCED: Human Cannabinoid receptor 2. (NCBI protein database NP_001832 with SNP at amino acid position 63.)
Usage cAMP assay for Gi-coupled human cannabinoid receptor 2 (CB2).
Quality control
1 . This cell line has been tested negative for Mycoplasma sp.
2. This cell line has been tested positive for CB2 specific response.
3. Surviving rate: More than 2.5 million/vial on the second day after thawing.
Ill
4. The receptor specific activity is stable for 10 weeks continuous passage. Cell culture condition
1 . Growth medium for Cannabinoid receptor 2 cell line: 90% DMEM with Glutamine, 10% FBS, 250 μg/ml G418 and 1 μg/ml puromycin 2. Freezing medium: 10% DMSO, 90% growth medium
Testing compounds on ACTOne-CB2 cells
ACTOne-CB2 cells (CB-80300-225) were maintained in cell culture medium consisting of 90% Dulbecco's Modified Eagle Medium (DMEM), 10% fetal bovine serum (FBS), 250 μg/ml G418 and 1 μg/ml puromycin. The day before the assay, the cells were trypsinized and diluted to the final concentration of 600K cells/ml in the growth medium. 20 μΙ of such cell suspension was added into each well of 384-well plates. Each well contained 12K cells. The plates were then transferred to a cell culture incubator and the cells were growing overnight.
On the second day, the cell plates were taken out from the incubator and an equal volume (20 μΙ) of 1X ACTOne membrane potential dye was added into each well and the plates were kept at room temperature in the dark for 2 hrs. The total volume after this step was 40 μΙ. The plates will be referred to as the cell plates. i) Agonist Assay
The agonist control picked here was CP-55940 (10mM stock in DMSO, Sigma C1 1 12). Dilute 10mM CP-55940 stock in DMSO containing 30 μΜ Isoproterenol and 2.5 imM Ro 20-1724. These concentrations are 100X the expected final testing concentrations.
Isoproterenol is used to stimulate the adenylyl cyclase through the activation of Gs-coupled endogenous β adrenoceptor. Ro20-1724 is a PDE4 specific inhibitor.
Table 8. An example of CP-55940 concentrations in a compound dilution plate
CP-55940 (μΜ)
Further dilute the solutions 1 :20 with 1 X DPBS in compound plates. At this step, the compound concentration is 5X testing concentration.
Table 9. An example of the final testing concentrations of CP-55940 in a cell assay plate
CP-55940 (nM)
The testing compounds were first diluted in DMSO to 2 mM each. They were further diluted to 100 μΜ in DMSO containing 30 μΜ Isoproterenol and 2.5 mM Ro 20- 1724. Further dilute the solutions 1 :20 with 1 X DPBS in compound plates. At this step, the compound concentration is 5X testing concentration.
The cell plates were placed on a Molecular Devices SpectraMax Gemini EM and the baselines (F0) were read before the addition of any compound. 10 μΙ of above agonist stimulation solutions (5X) was added into each well. The plates were recorded again on Gemini EM 50 min (Ft) after the compound addition. The ratio of Ft/FO (Fold) was calculated for each well; data was analyzed and graphed using GraphPad Prism.
Results
As can be seen from Figure 10 the compounds have no agonist activity on CB2.
ii) Antagonist Assay
Based on the above data, 200 nM CP-55940 (final) was used in the antagonist assay.
The assays were again performed on 384-well plates. The day before the assay, the cells were trypsinized and diluted to the final concentration of 600K cells/ml in growth medium. 20 μΙ of such cell suspension was added into each well of 384-well plates. Each well contained 12K cells. The plates were then transferred to a cell culture incubator and the cells were growing overnight.
On the second, the cell plates were taken out from the incubator and an equal volume (20 μΙ) of 1X ACTOne membrane potential dye was added into each well and the plates were kept at room temperature in the dark for 2 hrs. The total volume after this step was 40 μΙ.
The testing compounds (2 mM in DMSO) were diluted (1 :400) in 1 X DPBS to 5 μΜ each. 10 μΙ of such solution was added into each well of 384-well plates and incubated at room temperature for 20 min. 10 μΜ of AM251 (Final) was used as a positive control.
The cell plates were read on on Gemini EM (F0). Afterwards, 12.5 μΙ of 5X agonist stimulation solution (125 μΜ Ro 20-1724, 1 .5 μΜ isoproterenol and 200 nM CP- 5590 in DPBS) (diluted from 100X solution prepared in DMSO) was added into each well. The cell plates were read again after 50 min (Ft).
Results
As can be seen from Figure 1 1 , the compounds have no antagonist activity on
CB2.
CB1 Assay
ACTOne-CB1 cells used for the assay
CELL LINE DESIGNATION Cannabinoid receptor 1 cell line
(CB-80300-205)
ORIGIN (PARENTAL CELL) HEK 293-CNG cell (CB-80200-200)
GENE INTRODUCED Genbank LocusID 1268
RECEPTOR INTRODUCED Human cannabinoid receptor 1 (NCBI protein database P21554)
Usage cAMP assay for Gi-coupled human cannabinoid receptor 1 (CB1 ). Quality control
1 . This cell line has been tested negative for Mycoplasma sp.
2. This cell line has been tested positive for CB1 specific response.
3. Surviving rate: More than 2.5 million/vial on the second day after thawing
4. The receptor specific activity is stable for 10 weeks continuous passage. Cell culture condition
1 . Growth medium for Cannabinoid receptor 1 cell line: 90% DMEM with Glutamine, 10% FBS, 250 μg/ml G418 and 1 μg/ml puromycin
2. Freezing medium: 10% DMSO, 90% growth medium Testing compounds on ACTOne-CB1 cells
ACTOne-CB1 cells (CB-80300-205) were maintained in cell culture medium consisting of 90% Dulbecco's Modified Eagle Medium (DMEM), 10% fetal bovine serum (FBS), 250 μg/ml G418 and 1 μg/ml puromycin. The day before the assay, the cells
were trypsinized and diluted to the final concentration of 600K cells/ml in the growth medium. 20 μΙ of such cell suspension was added into each well of 384-well plates. Each well contained 12K cells. The plates were then transferred to a cell culture incubator and the cells were growing overnight. On the second day, the cell plates were taken out from the incubator and an equal volume (20 μΙ) of 1X ACTOne membrane potential dye was added into each well and the plates were kept at room temperature in the dark for 2 hrs. The total volume after this step was 40 μΙ. The plates will be referred to as the cell plates.
Table 10. An example of CP-55940 concentrations in a compound dilution plate
Further dilute the solutions 1 :20 with 1 X DPBS in compound plates. At this step, the compound concentration is 5X testing concentration.
Table 11. An example of the final testing concentrations of CP-55940 in a cell assay plate
The testing compounds were first diluted in DMSO to 2 mM each. I. They are further diluted to 100 μΜ in DMSO containing 30 μΜ Isoproterenol and 2.5 mM Ro 20- 1724. Further dilute the solutions 1 :20 with 1 X DPBS in a compound plate. At this step, the compound concentration is 5X testing concentration
The cell plates were placed on a Molecular Devices SpectraMax Gemini EM and the baselines (F0) were read before the addition of any compound. 10 μΙ of above
agonist stimulation solutions (5X) was added into each well. The plates were recorded again on Gemini EM 60 min (Ft) after the compound addition. The ratio of Ft/FO (Fold) was calculated for each well; data was analyzed and graphed using GraphPad Prism. Results
As can be seen from Figure 12 the compounds have no agonist activity on CB1 . ii) Antagonist Assay
Based on the above data, 400 nM CP-55940 (final) was used in the antagonist assay. The assays were again performed on 384-well plates. The day before the assay, the cells were trypsinized and diluted to the final concentration of 600K cells/ml in growth medium. 20 μΙ of such cell suspension was added into each well of 384-well plates. Each well contained 12K cells. The plates were then transferred to a cell culture incubator and the cells were growing overnight. On the second day, the cell plates were taken out from the incubator and an equal volume (20 μΙ) of 1X ACTOne membrane potential dye was added into each well and the plates were kept at room temperature in the dark for 2 hrs. The total volume after this step was 40 μΙ.
The testing compounds (1 imM in DMSO) were diluted (1 :200) in 1 X DPBS to 5 μΜ each. 10 μΙ of such solution was added into each well of 384-well plates and incubated at room temperature for 20 min. 10 μΜ of AM251 (Final) was used as a positive control.
The cell plates were read on on Gemini EM (F0). Afterwards, 12.5 μΙ of 5X agonist stimulation solution (125 μΜ Ro 20-1724, 1 .5 μΜ isoproterenol and 2 μΜ CP- 5590 in DPBS) (diluted from 100X solution prepared in DMSO) was added into each well. The cell plates were read again after 60 min (Ft).
Results
As can be seen from Figure 13, the compounds have no antagonist activity on
CB1 . in vivo analgesic effects of Compound 29
Compound 29 was tested in rats suffering from neuropathic pain induced by partial ligation of the sciatic nerve. Two routes of compound administration were used - intrathecal and intraperitoneal.
Assay 1 - intrathecal injections
• Species: Rats; Sprague Dawley
• Injury: Partial nerve ligation (PNL)
• Test: von Frey test for allodynia
• Route of administration: Intrathecal
• Vehicle: 25% DMSO, 15% ethanol, 60% saline
• Tested: 2 weeks post injury, 4 days post catheter placement
• Comparison: GlyT2 inhibitor ALX1393 (40 μg bolus injection) The results are shown in Figure 14.
Assay 2 - intraperitoneal injection
• Species: Rats; Sprague Dawley
• Injury: Partial nerve ligation (PNL)
• Test: von Frey test for allodynia
• Route of administration: Intaperitoneal
• Vehicle: 10% DMSO, 1 % Soludol in saline
• Tested: 2.5 weeks post injury
• Compound 29: 30 mg/kg (N = 3), and 3 mg/kg (N = 3) · Comparison: GlyT2 inhibitor ORG25543 3 mg/kg N = 2
The results are shown in Figure 15.
As used herein, except where the context requires otherwise, the term "comprise" and variations of the term, such as "comprising", "comprises" and "comprised", are not intended to exclude further additives, components, integers or steps. It will be understood that the invention disclosed and defined in this specification extends to all alternative combinations of two or more of the individual features mentioned or evident from the text or drawings. All of these different combinations constitute various alternative aspects of the invention.
References
1 . Gaskin DJ, Richard P. The economic costs of pain in the United States. J Pain :2012;13:715-24.
2. The high price of pain: the economic impact of persistent pain in Australia. Access Economics Reports. 2007.
3. Wiffen PJ et al Gabapentin for acute and chronic pain. The Cochrane database of systematic reviews. 2005:CD005452.
4. von Hehn CA et al. Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. Neuron. 2012;73:638-52. 5 Vandenberg, R. J., Ryan, R. M., Carland, J. E., Imlach, W. L. & Christie,
M. J. Glycine transport inhibitors for the treatment of pain. Trends in pharmacological sciences 35, 423-430 (2014).
6. Lu Y et al. A feed-forward spinal cord glycinergic neural circuit gates mechanical allodynia. J. Clin Invest. 2013;123:4050-62. 7. Dohi T et al. Glycine transporter inhibitors as a novel drug discovery strategy for neuropathic pain. Pharmacol & Therap. 2009;123:54-79.
8. Roux MJ, Supplisson S. Neuronal and Glial Glycine Transporters have Different toichiometries. Neuron. 2000;25:373-83.
9. Wiles, A. L, Pearlman, R. J., Rosvall, M., Aubrey, K. R. & Vandenberg, R. J. N-Arachidonyl-glycine inhibits the glycine transporter, GLYT2a. Journal of neurochemistry 99, 781 -786 (2006).
10. Vuong, L. A., Mitchell, V. A. & Vaughan, C. W. Actions of N-arachidonyl- glycine in a rat neuropathic pain model. Neuropharmacology 54, 189-193 (2008).
1 1 . Carland, J. E., Mansfield, R. E., Ryan, R. M. & Vandenberg, R. J. Oleoyl- L-carnitine inhibits glycine transport by GlyT2. British journal of pharmacology 168, 891 -
902 (2013).
Claims
CLAIMS 1. A compound of formula (I):
or pharmaceutically acceptable derivatives thereof, wherein:
X is an amino acid or derivative thereof;
L is an amide or retro amide;
Y is Cio - C24 alkyl or alkenyl;
X, L and Y may be independently substituted or unsubstituted; and wherein the compound is not
3. A compound according to claim 1 or 2, wherein X is selected from the group consisting of: non-naturally occurring amino acids, naturally occurring aromatic amino acids and naturally occurring hydrophobic amino acids. 4. A compound according to any one of claims 1 -3, wherein X is substituted with 1 , 2, or 3 Ci - C3 alkyl groups at the a carbon of the amino acid or derivative thereof.
5. A compound according to claim 4, wherein the Ci - C3 alkyl is methyl.
6. A compound according to any one of the preceding claims, wherein X is selected from the group consisting of: glycine, L-carnitine, L-serine, D-serine, L-lysine, D-lysine, L-lysine derivative wherein the carbon chain of the lysine side group is of C1 -C3 in length, L-arginine, L-methionine, L-leucine, D-leucine, L-alanine, D-alanine, B-alanine, L-valine,- D-valine, D-phenylalanine, L-phenylalanine derivative wherein the carbon chain of the phenylalanine side group is of two carbons in length, L-tryptophan, L- tyrosinol- L-dopamine, L-aspartate, D-aspartate, L-glutamate, L-histidine, L-lysine methylester, L-norleucine. 7. A compound according to claim 6, wherein X is selected from the group consisting of: glycine, D-lysine, L-tryptophan L-lysine methylester, and L-leucine.
8. A compound according to any one of the preceding claims, wherein L is substituted with a C1 - C3 alkyl group at the nitrogen of the amide or retro amide.
9. A compound according to claim 8, wherein the Ci - C3 alkyl is methyl. 1 0. A compound according to any one of the preceding claims, wherein L is an amide.
1 1 . A compound according to any one of the preceding claims, wherein Y includes 1 - 4 cis double bonds.
1 2. A compound according to any one of the preceding claims, wherein Y is monounsatu rated and includes 1 cis double bond.
1 3. A compound according to claim 1 2, wherein the cis double bond is 5 - 1 5 carbons from L.
14. A compound according to claim 1 2 or 1 3, wherein the cis double bond is 8 - 10 carbons from L. 1 5. A compound according to any one of claims 12 to 14, wherein Y is a
monounsatu rated Ci8 carbon chain.
16. A compound according to any one of claims 12 to 14, wherein Y is a monounsatu rated C16 carbon chain.
17. A compound according to claim 16, wherein the monounsaturated Ci6 carbon chain includes a cis-double bond in the ω 5, 6, 7, 9, or 1 1 position. 18. A compound according to any one of claims 1 to 10, wherein Y is a saturated C14 carbon chain.
19. A compound according to claim 1 selected from the group consisting of:
130
131
132
ı33
134
22. A method of treating pain by administering an effective amount of a compound according to any one of the preceding claims, a salt or pharmaceutically acceptable derivative thereof, to a subject in need thereof.
23. A method of treating pain by administering an effective amount of at least one compound selected from the group consisting of:
a salt, or pharmaceutically acceptable derivative thereof, to a subject in need thereof.
24. Use of an effective amount of a compound according to any one of claims 1 to 21 , a salt or pharmaceutically acceptable derivative thereof, in the manufacture of a medicament for treatment of pain in a subject in need thereof.
Use of an effective amount of at least one compound selected from the group isting of:
a salt, or pharmaceutically acceptable derivative thereof, in the manufacture of a medicament for treatment of pain in a subject in need thereof.
26. A compound according to any one of claims 1 to 21 , a salt or pharmaceutically acceptable derivative thereof, for use in treating pain in a subject in need thereof. 27. A compound selected from the group consisting of:
143
a salt, or pharmaceutically acceptable derivative thereof, for use in treating pain in a subject in need thereof.
28. A method according to claim 22 or 23, a use according to claim 24 or 25, or a compound according to claim 26 or 27, wherein the pain is chronic pain.
29. A method according to claim 22 or 23, a use according to claim 24 or 25, or a compound according to claim 26 or 27, wherein the pain is neuropathic pain.
30. A pharmaceutical composition comprising a compound according to any one of claims 1 to 21 , together with one or more pharmaceutically acceptable carriers.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2017900163 | 2017-01-19 | ||
AU2017900163A AU2017900163A0 (en) | 2017-01-19 | Novel glycine transport inhibitors for the treatment of pain |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018132876A1 true WO2018132876A1 (en) | 2018-07-26 |
Family
ID=62907507
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU2018/050035 WO2018132876A1 (en) | 2017-01-19 | 2018-01-19 | Novel glycine transport inhibitors for the treatment of pain |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2018132876A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3574899A1 (en) * | 2018-05-28 | 2019-12-04 | Université de Bourgogne | Oleic acid derivatives, pharmaceutical composition or food composition comprising said oleic acid derivatives, and their uses |
WO2024050108A3 (en) * | 2022-09-02 | 2024-04-04 | University Of Florida Research Foundation, Inc. | Compositions and methods of use |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003006007A1 (en) * | 2001-07-11 | 2003-01-23 | Research & Innovation Soc.Coop. A R.L. | Use of compounds as functional antagonists to the central cannabinoid receptors |
WO2003007876A2 (en) * | 2001-06-25 | 2003-01-30 | University Of Massachusetts | N-fatty acid-amino acid conjugates and therapeutic uses |
WO2005073164A1 (en) * | 2004-01-30 | 2005-08-11 | Peplin Biolipids Pty Ltd | Therapeutic and carrier molecules |
WO2013048453A1 (en) * | 2011-09-30 | 2013-04-04 | Ray Jay Richard Ii | Compounded transdermal pain management |
WO2014056939A1 (en) * | 2012-10-08 | 2014-04-17 | Universität Zürich | Lipidic biomaterials for encapsulation and triggered release |
US20140127142A1 (en) * | 2011-06-13 | 2014-05-08 | Kao Corporation | Toothpaste composition for dentin hypersensitivity |
-
2018
- 2018-01-19 WO PCT/AU2018/050035 patent/WO2018132876A1/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003007876A2 (en) * | 2001-06-25 | 2003-01-30 | University Of Massachusetts | N-fatty acid-amino acid conjugates and therapeutic uses |
WO2003006007A1 (en) * | 2001-07-11 | 2003-01-23 | Research & Innovation Soc.Coop. A R.L. | Use of compounds as functional antagonists to the central cannabinoid receptors |
WO2005073164A1 (en) * | 2004-01-30 | 2005-08-11 | Peplin Biolipids Pty Ltd | Therapeutic and carrier molecules |
US20140127142A1 (en) * | 2011-06-13 | 2014-05-08 | Kao Corporation | Toothpaste composition for dentin hypersensitivity |
WO2013048453A1 (en) * | 2011-09-30 | 2013-04-04 | Ray Jay Richard Ii | Compounded transdermal pain management |
WO2014056939A1 (en) * | 2012-10-08 | 2014-04-17 | Universität Zürich | Lipidic biomaterials for encapsulation and triggered release |
Non-Patent Citations (4)
Title |
---|
DATABASE Registry [O] 11 November 1988 (1988-11-11), retrieved from STN Database accession no. 117415-29-9 * |
DATABASE Registry [O] 25 October 1991 (1991-10-25), retrieved from STN Database accession no. 136897-50-2 * |
TORTORIELLO, G ET AL.: "Targeted Lipidomics in Drosophila melanogaster Identifies Novel 2-Monoacylglycerols and N-acyl Amides", PLOS ONE, vol. 8, no. 7, 11 July 2013 (2013-07-11), pages 1 - 10, XP055505088 * |
WU, CHIA-SHAN ET AL.: "GPR55, a G-Protein Coupled Receptor for Lysophosphatidylinositol, Plays a Role in Motor Coordination", PLOS ONE, vol. 8, no. 4, 2 April 2013 (2013-04-02), pages 1 - 14, XP055505079 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3574899A1 (en) * | 2018-05-28 | 2019-12-04 | Université de Bourgogne | Oleic acid derivatives, pharmaceutical composition or food composition comprising said oleic acid derivatives, and their uses |
WO2019228994A1 (en) * | 2018-05-28 | 2019-12-05 | Université de Bourgogne | Oleic acid derivatives, pharmaceutical composition or food composition comprising said oleic acid derivatives, and their uses |
WO2024050108A3 (en) * | 2022-09-02 | 2024-04-04 | University Of Florida Research Foundation, Inc. | Compositions and methods of use |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Johnston | Neuropharmacology of amino acid inhibitory transmitters | |
Gajcy et al. | A role of GABA analogues in the treatment of neurological diseases | |
JP7036792B2 (en) | Spiro-lactam NMDA receptor modifiers and their use | |
AU2016334396B2 (en) | (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and related compounds as GABA aminotransferase inactivators for the treatment of epilepsy, addiction and hepatocellular carcinoma | |
USRE49569E1 (en) | Alkylamine derivative | |
US20230107216A1 (en) | Pantetheine derivatives and uses thereof | |
JP2001511172A (en) | A compound constituting an effector of a central nervous system receptor particularly sensitive to a neurostimulant amino acid, its production and its biological use | |
Rao et al. | Glutamatergic synaptic dysfunction in hyperammonemic syndromes | |
WO2018132876A1 (en) | Novel glycine transport inhibitors for the treatment of pain | |
NZ514738A (en) | Method of treating cartilage damage | |
US6451761B1 (en) | N′N′-dichlorinated omega-amino acids and uses thereof | |
KR20040039394A (en) | Neuroprotective treatment methods using selective inos inhibitors | |
JP2022501321A (en) | Use of histidine, glycine and other amino acids for the prevention of insulin resistance and / or diabetes | |
US20230093594A1 (en) | Pantethenoylcysteine derivatives and uses thereof | |
Centelles | Glutamate transporters: the regulatory proteins for excitatory/excitotoxic glutamate in brain | |
US20220306564A1 (en) | Compounds for the treatment of neuromuscular disorders | |
Kopelevich | Advances in the Search for Medicinal Drugs Based on γ-Aminobutyric Acid | |
Darmaun et al. | Use of isotope dilution methods to investigate glutamine metabolism in vivo in humans | |
WO2024056865A1 (en) | Compounds for the treatment of neuromuscular disorders | |
BG112806A (en) | Adamantane derivative with antiviral and anti-parkinson activity | |
Mæhre et al. | Articles in PresS. Am J Physiol Gastrointest Liver Physiol (October 2, 2014). doi: 10.1152/ajpgi. 00244.2014 | |
Mavencamp | Design, synthesis and biological evaluation of a family of excitatory amino acid transporter 3 (EAAT3) preferring inhibitors | |
EA033913B1 (en) | Use of phenylcreatine | |
White | Studies of novel glycine-containing lipids that differ greatly in type 2 diabetes | |
WO2017138838A1 (en) | Arylcycloalkylamine derivatives exhibiting a neuroprotective, analgesic and antidepressant effect |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18742011 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18742011 Country of ref document: EP Kind code of ref document: A1 |